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Summary of the work incorporated in the thesis with the title “SYNTHESIS
CHARACTERISATION AND BIOLOGICAL EVALUATION OF SOME NOVEL
HETEROCYCLIC COMPOUNDS” has been described as under.
Heterocyclic compounds bearing imidazo[1,2-a]pyridine ring system are
endowed with variety of biological activities. Our strategy is based on to
develop new bioactive entities especially with pharmacological activities
bearing heterocyclic ring system. Literature survey reveals that nitrogen
containing heterocyclic compounds like imidazo[1,2-a]pyridines have received
considerable attention in medicinal science due to their biological and
pharmacological activities like anti-inflammatory, herbicidal, hypnotic,
sedative, antimicrobial, antitubercular, CNS depressant, antithyroid and many
other therapeutic activities.
These valid observations prompted us to design and synthesize some
heterocycles like chalcones, pyrazolines, cyanopyridines, mannich bases,
pyrimidines, isoxazoles, imidazolinones etc., bearing imidazo[1,2-a]pyridine
nucleus, which have been described as under.
PART-I: STUDIES ON MANNICH BASES
The compounds containing bridge N-atom exhibit pronounced
pharmacological      activities. Mannich base derivatives with bridge N-atom
have been found to be potent drug in medicinal science and possess a wide
range of therapeutic activit ies l ike antihypertensive, antidepressant,
anticholestemic, antifungal and antibacterial etc. By considering this valid
observations, we have synthesized some newer mannich bases, which have
been shown as under.
SECTION-I: Synthesis and biological evaluation of N-{[7-methyl-2-(p-
methylphenyl)imidazo[1,2-a]pyridin-3-yl]methyl}-N,N-diaryl/
alkylamines
N
N
CH3
CH3
NR
R
Type-(I)  
R = Aryl, Alkyl
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Mannich bases of Type (l) have been synthesized by the condensation
of 7-methyl-2-(p-methylphenyl) imidazo[1,2-a]pyridine with different secondary
amines and formaldehydes in the presence of acid catalyst.
PART-II: STUDIES ON 1,3,4-OXADIAZOLES
Oxadiazoles are associated with good therapeutic activity such as
hypnotic, anaesthetic, antibacterial, antifungal, insecticide, and preservatives.
In order to develop medicinally important compounds, we have synthesized
some new oxadiazole derivatives shown as under.
SECTION-I: Synthesis and biological evaluation of 7-methyl-2-(p-methyl
phenyl) imidazo[1,2-a]pyridine-3-(5-aryl-1,3,4-oxadiazol-2-yl)
The oxadizole derivatives of type (II) have been prepared by the
condensation of aceto hydrazide with different aromatic acid in presence of
phosphorous oxychloride.
PART - III : STUDIES ON PYRAZOLONES
Pyrazole derivatives have been found to possess wide range of
therapeutic activities like anticonvulsant, antiinflammatory, antitubercular, CNS
depressant, fungicidal, herbicidal, hypnotic. Prompted by these facts, we have
synthesised some novel pyrazole derivatives which have been described as
under.
SECTION-I: Synthesis and biological evaluation of 2-{[7-methyl-2-(p-
methylphenyl)imidazo[1,2-a]pyridin-3-yl]carbonyl}-3-aryl/
alkyl-5,4-dihydro-1H-pyrazol-5-one.
N
N
CH3
CH3
N
O
N
R
Type-(II)   R = Aryl
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Substituted pyrazolone of type(III) have been prepared by condensation
of 7-methyl-2- (p-methylphenyl)imidazo [1,2-a] pyridine-3-carbohydrazide with
different β-ketoester.
PART-IV: STUDIES ON 1,2,4-TRIAZOLES
Compounds bearing 1,2,4-triazole nucleus shows variety of biological
activity such as antitubercular, amoebicidal, hypnotic, fungicidal, herbicidal,
antiinflammatory, CNS depressant, anticonvulsant, antitumor etc. Due to the
wide range of biological activity, it was contemplated tosynthesise some novel
aryl amide, thiadiazole, triazoles, thiadiazepines anddihydro thiadiazoles
bearing triazole nucleus, which have been described as under.
PART - IV(a): STUDIES ON ARYLAMIDES
Substituted arylamide derivatives shows different biological activity such
as antipyratic, analgesic, antiseptic, antiamoebic etc. Some new arylamide
derivatives synthesise with a view to studing their antibacterial and antifungal
activity, which have been described as under.
SECTION-I: Synthesis and biological evaluation of 5-[7-methyl-2-(p-
methylphenyl) imidazo[1,2-a]pyridin-3-yl]3-mercapto-4H-
1,2,4-triazol-4-yl-arylamide
Type-(III)   R = Aryl, Alkyl
N
N
CH3
CH3
O
N
N
O
R
Type-(IV)   
R = Aryl
N
N
CH3
CH3
N
N
NN
R
O
H
SH
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Arylamide derivatives of type(IV) have been synthesised by the condensation
of 3-mercapto-1,2,4-triazole with different aryl acid chloride.
PART- IV(b): STUDIES ON 1,3,4-THIADIAZOLO TRIAZOLES
Thiadiazole derivatives have been found to be potent drug in
pharmaceutical and possess a wide spectrum of biological activity such as
antifungal, antibiotic, pesticidal, herbicidal and antithyroid. Some novel triazoles
with 1,3,4-thiadiazole ring are prepared as under.
SECTION-I: Synthesis and biological evaluation of 3-[7-methyl-2-(p-
m e t h y l p h e n y l ) i m i d a z o [ 1 , 2 - a ] p y r i d i n - 3 - y l ] 6 - a r y l
[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol
Substituted triazolo-1,3,4-thiadiazole of type(V) have been prepared by
condensation of 3-mercapto-4,N-amino-5-benzhydryl-1,2,4-triazole with
different aromatic acid in presence of phosphorous oxychloride.
PART-V: STUDIES ON IMIDAZOLINONES
The group of compounds containing the imidazolinone ring system have
a          prominent feature in medicinal chemistry. 5-Oxoimidazoline derivatives
have been reported to be active as anticonvulsant, potent CNS depressant,
anticancer, sedative, hypnotics and as mono amino oxidase (MAO) inhibitor.In
view of the above finding some new imidazolinone derivatives bearing
imidazo[1,2-a]pyridine nucleus, which have been described as under.
SECTION-I: Synthesis and biological evaluation of (5Z)-5-{[7-methyl-2-
(p-methylphenyl) imidazo[1,2-a]pyridine-3-yl]methylene}-3-
aryl-2-phenyl-3,5 dihydro-4H-imidazol-4-ones
N
N
CH3
CH3
N
N
NN
SR
Type-(V)  R = Aryl
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The imidazolinone derivatives of Type (VI) have been synthesized by
the reaction of azalactone with different arylamine in pyridine.
PART-VI: STUDIES ON ISOXAZOLES
Isoxazoles are of considerable chemical  and pharmaceut ical
impor tance.  Many isoxazo le  der ivat ives have d isp layed d iverse
pharmacological activities in view of our on going interest in the synthesis of
substituted isoxazoles, the synthesis of some new potentially bioactive
isoxazole derivatives have been under taken, which have been described as
under.
SECTION-I: Synthesis and biological evaluation of 7-methyl-2-(p-methyl
phenyl)-3-(3-arylisoxazol-5-yl)imidazo[1,2-a] pyridines
Isoxazole derivatives of Type (VII) have been prepared by the
cyclocondensation of chalcone with hydroxylamine hydrochloride in the
presence of sodium acetate in glacial acetic acid.
PART-VII : STUDIES ON CYANOPYRIDINES
Cyanopyridine derivatives represents one of the modest class of the
compounds possessing wide range of therapeutic activities such as anti-inlammatory
Type-(VI)  R = Aryl
N
N
CH3
CH3
N
N O
R
Type-(VII)  R = Aryl
N
N
CH3
CH3
O
N
R
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CNS depressant, analgesic, antimicrobial and anticonvulsant. With a view to
getting better therapeutic agents and to evaluate its pharmacological profile,
different types of cyanopyridine derivatives have been synthesized which have
been described as under.
SECTION-I: Synthesis and biological evaluation of 4-[7-methyl-2-(p-
methylphenyl)imidazo[1,2-a]pyridin-3-yl]-2-methoxy-6-aryl
nicotinonitriles
Cyanopyridines of Type (VII I )  have been synthesized by the
cyclocondensation of  chalcones with malanonitrile and sodium methoxide.
PART-VIII: STUDIES ON THIOPYRIMIDINES
In view of powerful biological activities shown by thiopyrimidines like
analgesic, antidiabetic, insecticidal, antibacterial etc, it was thought worthwhile
to synthesized some new thiopyrimidine derivatives possessing better
biological active value with least side    effect, which have been described in
following section.
SECTION-I :Synthesis and biological evaluation of  6-[7-methyl-2-(p-
methylphenyl)imidazo[1,2-a]pyridin-3-yl]-4-arylpyrimidin-
2(1H)-thiones
Type-(VIII)  R = Aryl
N
N
CH3
CH3
N
OCH3
N
R
Type-(IX)  R = Aryl
N
N
CH3
CH3
NH
N
S
R
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Thiopyrimidines of Type (IX) have been synthesized by the cyclocondensation
of chalcones  with thiourea in the presence of basic catalyst.
PART-IX  : STUDIES ON SCHIFF’S BASES
Arylaminomethyl derivatives represents one of the modest class of
biological  active agents which have been deeply studies during search on
new potential agents. These have been reported to be active as antimicrobial,
antitubercular, anticancer, insecticidal etc. In view of these valid observations,
it was contemplated to synthesis some new arylaminomethyl derivatives
possessing higher biological activity which have been described as under.
SECTION-I :Synthesis and biological evaluation of N’-[(1Z)-7-methyl-2-
(p-methylphenyl)imidazo[1,2-a]pyridine-arylmethylene]3-
carbohydrazide
The azomethines of Type (X) have been prepared by the condensation
of  7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridine-3-carbohydrazide with
different aromatic aldehydes.
PART - X : STUDIES ON 4-THIAZOLIDINONES
Compounds bearing thiazolidinone nucleus show wide range of
biological activity such as antimicrobial, CNS depressant, antiinflammatory,
antitubercular,sedative,     anticonvulsant, analgesic and antihypertensive. By
considering these valid observations, we have synthesised some new
thiazolidinones which have been described as under.
SECTION-I :Synthesis and biological evaluation of 7-methyl-2-(p-methyl
phenyl)imidazo[1,2-a]pyridine-3-carboxamide-N-(2-aryl-4-
oxo-1,3-thiazolidin-3-yl).
N
N
CH3
CH3
NH
N
R
O
Type-(X)   R = Aryl
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The thiazolidinone derivatives of type (XI) have been undertaken by the
condensation of Schiff’s base of type(X) with mercaptoacetic acid.
PART - XI : STUDIES ON 2-AZETIDINONES
The β-lactam drugs are still the most prescribed antibiotics used in
medicine. Azetidinone possess a wide spectrum of bilogical activities such
as antibiotic, antideoressant sedative, hypnotic etc. These valid observation
led us to synthesise some novel azetidinone derivatives in search of agent
having better potency which have been describe as under.
SECTION-I :Synthesis and biological evaluation of 7-methyl-2-(p-methyl
phenyl)imidazo[1,2-a]pyridine-3-carboxamide-N-(3-chloro-
4-aryl-2-oxoazetidin-1-yl).
2-Azetidinone derivatives of type (XII) have been synhesised by the
condensation of Schiff’s base of type(X) with chloroacetyl chloride in pres-
ence of triethylamine as a basic catalyst.
Type-(XI)  R = Aryl
N
N
CH3
CH3
NH
O
N
S
R
O
Type-(XII)  R = Aryl
N
N
CH3
CH3
NH
O
N R
O
Cl
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Characterization and Biological Study
In all, approximately 120 novel compounds have been synthesized.
Some representative compounds of the newly synthesized series have been
characterized by elemental analysis, infrared and 1H nuclear magnetic
resonance spectroscopy and further supported by mass spectrometry to
establish the identity of the structures of the compounds. The purity of all the
compounds have been checked by thin layer chromatography.
 All the compounds have been evaluated for their in vitro biological assay
like antimicrobial activity towards Gram positive and Gram negative bacterial
strains and antifungal activity towards different fungus at a concentration of
40µg. The biological activity of the synthesised compounds have been
compared with standard drugs.
Signature of the Guide                                                     Signature of the Student
(Dr. Kalpesh J.Ganatra)                                                    (Sunil G. Sanghani)
Synthesis, Characterisation and....
12
INTRODUCTION
The advancement in science and technology has led to remarkable progress in
diagnosis, treatments and pharmaceutics in the field of medicine. The primary objective
of medicinal chemistry is the design and discovery of new compounds that a suitable for
use as drugs. Recent drug discovery technique based on Structure Activity Relationship,
High throughput Screening and spectroscopy have spearheaded the discovery of many
synthetic and natural drugs.
Since ancient times the people of the world have used a wide range of natural
products for medicinal purposes. These products, obtained from animal, vegetable and
mineral sources, were effective and sometime toxic. However improved communication
through widespread publication and circulation of herbals and pharmacopoeias, resulted
in the progressive removal of preparation that either ineffective or to toxic from herbals
and pharmacopoeias. It also led to a more rational development of new drugs. Initially
this development was centred around the natural products isolated from plant and animal
material, but as knowledge increased a wider range of pharmaceutically active compounds
were used as the starting point for the development of drugs. The compounds on which
a development is based are now known as lead compounds, while the synthetic
compounds developed from a lead are referred to as its analogues.
Research in the field of pharmaceutical has its most important task in the
development of new & better drugs and their successful introduction into clinical practice.
Central to there efforts, accordingly stand the search for pharmaceutical substances and
preparation which are new and original. In addition to there objectives, we may search
for newer drugs which exhibit some clear advantages over a drug already known. Such
advantages may be qualitative or quantitative improvement in activity, the absence of
undesirable side effects, lower toxicity, improved stability or decreased cost.
The word ‘drug’ is derived from the French word ‘drogue’ which means a dry
herb. According to “WHO” a drug may be defined as “any substance or product which
is used or intended to be used for modifying or exploring physiological system or
Synthesis, Characterisation and....
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pathological status for the benefit of recipient”. Drug action is believed to be due to the
interaction of the drug with enzymes, receptors and other molecules found in the biological
system. The binding of a drug to the active or other sites of an enzyme usually has the
effect of preventing the normal operation of that enzyme. The drug’s therapeutic effect
will depend on the stability of the drug-enzyme complex as well as the fraction of active
and all staric sites occupied by the drug. The stronger the binding of the drug to the
enzyme and greater the number of sites occupied, the more effective the drug as likely to
be in inhibiting the action of the enzyme.
The degree of drug activity is directly related to the concentration of the drug in
the aqueous medium in contact with the active or receptor site. The factors affecting this
concentration in a biological system can be classified in to two phase.
(I) The pharmacokinetic phase
It is concerned with the study of the parameters that control the journey of the
drug from its point of administration to its point of action. It includes the adsorption,
distribution, metabolism and elimination of a drug.
(II) The pharmacodynamic phase
It is concentration with the result of the interaction of drug and body at the receptor
site, that is, what the drug does to the body. This includes physiological and biological
effects of drugs and their mechanism of action at macromolecular/sub cellular organ
system.
The role of the medicinal chemist is to design a drug structure that has the maximum
beneficial effects with a minimum of side effects. This design has to take into account the
stereoelectronic characteristics of the target active or receptor site and also such factors
as the drug’s stability in situ, its polarity and its relative solubility in aqueous media and
lipids. The stereochemistry of the drug is particularly important because stereoisomers
often have different biological effects that range from inactive to highly toxic.
Today, the chief sources of agents for the cure, the mitigation or the prevention of
diseases are the organic compounds, natural or synthetic, together with so-called
Synthesis, Characterisation and....
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organometallics. Such agents have their origin in a number of ways (a) from naturally
occurring materials of both plant and animal origin, and (b) from the isolation of organism
of organic compounds synthesized in laboratory whose structures are closely related to
those of naturally occurring compounds for eg. atropine, steroids, morphine, cocaine
etc. that have been known to possess useful medicinal properties.
Heterocyclic compounds hold a special place among pharmaceutically important
natural and synthetic materials. The remarkable ability of heterocyclic nuclei to serve
both as biomimetics and reactive pharmacophors has largely contributed to their unique
value as traditional key elements of numerous drugs for example, the antibiotic penicillin
and streptomycin, the sedative Phenobarbital, and the nonnutritive sweetener saccharin
all have heterocyclic rings. Many natural pigments such as indigo, hemoglobin and
thelocyanin are heterocycles.
Heterocyclic compounds have great biological significance because:
  a. They have a specific chemical reactivity.
  b. They resemble essential metabolism and can also provide false synthons in
biosynthetic process.
  c. They fit receptors and block their normal working.
  d. They provide convenient building blockers to which biologically active substituents
can be attached.
AIMS AND OBJECTIVES:
The current interest in the creation of large searchable libraries of organic
compounds has captured an imagination of organic chemist and the drug discovery
community, considering the necessity for new and novel chemical inhibitors of biological
functions. We have planned to introduce chemical diversity in the molecular frame work
of some heterocyclic compounds, in order to synthesize pharmacologically interesting
heterocyclic compounds.
Synthesis, Characterisation and....
15
During the course of our research work, looking to the application of heterocyclic
compounds, several entities have been designed, generated for their pharmacological
profile against several strains of bacteria and fungi and characterized using spectral studies.
Aims and objectives of the present investigation are as under.
1. To generate several derivatives like mannich bases, pyrazolones, oxadiazoles,
imidazolinones, cyanopyridines, isoxazoles, azetidinones, thiazolidinones bearing
imidazo[1,2-a]pyridine moiety.
2. To generate several derivatives like arylamides, 1,3,4-thiadiazoles bearing 1,2,4-
triazole moiety.
3. To characterize these products for structure elucidation using spectroscopic
technique like IR, 1H-NMR and Mass spectral studies.
4. To check the purity of all compounds using thin layer chromatography (TLC).
5. To evaluate these new product for better drug potential against different strain of
bacteria, fungi and for antimicrobial activity.
Synthesis, Characterisation and....
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INTRODUCTION
Nitrogen bridgehead-fused heterocycles containing an imidazole ring are common
structural motifs in pharmacologically important molecule, with activities spanning a diverse
range of targets.1 Aza-indolizine are of two types, imidazo[1,2-a]pyridine (I) and
imidazo[1,5-a]pyridine (II).
The aza-indolizine contains a phenyl ring fused to a imidazole ring as indicated in
the structure, hence it is also known as imidazo[1,2-a]pyridine.2 Several procedure for
their synthesis have been extensively studied. Such studies have been stimulated by various
promising applications, especially in the case of bridgehead nitrogen containing fused
heterocyclic entities.
The constitution of imidazo[1,2-a]pyridine was reviewed by Kickhoffen3 in 1955
and then W. L. Mosby4 in 1961. Imidazo[1,2-a]pyridine derivatives are not only known
for their pharmacological applications but also used in disperse dyes.5
SYNTHETIC ASPECT
The following classical methods have been reported in the literature for the
synthesis of imidazo[1,2-a]pyridines.
  (i). Chichibabin6 has synthesized imidazo[1,2-a]pyridine from 2-aminopyridine
and chloro acetaldehyde in presence of  sodium bicarbonate.
  (ii). Reaction of 2-chloropyridine with 1,2,3-triazoles and subsequent elimination
of nitrogens give imidazo[1,2-a]pyridine.7
  (iii). Paudler et al.8 have synthesized 5-amino-3-formyl imidazo[1,2-a]pyridine
from acid catalyzed hydrolysis of 1,4-diazacycl[3,2,2]azine.
N
N
( I ) ( II )
1
2
3
4
5
6
7
8
9
N
N
1 2
3
45
6
7
8
9
a
bb
c c
a
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  (iv). H. Galons et al.9 have synthesized imidazo[1,2-a]pyridine by Cyclizations of 1-
(2-alkynyl)-2-aminomethylimidazoles, which are obtained from substituted
imidazoles via six steps.
  (v). Imidazo[1,2-a]pyridine nucleus can be also synthesized by the reaction of  α-
ketohydrazidoyl halide with heterocyclic amines.10
  (vi). Groziak et al.11 have synthesized imidazo[1,2-a]pyridine by the condensation of
2-aminopyridine with glyoxal trimer dehydrate in aqueous NaHSO3.
  (vii). Tsai et al.12 have prepared 3-amino imidazo[1,2-a]pyridine derivatives by a
three component condensation reaction between 2-aminopyridine, aldehyde
and an isonitrile in the presence of scandium triflate as a catalyst.
  (viii). H. J. Knolker et al.13 have prepared substituted imidazo[1,2-a]pyridine
derivatives by reaction of arylacetyl imidazoles with acetylenedicarbylic ester.
Shawali et al.14 have synthesized imidazo[1,2-a]pyridine nucleus by the reaction
of α-ketohydroximoylchloride with 2-aminopyridine.
N
N
R1
R
N NH2
N
N
O
N NH2
N NH2 N Cl
N
N
R1
R
C
C
R2
N
O
Cl
O
COOR
COOR
O
O
O
O
OH
OH
OH
OH
(iii)
(v)
(vi)
(iv)
(i) (ii)
R2
2
R2
R2
N
N
N
H
N NN
N Cl
CH3
O
Br
N
NHR
R1
CHOR
N+
C-
H3O
+
(vii)
(viii)
R2
R2
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Yong Sook Lee and Kee-Jung Lee15 have been Synthesized imidazo[1,2-a]pyridine
deivatives from 2-Amino-3-chloro-1,4-naphthoquinone and Pyridine Derivatives via
one-pot synthesis.
Shujiang Tu and co-workers16  have treated 4-(arylmethylene)-2-phenyloxazol-
5(4H)-ones with pyridine-2-amine uner microwave irradiation (MW) to afford a series
of 3-(arylmethyl)-3-(benzoylamino)imidazo[1,2-a]pyridin-2(3H)-ones.
Shankarappa A. Biradar and co worker17 have found synthesis of 6-bromo-2-
(3,4-dichlorophenyl)imidazo[1,2-a]pyridine, using microwave irradiation. It is a simple
method to prepare imidazo-pyridine.
O
O
Cl
NH2
O
O
NH2
N+
R
O
O
N
N R
NBS
N R
N
NH
O
O NH2
Bn
N
NH
O
O NH
Bn
Br
Br
N
NH
O
O
Bn
N
N
R
NBS
N R
O
N
O
Ar
N
NH2 N
N
O
NH
ArO+
MW
N NH2
Br
N
N
Cl
Cl
Br
Cl
Cl
O
Br
Microwave
DMF+
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Amanda L. Rousseau et al.18 have synthesized imidazo[1,2-a]pyridine nucleus
by the novel use of ZnCl2 to catalyze the one-pot synthesis using microwave irradiation.
Imidazo[1,2-a]pyriridine were synthesized by the reaction between 5-bromo-2-
aminopyridine and 2-bromo-1-(3,4-dichlorophenyl)ethanone using different method.19-22
Alan R. Katritzky and co-workers23 were synthesized 3-Substituted imidazo[1,2-a]pyridine
regiospecifically in one pot synthesis by reaction of 2-aminopyridines with 1,2-
bis(benzotriazolyl)-1,2-(dialkylamino)-ethanes.
MECHANISM
The majority of  imidazo[1,2-a]pyridine have been synthesized by the reaction of
2-aminopyridine with an α-halocarbonyl compound which form oniumhalide (III) which
is further cyclized at room tempeture to gives imidazo[1,2-a]pyridine.
N NH2
N+
N
H
N O
N
O
+
N
O
N
O
Bt
Bt Bt
Bt
N+
N
H
N
O
N
N
N
O
-BtH
-BtH
Bt : Benzotriazolyl
N
NH2
R4
R3
R2
R1
X
R5 R6
O
N+
NH2
R4
R3
R2
R1 R5
R6
O
N
N
R4
R3
R2
R1
R6
R5
X
+
(III)
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THERAPEUTIC IMPORTANCE
Imidazo[1,2-a]pyridines are potential bioactive agents due to their wide spectrum
of therapeutic importance. A large number of substituted imidazo[1,2-a]pyridine
derivatives have been synthesized and tested for various biological activities such as,
01. Antiulcer24-25
02. Antibacterials26-27
03. Antifungal agents28
04. Calcium channel blockers29
05. Harbicidal30
06. Cyclin-dependent kinases (CDK) inhibitors31
07. GABAA receptor modulator
32
08. Anti-inflammatory33
09. Antiherpetic activity34,35
10. Anticytomegalo-zoster and antivaricella-zoster virus36-38
11. β-Amyloid formation inhibitors39
12. Cardiotonic agents40
13. Anthelmintic41
14. Gastric antisecretory42-43
Several imidazo[1,2-a]pyridines already in market include Alpidem44 which has
nonsedative anxiolytic properties and Zolpidem45 which is a hypnotic drug. Both
Alpidem and Zolpidem have higher affinity for benzodiazepine-1 and benzodiazepine-
2 receptors.46 Zolimidine47 is a antiulcer drug and the PDE-3 inhibitor Olprinone.48
N
N
Cl
Cl
O
N
CH3
CH3
N
N
CH3
CH3
O
N
CH3
CH3
Alpidem Zolpidem
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S. Kristjan, Gudmundsson and A. Brian Johns 49 and A. Chaouni-Bendallah et al.50
worked on synthesis of a novel 2,3,8-substituted imidazo[1,2-a]pyridine (IV) with
potent activity against herpes simplex viruses.
James J. Kaminski and co-workers51 have investegated the 2-(cynomethyl)-3-
methyl-8-(phenylmethoxy)imidazo[1,2-a]pyridine (V) as an antiulcer agent. I. Aramori
et al.52 have been synthesized highly potent and selective non-peptide bradykinin receptor
antagonist (VI).
N
N
S
O
CH3
O
N
N
N
H
O CH3
NC
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Zhonghui Lu, Gregory R. Ott. and co-worker53-54 have been discovered a series
of 2,3-substituted imidazo[1,2-a] pyridine derivatives like substituted (3S,4S)pyrrolidine-
N-hydroxy-3-carboxamide (VII) and (3R,4R)pyran-N-hydroxy-3-carboxamide (VIII)
have potent selectivity against tumor necrosis factor-α converting enzym(TACE).
Kristian S. Gudmundsson55 have reported the synthesis and antiviral activities of
newer Erythrofuranosyl imidazo[1,2-a]pyridine C-nucleosides.When they screened their
compounds for anti-HCMV and HSV-1 activity, the α-D anomer of 2,6,7-trichloro-3-
(erythrofuranosyl)imidazo[1,2-a]pyridine (IX) proved to be the most active member of
the series.
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Alain Gueiffer and co worker56  were prepared a series of novel imidazopyridine
and screened at selected dopamine, serotinin and adrenergic receptor subtypes.they
showd 2-mothoxyphenyl substituted 2-piperazinylmethylimidazopyridine (X) displayed
substantial agonist efficacy in mitogenesis experiments.
The imidazo[1,2-a]pyridine units appear as important building blocks in both
natural and synthetic bioactive compounds.57-59 John R. Ferguson et al.60 have synthesized
glucuronide conjugeted imidazo[1,2-a]pyridine derivatives (XI), a new potassium-
competetitive acid blocker (P-CAB) for the treatment of acid-related diseases.
Mohamed A. Ismail61 have synthesized some novel imidazo[1,2-a]pyridine like
bis-benzamidinoimidazo[1,2-a]pyridine (XII) and 5,6,7,8-tetrahydo imidazo[1,2-a]pyridine
(XIII) analogues which are potential for this series and their evaluate antiprotozoal activity.
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Alain Gueiffier and co-worker62 have reported the synthesis and the antiviral
activities of C-3 acyclic nucleoside analogues of imidazo[1,2-a]pyridine and pyrimidine.
In contrast, some derivatives in the imidazo[1,2-a]pyrimidine series were devoid of
antiviral activity. Some compounds showed a marked activity against cytomegalovirus
and  varicella-zoster virus. Kerry jenkins and co-workers63 have optimised the SAR of
imidazo[1,2-a]pyridine derivatives like pyrimidin-2-amine (XIV) and pyridin-2-amine
(XV) having potent IRAK-4 inhibition property.
Kyle A. Emmitte, Brian J. Wilson, et al.64 have been discovered imidazo[1,2-a]
pyridine like (XVI) and (XVII). Both compounds are inhibitors of insulin like growth
factor-1 reseptor. Recently Renata B. Lecerda et al.65 discovered new N-phenyl-2-
(pyridin-2-yl)imidazo[1,2-a]pyridin-3-amine as a novel in vivo antinociceptive and
anti-inflammatory symbiotic prototype that act as selective PGHS-2 inhibitor and p38
MAPK pathway modulator.
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Thus the important role displayed by imidazo[1,2-a]pyridine and its derivatives
for various therapeutic and biological activities prompted us to synthesize some Chalcones,
Cyanopyridines, Thiopyrimidines, Mannich bases, Isoxazoles, Schiff ’s bases,
Imidazolinones, Azitidinones, Thaizolidinones, Oxadiazoles, Triazoles, derivatives bearing
imidazo[1,2-a]pyridine moiety in order to achive compounds having better biological
activities as described in the following parts.
STUDIES ON IMIDAZO[1,2-a]PYRIDINE DERIVATIVES
PART-I :   STUDIES ON MANNICH BASES
PART-II :   STUDIES ON 1,3,4-OXADIAZOLES
PART-III :   STUDIES ON PYRAZOLONES
PART-IV :   STUDIES ON 1,2,4-TRIAZOLES
PART-V :   STUDIES ON IMIDAZOLINONES
PART-VI :   STUDIES ON ISOXAZOLES
PART-VII :   STUDIES ON CYNOPYRIDINES
PART-VIII :   STUDIES ON THIOPYRIMIDINES
PART-IX :   STUDIES ON SCHIFF’S BASES
PART-X :   STUDIES ON THIAZOLIDINONES
PART-XI :   STUDIES ON 2-AZETIDINONES
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INTRODUCTION
Mannich bases containing bridged N-atom exhibit pronounced biological
activities. The study of mannich reaction has attracted a great deal of attention to the
chemists because it plays a vital role owing to their wide range of industrial applications.
Mannich bases are also employed as intermediate in chemical synthesis.1-3
Mannich bases possess diverse pharmacological action like antibacterial,
antimalarial and analgesic. Several therapeutic important molecules prepared through
mannich reactions have received more attention in recent years.4-6 Mannich bases have
also gained importance because of their technological applications in polymer chemistry,7
especially as paints and surface active agents and exhibits complexation characteristic
with many transition metal ions.
Over the years there has been much controversy about the mechanism of the
mannich reaction. Studies of the reaction kinetics have led to the following mechanistic
proposals.
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SYNTHETIC ASPECT
Different methods have been cited in literature to synthesize mannich bases by
several workers.8,9 Some other methods using various interesting substrates are
1. Chris tos  A.  Kontogiorgis  e t  a l . 10 have synthesized mannich bases of
coumarin.
2. Venkatesha Prabhu G. et al.11 have synthesized aminobenzylated mannich bases
by the condensation reaction between heterocyclic secondary amines and
benzaldehyde.
3. Pandeya and  Sriram D. Dave12  have  synthesized  mannich  bases  by  the
condensation of the acidic group of isatin with formaldehyde and secondary
amines.
4. Efficient and expeditious microwave assisted-synthesis of novel bis-Mannich bases
of 2-naphthols derived from aromatic aldehydes and diamines namely piperazine
and N,N’-dialkylethylenediamines under solvent-free conditions by Po-Jung J.
Huang and co workers.13
5. Seshaiah Krishnan et. al.14 have synthesized mannich bases from the schiff base
of isatin in presence of formaldehyde and diphenyl amine.
6. Yung-son Hon  et. al.15 have prepared mannich bases from the reaction of phenolic
 compounds with a preheated mixture of dibromomethane and diethylamine.
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7. Bela Pete and Csaba Szantay16 studied reductive amination of the formyl, and
simultaneous reduction of the nitro group in a single step instead of the usual
alkylation followed by reduction.
BIOLOGICAL IMPORTANCE
Mannich bases have gained importance due to their application in pharmaceutical
chemistry. They have been encountered with
1. antibacterial17
2. anticancer18
3. analgesic19
4. anticonvulsant20
5. antimalarial21
6. antiviral22
7. CNS depressant activities23
8. Antiinflammatory24-25
9. Cytotoxic and anticancer26
10. Tranquilizing27
11. Antifungal28
12. Antipsychotic29
13. Antitumor30
14. Antileishmanial31
B.Shivarama Holla et al.32 have prepared 1,2,4-triazole-3-thione mannich bases
(Ia) and tested for anthelmintic activity and  N-methylpiperazine derivatives (Ib) were
tested for antibacterial and antifungal activity.
NO2
R1R2NH
Pd/C, H2, Dioxan, rt
CHO
NH2
NR1R2
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Gul H. I. et al.33 have reported antifungal activity of some mono, bis and
quaternary mannich bases derived from acetophenone. Li Y, Yang Z. S. et al.34 have
synthesized some mannich base derivatives (II) and reported their antimalarial activity.
T. Lorand and B. Kocsis35 have synthesized  mannich ketones of 1-indanones,
1-tetralones and reported their antibacterial activity. H.M.Hassan and S. A. M. Shedid36
have synthesized mannich bases containing 1,8-napthpyridine moiety as an antimicrobial
agents .
Ojanen T. et al.37 have documented antifungal activity of bis mannich bases derived
of acetophenones. M. Gul et. al.38 have synthesized some mono mannich bases and
evaluate their anticonvulsant activity. Shingare M. S. et al.39 have described the synthesis
and the antiviral activity of 2-thionebenzimidazole mannich bases (III).
V. Ravichandran et al.40 have prepared a series of new indol-2-one mannich base
(IV) and all the synthesized compounds were tested for their antibacterial activities against
Gram +ve and Gram –ve bacteria, and antifungal activities.
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A new series of 4-aminoquinoline Mannich base(V) derivatives have been
synthesized by Kaylene J. Raynes and co-werker41 in which the propyl and isopropyl
alkyl derivatives were found to be the most active, consequently these derivatives were
in vivo tested against a nonsensitive strain of Plasmodium berghi. Series of substituted
cyclohexyl mannich base (VI) and (VII) have been prepared by Tamas Lorand et al.42
they proved that an increased preference for the trans isomer was attributed to a weak
intramolecular hydrogen bond between the OH and the N, as demonstrated by X-ray
crystallography. After reduction, the antibacterial activity of the product decreased
dramatically (“S-form”) but it was not completely abolished in deep rough mutants of
Gram-negative bacteria.
Olcay Bekircan and Hakan Bektas43 synthesized mannich bases (VIII) containing
both 1,2,4-triazole and isatin rings. Meric Koksal and Hakki Erdogan44 prepared novel
OR N
O
OR N
O
( VI ) ( VII )
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Mannich bases of 5-nitro-3-substituted piperazinomethyl-2-benzoxazolinones (IX) and
studied their analgesic and anti-inflammatory activity.
Andrea Noren-Muller et. al.45 have synthesized novel mannich bases of hexahydro
furo[3,2-b]furan (X) having protein phosphatase inhibitor activity. Paul M. O’Neill and
co-worker46 have been synthesized new series of 7-chloroquinoline mannich bases (XI)
and studied their preclinical pharmacology and antimalarial activity.
A number of novel mannich bases of substituted chromeno[7,8-b][1,4]oxazine-
2,9-dione (XII) were synthesized for the purpose of pharmacological evaluation by
Z. M. Nofal et al.47 Compounds tested for anti-tumor activity in vitro on Ehrlich ascites
carcinoma cell.
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In view of the importance of mannich bases as versatile synthetic intermediates
and the availability of scanty literature on therapeutic properties, we have undertaken
the preparation of mannich bases in following sections.
SECTION-I: SYNTHESIS AND BIOLOGICAL SCREENING OF N-{[7-
METHYL-2-(p-METHYLPHENYL)IMIDAZO[1,2-a ]
PYRIDIN-3-YL]METHYL}-N,N-DIARYL/ALKYL AMINES.
O
NH
O O
CH3
Br
R O
R
a
b
c
N(C2H5)2
N
N N
( XII )
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SECTION-I
SYNTHESIS AND BIOLOGICAL EVALUATION OF N-{[7-METHYL-2-(p-METHYL-
PHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]METHYL}-N,N-DIARYL/ALKYL
AMINES.
In view of getting better therapeutic agent and considering the association of
various biological activity with imidazo[1,2-a]pyridine  nucleus, the preparation of
mannich bases of Type - I have been undertaken from 2-(p-methylphenyl)-7-methyl-
imidazo[1,2-a]pyridine  with primary /secondary amines and formaldehyde in methanol.
The constitution of the synthesized compounds have been characterized by
elemental analysis, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all the compounds have been checked by
thin layer chromatography (TLC).
All the compounds have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards fungus strains at a different concentration. The biological
activity of the synthesized compounds were compared with standard drugs, as shown in
Table-2.
Type-I
N
NCH3
CH3
N
R'
R
R=Alkyl / Aryl
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF N-{[7-METHYL-2-(p-
METHYLPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]METHYL}-N,N-DIARYL/
ALKYL AMINES
[A] Preparation of 2-chloro-1-(p-methylphenyl)ethanone
Chloroacetyl Chloride(1.13 gm, 0.01m) was added to a solution of  toluene(7 ml.
0.07m) and anhydrus AlCl3(3.0 gm, 0.02m) at 0°C. The reaction mixture was stirred re
at 20°C for about 8 hrs. The product was seperated from the reaction mixture by addition
of con. HCl. The product was then extracted with ethtyl acetate and the solid was wash
with n-pentane. Yield 73% (1.92 gm), m.p. 98°C. Calculated(%) for C9H9ClO(189.6);
C: 64.11, H: 5.38, Found(%) C: 64.03, H: 5.24.
TLC solvent system : Ethyl acetate : Hexane (2 : 8)
[B] Preparation of 2-(p-methylphenyl)-7-methylimidazo[1,2-a]pyridine
A mixture of 2-chloro-1-(p-methylphenyl)ethanone (1.89 gm, 0.01m) and
2-amino-4-methyl pyridine(1.08 gm, 0.01m) in DMF(10ml.) were refluxed at 140°C
for about 6 hrs. Finally the solid product was isolated and purified by methanol. Yield
75% (1.81 gm), m.p. 188°C. Calculated(%) for C14H11N2Cl(170.4); C: 69.28, H: 4.57,
N:11.54, Found(%) C: 69.39, H, 4.65, N: 11.62.
 TLC solvent system : Ethyl acetate : Hexane (4 : 6).
[C] Preparation of 2-(p-methylphenyl)-3-(morpholinylmethyl)-7-methyl-
imidazo[1,2-a]pyridine
A solution contaning 2-(p-methylphenyl)-7-methylimidazo[1,2-a]pyridine (1.70g, 0.01
mol), formaldehyde (0.3g, 0.01 mol) and morpholine (0.88gm, 0.01 mol) in methanol (10 ml)
was refluxed for 8 hrs. and left overnight. The content were poured on to crushed ice.
The product was isolated, dried and crystallised from hexane. Yield 60%(1.47 gm),
m.p. 140°C. Calculated(%) for C20H23N3O(321.4); C: 74.74, H: 7.21, N: 13.07,
Found(%) C: 74.50, H: 7.02, N: 12.89.
TLC solvent system : Ethyl acetate : Hexane (8 : 2).
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Similarly other amines were condensed with 2-(p-methylphenyl)-7-methyl-imidazo[1,2-
a] pyridine. The physical constants are recorded in Table-1.
[D] Biological screening of N-{[2-(p-methylphenyl)-7-methyl-imidazo[1,2-a]
pyridin-3-yl]methyl}-N,N-diaryl/alkylamines
All the products have been evaluated for antimicrobial activity as described under.
(a) Antimicrobial activity:-
The antimicrobial activity was done by “Broth Dilution Method” which has
been described as under.
(I)  Minimal Bactericidal Concentration [MBC]:-
The purified products were screened for their antimicrobial activity. The serial
dilutions were prepared in primary and secondary screening. The control tube containing
no antibiotic was immediately sub cultured of S.Aureus, E.Coli, S.Pyogenes &
P.aeruginosa by spreading a loopful evenly over a quarter pf plate of medium suitable
for the test organism and put for incubation at 37 oC overnight. The tubes were then
incubated overnight. The MBC of the control organism is read to check the accuracy of
the drug concentration. The lowest concentration inhibiting growth of the organism is
recorded as the MBC. All the tubes not showing visible growth are sub cultured and
incubated overnight at 37 oC. The amount of growth from the control tube before
incubation which represents the original inoculum is compared. Subcultures may showed
similar number of colonies indicating bacteriostatis, a reduced number of colonies
indicating a partial or slow bactericidal activity & no growth, if the whole inoculum was
been killed.
(II) Methods used for primary and secondary screening:-
Each synthesized drug was diluted obtaining 2000 microgram /ml concentration,
as a stock solution.
Primary screen:   In primary screening 500 micro/ml, 250 micro/ml, and
125 micro/ml, concentrations of the synthesized drugs were taken. The
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active synthesized drugs found in this primary screening were further tested
in a second set of dilution against all microorganisms.
Secondary screen: The drugs found active in primary screening were similarly
diluted to obtain 100 micro/ml, 50 micro/ml, 25 micro/ml, 12.5 micro/ml,
6.250 micro/ml, 3.125 micro/ml and 1.5625 micro/ml Concentrations.
Reading Result:-The highest dilution showing at least 99 % inhibition
zone is taken as MIC.The result of this is much affected by the size of the
inoculum. The test mixture should contain 108 organism /ml.
(III)  The Standard Drugs:-
The standard drugs used in the present study  for evaluating antimicrobial
activity are Ampicillin, Chloramphenicol, Ciprofloxacin, & Norfloxacin.
The Minimal Bactericidal Concentration were measured in Μicrogram/ml. and
recorded in Table-2.
(b) Antifungal activity:-
The antifungal activity was determined by “Broth Dilution Method”. C. Albicans,
A. Niger & A. Clavatus were employed for anti fungal activity. Greseofulvin & Nystatin
were used as the standard drug for measuring Minimal Fungicidal Concentration
(MFC).The Minimal Inhibition Concentration are recorded in Table-2.
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1a C4H8O- C20H23N3O 321.4 140 60 13.07 12.89 0.45 S1
1b C4H8- C20H23N3 305.4 123 63 13.76 13.40 0.55 S2
1c C5H11N- C21H26N4 334.4 136 65 16.75 16.13 0.40 S1
1d C6H13N- C22H28N4 386.8 146 64 16.08 15.88 0.60 S1
1e C5H10- C21H25N3 319.4 168 65 13.15 12.89 0.45 S2
1f C7H14- C23H29N3 347.4 109 62 12.09 11.86 0.40 S2
1g C4H11N- C20H24N4 320.4 131 61 17.48 17.16 0.50 S2
1h C9H19N- C25H34N4 390.5 143 57 14.35 14.19 0.30 S2
1i C2H6- C18H21N3 279.3 112 65 15.04 14.86 0.55 S1
1j C4H10- C20H25N3 307.4 121 66 13.67 13.39 0.50 S1
S1 Hexane : Ethyl acetate (2 : 8),   S2 Chlorofom : Methanol (8 :2)
Sr.     R         Molecular      Molecular    M.P. Yield % of Nitrogen    Rf Solvent
No          Formula       Weight      oC  %    Calcd.  Found   Value System
1      2              3           4       5   6       7     8      9        10
TABLE:-1 PHYSICAL CONSTANTS OF N-{[7-METHYL-2-(p-METHYLPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]METHYL}-
N,N-DIARYL/ALKYL AMINES
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IR SPECTRAL STUDIES OF 2-(P-METHYLPHENYL)-3-(MORPHOLINYL
-METHYL)-7-METHYL-IMIDAZO[1,2-A]PYRIDINE
 Observed
Alkane   C-H str. (asym.) 2958 2975-2950 48
-CH2   C-H str. (sym.) 2860 2880-2860  ,,
  C-H i.p.def. (asym.) 1452 1470-1435  ,,
  C-H o.o.p.def. 1384 1395-1370 ,,
Aromatic   C-H  str. 3060 3090-3030 49
  C=C str. 1581 1540-1480  ,,
  C-H i.p.def. 1126 1125-1000 ,,
  C-H o.o.p. (def) 833 835-810  ,,
Imidazo[1,2-a]   C=N str. 1598 1612-1593 48
pyridine   C-N str. 1176 1220-1020  ,,
  C=C str. 1498 1540-1480  ,,
Ether   C-O-C str. 1249 1260-1200 49
Type     Ref.
        Reported
Frequency in cm-1
 Vibration
Instrument  : SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range
: 4000-400 cm-1 (KBr disc.)
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cm
 534.2
 607.5
 688.5
 750.3
 833.2
 866.0
 958.6
1024.1
1062.7
1126.4
1176.5
1215.1
1249.8
1384.8
1407.9
1452.3
1498.6
1581.5
1598.9
2860.2
2958.6
3060.8
3406.1
Mode
N
N
CH3
CH3
N
O
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NMR SPECTRAL STUDIES OF 2-(P-METHYLPHENYL)-3-(MORPHOLINYL-
METHYL)-7-METHYL-IMIDAZO[1,2-A]PYRIDINE
Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER
Spectrometer (300MHz)
a
b
c
ed
d' e'
N
N
CH3
CH3
N
O
g'
h'
g
h
f
   1. 2.38 3H singlet Ar-CH3 -
   2. 2.40 3H singlet Py-CH3 -
   3. 2.47 4H dd Mor-H(gg’) -
   4. 3.66 4H dd Mor-H(hh’) -
   5. 3.93 2H singlet C-H(f) -
   6. 7.05 1H dd Ar-H(b) -
   7. 7.25 2H doublet Ar-H(ee’) J=6
   8. 7.53 1H doublet Ar-H(c) J=9
   9. 7.68 2H doublet Ar-H(dd’) J=6
  10. 8.15 1H singlet Ar-H(a) -
Signal
  No.
Signal Position
    (δppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
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MASS SPECTRAL STUDIES OF 2-(p-METHYLPHENYL)-3-(MORPHOLINYLMETHYL)-7-METHYLIMIDAZO[1,2-a]PYRIDINE
N
N
CH
3
C
H
3
N
O
m
/z
 =
 321
.4
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CODE NO. E. COLI P.AERUGINOSA S. AUREUS S.PYOGENUS
MTCC 443 MTCC 1688 MTCC 96 MTCC 442
1 1a 250 62.5 500 1000
2 1b 100 100 100 1000
3 1c 50 250 500 500
4 1d 500 500 250 500
5 1e 250 500 200 1000
6 1f 250 250 100 250
7 1g 200 100 500 250
8 1h 100 200 500 500
9 1i 500 200 250 500
10 1j 200 500 100 1000
11 AMPICILLIN 100 100 250 100
12 CHLORAMPHENICOL 50 50 50 50
13 CIPROFLOXACIN 25 25 50 50
14 NORFLOXACIN 10 10 10 10
ANTIBACTERIAL ACTIVITY TABLE
MINIMAL BACTERICIDAL CONCENTRATION
SR. 
NO.
CODE NO. C. ALBICANS A. NIGER A. CLAVATUS
MTCC 227 MTCC 282 MTCC 1323
1 1a 200 >1000 >1000
2 1b 100 >1000 >1000
3 1c 500 >1000 >1000
4 1d 200 500 500
5 1e 250 200 250
6 1f 100 500 500
7 1g 100 1000 >1000
8 1h 200 500 500
9 1i 500 500 250
10 1j 500 >1000 >1000
11 NYSTATIN 100 100 100
12 GRESEOFULVIN 500 100 100
SR. 
NO.
ANTIFUNGAL ACTIVITY TABLE
MINIMAL FUNGICIDAL CONCENTRATION
TABLE: 2 BIOLOGICAL EVALUATION OF N-{[7-METHYL-2-(p-METHYL-
PHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]METHYL}-N,N-DIARYL/
ALKYL AMINES.
(µg/ml)
(µg/ml)
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INTRODUCTION
1,3,4-Oxadiazole is a thermally stable neutral aromatic molecule1 which has been
known for about 80 years. It is only in the last decade that investigations in this field
have been intensified because of large number of application of 1,3,4-oxadiazoles in the
most diverse areas viz drug synthesis, dye stuff industry, heat resistant materials, heat
resistant polymers and scintillators. Reviews of the relevant literature prior to 1965 are
available.2
SYNTHETIC ASPECT
1,3,4-oxadiazoles are best obtained by synthesis from acyclic precursors. Such
reactions are ‘one-bond’ or ‘two-bond’ cyclisation. Different methods for the synthesis
that have cited in literature.3-10
1. Some acetyl oxadiazoline derivatives have been prepared by L. Kimberley et al.11
2. 1,3,4-oxadiazoles were efficiently synthesized from the cyclization–oxidation
reaction of acyl hydrazones by Minoo Dabiri et al.12
3. Eugene L. Piatnitski Chekler and co-workers13 have synthesized oxadiazoles
by reaction of carboxylic acids with thiosemicarbazides.
4. Cristian Dobrota et al.14 have prepared 1,3,4-oxadiazoles by Dess–Martin reagent.
R1
NHNH2
O
+ R2 CHO
O
NN
R1 R2CAN 
reflux, CH2Cl2 (dry)
11 Hrs
+
O
NN
R1 NH
R2
EDCL or EDCL-resin
MDC or DMF, 25oC
R1
COOH
NH
NH
R2
NH2
S
O
NN
R1 R2DMP (1)
r.t.
R1 N
O
N R2
H H
I
O
O
OAcAcO
OAc
(1)
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5. Dong Han et al.15 synthesized a series of novel fructose-based 3-acetyl-5-alkyl-
2,3-dihydro-1,3,4-oxadiazole derivatives and studies of the reaction mechanism.
6. Sara Cesarini and co-workers16 generated 1,3,4-oxadiazoles using TFAA as a
dehydration agent.
THERAPEUTIC IMPORTANCE
2,5-Disubstituted 1,3,4-oxadiazole derivatives have been tested for various
pharmacological properties viz.
1. Anticonvulsant17
6. MAO inhibitor18
7. Antihypertensive19
8. Herbicidal20-21
9. Antiviral and Anticancer22-23
10. Analgesic24
11. Antiinflammatory25
12. Cardiovascular26
13. Antibacterial27
14. Antifungal28
The 1,3,4-oxadiazoles derivatives have been reported as novel PMO inhibitor,29
microbicides,30 anxiolytic & antiserotonin,31 antagonist,32 and pesticides.33 Mallur et al.34
have reported antimicrobial activity of oxadiazole derivatives, while Hewawasam et al.35
have showed calcium activated potassium channel opener activity. Azziza et al.36 have
documented antibacterial activity of oxadiazoles.
MW
160oC, 30 mins
O O
O
N
NHCOR
O
O
O O
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O O N
N
Ac
R
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Mohamed Ashraf Ali and Mohammad Shaharyar37 have synthesized a series of
oxadiazole-mannich bases(I) as antimycobacterial agent.
Ki Dong Koo et al.38 have synthesized a novel series of DPPIV inhibitors with
1,3,4-oxadiazolyl ketone derivatives(II) and its structure activity relationships were discussed.
Several novel 1-substituted-phenyl-b-carbolines bearing the 2-substituted-1,3,4-oxadiazol
-5-yl groups at C-3(III) were synthesized and evaluated for their in vitro anticancer
activity by Anelise S. Nazari Formagio et al.39
Brian A. Johns et al.40 have reported the use of  1,3,4-oxadiazole in combination
with 8-hydroxy-1,6-naphthyridine ring system like (IV) which show antiviral activity
through inhibition of viral DNA integration. Suk Ho Lee and co-workers41 have
prepared novel oxadiazole-diarylpyrazole-4-carboxamide series like (V) of small
molecule that show potency comparable to that of known CB1 antagonists. Gell et al.42
have reported oxadiazoles as P38 kinase inhibitor. Grover et al.43 have investigated 1,3,4-
oxadiazoles as antifungal and antibacterial agents. Li Xinghai and co-worker44 have
synthesised oxadiazoles and reported them as novel insecticidal agents.
S
O
O
NH NH
R2
R2
N
N
O
NN
OR1
R1
S
S
( I )
N
N
N
OO
O
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N
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R
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( IV )
N
N
N N
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F
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NHAc
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N N
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ONH
Br
Cl
Cl
CH3
CH3
CH3
( V )
Tram Huynh et al.45 designed, synthesized and identified them as selective pyrazole
based inhibitor(VI) of co-activator associated Arginine Methyltransferase through SAR
study. Marietta Toth and co-workers46 have synthesized a series of D-glucopyranosyl-2-
substituted-1,3,4-oxadiazoles like (VII). The 1,3,4-oxadiazoles were practically inefficient
as inhibitors glycogen phosphorylase.
( VI ) ( VII )
N
N O
N N
S
N
F3C
NH
O
NH2
O
OH
OH
OH
OH N
O
N
V. Padmavathi et al.47 have prepared a new class of heterocycles pyrrolyl
oxadiazoles(VIII) from arylsulfonylethenesulfonylacetic acid methyl ester and tested for
their antimicrobial and cytotoxic activities. Synthesis and biological evaluation of
various aroylpropionic acid derivatives containing 1,3,4-oxadiazole nucleus were reported
by Mymoona Akhter et al.48 All the analogues of (IX) were tested in vivo for their
anti-inflammatory activity.
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( VII ) ( IX )
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Maria Koufaki et al.49 have designed and synthesized new analogues containing
1,2-dithiolane-3-alkyl and protected or free catechol moieties connected through
heteroaromatic rings such as 1,3,4-oxadiazole like (X) having strong neuroprotective
activity.
In view of therapeutic activities of 1,3,4-oxadiazoles, it was contemplated to
synthesise some new 1,3,4-oxadiazoles in search of agents possessing higher biological
activity with least side effect, which have been described as under.
SECTION-I: SYNTHESIS AND BIOLOGICAL EVALUATION OF 7-
METHYL-2-(p-METHYLPHENYL)IMIDAZO[1,2-a ]
PYRIDINE-3-(5-ARYL-1,3,4-OXADIAZOL-2-YL).
[ ]n O
NN S
S
( X )
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 7-METHYL-2-(p-METHYL-
PHENYL)IMIDAZO[1,2-a]PYRIDINE-3-(5-ARYL-1,3,4-OXADIAZOL-2-YL).
Many oxadiazole derivatives are associated with diversified biological properties.
Hence, it would be interest that oxadiazole ring is coupled to imidazo[1,2-a]pyridine
moiety, the resulting compounds may possess significant biological potency. Hence the
synthesis of 1,3,4-oxadiazol (Type - II) have been undertaken by cyclo condensation of
different aromatic acid with 2-(4-methylphenyl)-7-methyl-imidazo[1,2-a]pyridine-3-
carbohydrazide in presence of phosphorous oxychloride as shown in reaction scheme.
The constitution of the synthesized compounds have been characterized by
elemental analysis, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all the compounds have been checked by
thin layer chromatography (TLC).
All the compounds have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards fungus strains at a different concentration. The biological
activity of the synthesized compounds were compared with standard drugs, as shown in
Table-4.
Type-II
N
NCH3
CH3
N
O
N
R
R=Aryl
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REACTION SCHEME
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 7-METHYL-2-(p-METHYL-
PHENYL)IMIDAZO[1,2-a]PYRIDINE-3-(5-ARYL-1,3,4-OXADIAZOL-2-YL)
[A] Preparation of 2-bromo-3-(p-methylphenyl)-ethyl-3-oxopropanoate.
A solution of bromine(3.5 gm, 0.022m) in acetic acid(10ml) was added dropwise
to a solution of 3-(4-methylphenyl)-ethyl-3-oxopropanoate(2.06 gm, 0.01m) in acetic
acid(10ml). The mixture was stirred at room temperature for 24 hrs. The solvent was
removed in vacuo and the residue was pour in to crush ice by addition of 1N NaOH
solution. The compound was extracted with dichloromethane. The organic layer was
dried over Na2SO4 and the solvent was removed in vacuum to afford the oily liquid.Yield
79% (2.25 gm), b.p. 148°C. Calculated (%) of C12H13BrO3 (285.1); C: 50.55, H: 4.60,
Found (%) C: 50.28, H: 6.16.
 TLC solvent system : Ethyl acetate : Hexane (2 : 8).
[B] Preparation of 7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridine-3-
ethylcarboxylate.
A mixture of 2-amino-4-methyl pyridine (1.08 gm, 0.01m) and 2-bromo-3-
(p-methylphenyl)-ethyl-3-oxopropanoate (2.85 gm, 0.01m) in ethanol (10ml.) was
refluxed for about 8 hrs. The excess ethanol evaporated in vacuum and red oil obtained
was partitioned between ether-water, The ether was evaporated and oil was allowed to
crystallise. Yield 73% (2.14 gm), m.p. 74°C, Calculated (%) of C18H18N2O2 (294.3);
C: 73.45, H: 6.16, N: 9.52, Found (%) C: 73.20, H: 6.24, N: 9.41.
 TLC solvent system : Ethyl acetate : Hexane (3 : 7).
[C] Preparation of 7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridine-3-
carbohydrazide.
A mixture of 7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridine-3-
ethylcarboxylate(2.94 gm, 0.01m) was heated under reflux with hydrazine hydrate(1.00 gm,
0.02m) in ethanol(10 ml) for about 5 hrs. Excess ethanol evaporated in vacuum and residue
poured in to crushed ice, solide product was crystalised in ethanol. Yield 84% (2.35 gm),
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m.p. 132°C. Calculated (%) of C16H16N4O (280.3); C: 68.55, H: 5.75, N: 19.99,
Found (%) C: 68.61, H: 5.82, N: 19.87.
TLC solvent system : Ethyl acetate : Hexane (5 : 5).
[D] Preparation of 7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridine-3-(5-
aryl-1,3,4-oxadiazol-2-yl).
A mixture of 7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridine-3-carbo
hydrazide (2.80g, 0.01m) and benzoic acid (1.22g, 0.01m) in phosphorous oxychoride
(10ml) was refluxed for 6 hrs. The contents were cooled and poured on to crushed ice,
and neutralised with sodium bicaronzte solution. The product was isolated and crystallised
from ethanol. Yield 55%(2.01 gm),  m.p. 162°C. Calculated (%) of C23H18N4O (366.4)C:
75.39, H: 4.95, N: 15.11, Found (%) C: 75.24, H: 4.79, N: 15.03.
TLC solvent system : Ethyl acetate : Hexane (8 : 2).
Similarly other acids are condensed with 7-methyl-2-(p-methylphenyl)imidazo[1,2-a]
pyridine-3-carbohydrazide. The physical constants are recorded in Table-3.
[E] Biological evaluation of N-{[2-(p-methylphenyl)-7-methyl-imidazo[1,2-a]
pyridin-3-yl]methyl}-N,N-diaryl/alkylamines.
Antimicrobial and antifungal testing were carried out as described in Part-1,
Section-I(D). The Minimal Bactericidal Concentration and The Minimal Fungicidal
Concentration(MBC & MFC) of the test solution are reported in Table-4.
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2a C6H5- C23H18N4O 366.4 162 55 15.29 15.03 0.53 S1
2b 3-OCH3-C6H4- C24H20N4O2 396.4 133 61 14.13 13.89 0.57 S1
2c 2,3-(OCH3)2C6H3- C25H22N4O3 426.4 158 67 13.14 12.93 0.56 S2
2d 3,5-(NO2)2C6H3- C23H16N6O5 456.4 190 62 18.41 18.16 0.60 S2
2e 2-C5H4N- C22H17N5O 367.4 174 51 19.06 18.83 0.58 S1
2f 3-C5H4N- C22H17N5O 367.4 162 59 19.06 18.86 0.52 S1
2g 4-C5H4N- C22H17N5O 367.4 180 63 19.06 18.76 0.54 S2
2h 2,4,5-(F)3C6H2- C23H15F3N4O 420.4 148 53 13.33 13.06 0.48 S1
2i 4-Cl-2,5-(F)2-C6H2- C23H15ClF2N4O 436.8 159 69 12.83 12.48 0.50 S2
2j 3-Cl-2,4,5-(F)3-C6H- C23H14ClF3N4O 454.8 154 50 12.32 12.08 0.58 S2
S1 Hexane : Ethyl acetate (2 : 8),   S2 Chlorofom : Methanol (7 : 3)
Sr.     R    Molecular    Molecular     M.P.    Yield       % of Nitrogen     Rf            Solvent
No                      Formula           Weight           oC            %         Calcd.        Found       Value        System
1      2                         3   4                 5            6              7             8          9             10
TABLE:-3 PHYSICAL CONSTANTS OF 7-METHYL-2-(p-METHYLPHENYL)IMIDAZO[1,2-a]PYRIDINE-3-(5-ARYL-1,3,4-
OXADIAZOL-2-YL)
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IR SPECTRAL STUDIES OF 7-METHYL-2-(p-METHYLPHENYL)
IMIDAZO[1,2-a]PYRIDINE-3-(5-PHENYL-1,3,4-OXADIAZOL-2-YL)
 Observed
Alkane   C-H str. (asym.) 2960 2975-2950 50
-CH3   C-H str. (sym.) 2866 2880-2860  ,,
  C-H i.p.def. (asym.) 1460 1470-1435  ,,
  C-H o.o.p.def. 1357 1395-1370  ,,
Aromatic   C-H  str. 3030 3090-3030 51
  C=C str. 1581 1540-1480  ,,
  C-H i.p.def. 1041 1125-1000  ,,
Imidazo[1,2-a]   C=N str. 1612 1612-1593 50
pyridine   C-N str. 1180 1220-1020  ,,
  C=C str. 1496 1540-1480  ,,
Oxadiazole   C=N str. 1595 1650-1580  ”
  N-N str. 1020 1050-1010 51
  C-O-C str. 1066 1140-1070   ”
Type     Ref.
        Reported
Frequency in cm-1
 Vibration
Instrument  : SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range
: 4000-400 cm-1 (KBr disc.)
Mode
-10.0
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
110.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cm
 505.3
 594.0
 688.5
 736.8
 765.7
 821.6
 839.0
 910.3
 956.6
1020.3
1041.5
1066.6
1128.3
1180.4
1220.9
1245.91298.0
1357.8
1436.9
1460.0
1496.7
1581.5
1595.0
1612.4
2866.0
2960.5
3030.0
N
N
CH3
CH3
N
O
N
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   1. 2.31 3H singlet Ar-CH3 -
   2. 2.92 3H singlet Py-CH3 -
   3. 7.02 1H dd Ar-H(b) -
   4. 7.35 3H multiplet Ar-H -
   5. 7.47 2H doublet Ar-H(ee’) J=6
   6. 7.82 2H doublet Ar-H(dd’’) J=6
   7. 7.85 2H multiplet Ar-H -
   8. 7.87 1H doublet Ar-H(c) J=6
   9. 7.94 1H singlet Ar-H(a) -
Signal
  No.
Signal Position
    (δppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
NMR SPECTRAL STUDIES OF 7-METHYL-2-(p-METHYLPHENYL)
IMIDAZO[1,2-a]PYRIDINE-3-(5-PHENYL-1,3,4-OXADIAZOL-2-YL)
Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER
Spectrometer (300MHz)
N
N
CH3
CH3
N
O
N
a
b
c
ed
d' e'
S
yn
th
esis, C
h
aracterisation
 an
d
....
62
MASS SPECTRAL STUDIES OF 7-METHYL-2-(p-METHYLPHENYL)IMIDAZO[1,2-a]PYRIDINE-3-(5-PHENYL-1,3,4-
OXADIAZOL-2-YL)
N
N
CH
3
C
H
3
N
O
N
m
/z
 =
 366
.4
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CODE NO. E. COLI P. AERUGINOSA S. AUREUS S. PYOGENUS
MTCC 442 MTCC 441 MTCC 96 MTCC 443
1 2a 250 250 500 250
2 2b 200 200 200 250
3 2c 500 500 1000 500
4 2d 1000 125 500 1000
5 2e 1000 250 250 250
6 2f 250 100 1000 1000
7 2g 1000 250 500 1000
8 2h 1000 125 250 1000
9 2i 250 100 250 500
10 2j 500 500 500 500
11 AMPICILLIN 100 100 250 100
12 CHLORAMPHENICOL 50 50 50 50
13 CIPROFLOXACIN 25 25 50 50
14 NORFLOXACIN 10 10 10 10
ANTIBACTERIAL ACTIVITY TABLE
MINIMAL BACTERICIDAL CONCENTRATION
SR. 
NO.
CODE NO. C. ALBICANS A. NIGER A. CLAVATUS
MTCC 227 MTCC 282 MTCC 1323
1 2a 500 250 250
2 2b 500 500 1000
3 2c 250 500 1000
4 2d 500 500 500
5 2e 500 1000 1000
6 2f 250 500 1000
7 2g 500 1000 1000
8 2h 500 500 500
9 2i 250 500 500
10 2j 500 1000 1000
11 NYSTATIN 100 100 100
12 GRESEOFULVIN 500 100 100
SR. 
NO.
ANTIFUNGAL ACTIVITY TABLE
MINIMAL FUNGICIDAL CONCENTRATION
(µg/ml)
(µg/ml)
TABLE: 4 BIOLOGICAL EVALUATION OF 7-METHYL-2-(p-METHYLPHENYL)
IMIDAZO[1,2-a]PYRIDINE-3-(5-ARYL-1,3,4-OXADIAZOL-2-YL).
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INTRODUCTION
5-Pyrazolone is a five member heterocycle having two itrogen atoms at the 1 and
2 position with carbonyl group at the 5-position. Knorr1 was reported the first pyrazolone
derivative by the reaction of phenyl hyrazine and ethylacetoacetate in 1883, which was
identified in 1887 as 1-phenyl-3-methyl-5pyrazolone. C. W. Alstetten2 was prepared
phenyl-2,3-dimethyl-4-N,N-dimethylamino-5-pyrazolinone derivative in 1922 by the
action of formaldehyde and formic acid with substituted-5-pyrazolinone.
SYNTHETIC ASPECTS
 Different methods reported in literature for the preparation of 5-pyrazplones are
as follow :-
1. α-Oxy/thio substituted-β-keto esters were synthesized through an efficient
cross-Claisen condensation of aryl oxy/thio acetic acid ethyl esters with acid
chlorides, then it is converted in situ into 4-oxy/thio substituted-1H-pyrazol-
5(4H)-ones by the addition of hydrazine or hydrazine derivatives.3
2. Steven A. Raw et al.4 have developed 1,3,4-trisubstituted-1H-pyrazoles
regioselectively by  three components condensation reaction between methyl-
hydrazine, ethylformateand 1,3-diketone in one-pot process.
3. C. P. Singh et al.5 have prepared 5-pyrazolones by the reaction of ethyl
acetoacetate with aroyl hydrazines.
X
R1
OC2H5O
R2 Cl
O
+ R2 OC2H5
X
R1
O O NN
O
R3
R2
X
R1
LiHMDS, -78oC
Toluene
R3-NHNH2
Ethanol
R OC2H5
OO
NH2 NH
CH3 H OC2H5
O N
N
CH3
R OC2H5
O
3 Steps, 
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4. Nora Benaamane et al.6 have prepared 5-pyrazolones by the reaction of
1,3-diketones with phenyl hydrazine.
5. A high speed, solvent-free, and practical synthesis of pyrazolones under
microwave irradiation was described by Sarbani Pal et al.7
MECHANISM
Mechanism of formation of 5-oxo-pyrazolones is illustrated as below.8
THERAPEUTIC IMPORTANCE
Pyrazolone derivatives exhibit broad spectrum of therapeutic activities. The
several biological activities associated with pyrazolones have been described as under.
1. Antiulcer9
2. Antitumer10
3. Antibacterial11
4. Anticancer12
5. Harbicidal13
6. Nurotonsin receptor14
7. Lipoxygenase inhibitor15
8. parasitical16
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9. antiinflamatory17
10. antitubercular18
11. antimicrobial19
Y. Takashima et al.20 have synthesized some pyrazolone derivatives showing
herbicidal activity. A. Akahne et al.21 have synthesized pyrazolone derivatives which
were found to be active against ischemic heart disease such as angina, diabetes and
melancholia. Rajeev Jain et al.22 have prepared pyrazolone derivatives (I) and reported
as potent antimicrobial agent. Yoshikuni et al.23 and bratusek et al.24 have synthesized
3-methyl-5-oxopyrazol derivatives of type (II) and (III) respectively.
K. Nakamura et al.25 have synthesized some pyrazolone derivatives and found to
be Cox-II inhibiting agents and useful for the treatment and prevention of inflammatory
condition, collagen diseases, antiimmune diseases, thrombosis, cancer and
neurodegenerative diseases. S. D. Bhardwaj et al.26 have found anticancer and anti-HIV
activity. M. Nakatsuka et al.27 have assessed pyrazolones as immunosuppressants.
B. J. Banks et al.28 have prepared pyrazolone derivatives which were active as
antiparasitic agets. Some co-workers have prepared pyrazolones and tested them for
their herbicidal and insecticidal,29 leukotriene inhibitor,30 thromboembotic disorders,31
antiinflammatory and antimicrobial,32 coagulation factor,33 anticancer,34-35 antiinfective,36
antibiotic,37 organ transplantation,38 therapeutic agents,39 antithrombotic agent,40 Aurora-2
and CDK-2 inhibitors41 activity and also use for treatment of cardiac disorder.42
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A. S. S. Salman et al.43 have synthesized some novel pyrazolone derivatives (IV)
which showed antimicrobial activity. V. Sharma and M. S. Y. Khan44 have synthesized
pyrazolone derivatives which were found to be active as non-steroidal antiinflammatory
drug. Shashikant V. Bhandari et al.45 reported various substituted 1,5-diarylpyrazolone
derivatives (V) and screened for analgesic, anti-inflammatory, ulcerogenic potential and
for their ability to release nitric oxide.
Samir Bondock et al.46 have synthesized novel pyrazolones (VI) which have
been evaluated as antimicrobial agents. A. F. Sherif and co-workers47 have synthesised
hybrid compounds (VII) and evaluated their anti-inflammatory activity, ulcerogenic
effects, acute toxicity, analgesic activity and in vitro antimicrobial activity.
Eleven N-substituted pyrazolo-1,3-oxazinones (VIII) were synthesised by Nora
Benaamane and co-workers6 and predicted their biological activity. COX-1 inhibitory
activity of the compounds was confirmed by experimental data. A series of novel 1-(4-
methylcoumarinyl-7-oxyacetyl)-3,5-dimethyl-4(arylazo)pyrazoles (IX) were synthesised
and evaluated for antibacterial and antioxidant activities by P. Manojkumar et al.48
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Mahindra T. Makhija et al.49 have designed novel pyrazolone using a de novo
design method and tested for in vitro inhibition of HIV-1 integrase. Xuesen Fan and
co-workers50 have developed novel pyrimidinylidene–pyrazolone nucleoside (X) with
potent in vitro anti-orthopoxvirus properties. Elisabeth Conchon et al.51 synthesized
indolylpyrazolones (XI) and evalueted their in vitro antiproliferative activities, and
Chk-1 inhibitory properties.
In the past years, considerable evidence have been accumulated to demostrate
the pharmacodynamic and chemotherapeutic activities of pyrazolone derivatives. To
further assess the potential of such type of compounds, the synthesis have been carried
out which have been described as below.
SECTION-I : SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-{[7-
METHYL-2-(p-METHYLPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-
-YL]CARBONYL}-3-ARYL/ALKYL-5,4-DIHYDRO-1H -
PYRAZOL-5-ONE.
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-{[7-METHYL-2-(p-METHYL-
PHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]CARBONYL}-3-ARYL/ALKYL-5,4-
DIHYDRO-1H-PYRAZOL-5-ONE.
The broad spectrum of pharmacological properties have been demonstrated by
the pyrazolone nucleus. Inspired by these facts, new pyrazolone derivatives of
imidazo[1,2-a]pyridine have been investigated. The 2-(4-methylphenyl)-7-methyl-
imidazo[1,2-a]pyridine-3-carbohydrazide on treatment with different β-ketoester
compounds yielded 2-{[7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridin-3-yl]-
carbonyl}-3-aryl/alkyl-5,4-dihydro-1H-pyrazol-5-one derivatives of Type - III as shown
in reaction scheme.
The constitution of the synthesized compounds have been characterised by
elemental analysis, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all the compounds have been checked by
thin layer chromatography (TLC).
All the compounds have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards fungus strains at a different concentration. The biological
activity of the synthesized compounds were compared with standard drugs, as shown in
Table-6.
Type-III
N
NCH3
CH3
O
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R=Alkyl / Aryl
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EXPERIMENTAL
S Y N T H E S I S  A N D  B I O L O G I C A L E VA L U AT I O N  O F 2-{[7-METHYL-2-
(p-METHYLPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]CARBONYL}-3-ARYL/
ALKYL-5,4-DIHYDRO-1H-PYRAZOL-5-ONE.
[A] Preparation of 2-bromo-3-(p-methylphenyl)-ethyl-3-oxopropanoate.
See, Part-2, Section-1 (A).
[B] Preparation of 7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridine-3-ethylcarboxylate.
See, Part-2, Section-1 (B).
[C] Preparation of 7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridine-3-
carbohydrazide.
See, Part-2, Section-1 (C).
[D] Preparation of 2-{[7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridin-3-yl]
carbonyl}-3-methyl-5,4-dihydro-1H-pyrazol-5-one.
In a round bottom flask a solution of 7-methyl-2-(p-methylphenyl)imidazo[1,2-a]
pyridine-3-carbohydrazide(2.80g, 0.01m) in ethanol (25 ml) was taken. Ethyl aceto-
acetate(1.30ml, 0.01m) was added and it was refluxed on a water bath for 6 hrs. The
excess of solvent was distilled off. The resulting solid was crystallized from ethanol.Yield,
59% (2.04 gm),  m.p. 181°C. Calculated (%) of C20H18N4O2 (346.3); C: 69.35, H:
5.24, N: 16.17, Found(%) C: 69.18, H: 5.09, N: 16.02.
TLC solvent system : Ethyl acetate : Hexane (7 : 3).
Similarly other β-ketoester condensed with 7-methyl-2-(p-methylphenyl)
imidazo[1,2-a]pyridine-3-carbohydrazide. The physical constants are recorded in
Table-5.
[E] Biological evaluation of 2-{[7-methyl-2-(p-methylphenyl)imidazo[1,2-a]
pyridin-3-yl]carbonyl}-3-methyl-5,4-dihydro-1H-pyrazol-5-one.
Antimicrobial and antifungal testing were carried out as described in Part-1,
Section-I(D). The Minimal  Bactericidal Concentration and Minimal Fungicidal
Concentration(MBC & MFC) of the test solution are reported in Table-6.
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3a CH3- C20H18N4O2 346.3 181 59 16.17 16.02 0.51 S1
3b CF3- C24H25N4F3O2 400.3 168 63 13.99 13.87 0.56 S1
3c C3H7- C22H22N4O2 374.4 173 65 14.96 14.83 0.58 S1
3d C2H5- C21H20N4O2 360.4 170 59 15.55 15.38 0.50 S2
3e C3H7- C22H22N4O2 374.3 190 58 14.96 14.83 0.47 S2
3f C6H5- C25H20N4O2 408.4 178 50 13.72 13.59 0.53 S2
3g C6H2F3- C25H17N4F3O2 462.3 208 53 12.12 11.96 0.59 S1
3h C6H2ClF2- C23H17N4ClF2O2 478.4 216(d) 61 11.70 11.47 0.60 S1
3i C6HClF3- C25H16N4ClF3O2 496.8 192 53 11.28 11.04 0.52 S1
3j 3-CF3-C6H4 C26H19N4F3O2 476.4 169 60 11.76 11.58 0.48 S2
S1 Hexane : Ethyl acetate (3 : 7),   S2 Chlorofom : Methanol (8 : 2)
Sr.     R         Molecular       Molecular      M.P.   Yield   % of Nitrogen      Rf    Solvent
No          Formula         Weight        oC    %       Calcd.      Found     Value    System
1      2              3             4         5     6           7         8        9          10
TABLE:-5 PHYSICAL CONSTANTS OF 2-{[7-METHYL-2-(p-METHYLPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]CARBONYL}-
-3-ARYL/ALKYL-5,4-DIHYDRO-1H-PYRAZOL-5-ONE.
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IR SPECTRAL STUDIES OF 2-{[7-METHYL-2-(p-METHYLPHENYL) IMIDAZO
[1,2-a]PYRIDIN-3-YL]CARBONYL}-3-ARYL/ALKYL-5,4-DIHYDRO-1H-
PYRAZOL-5-ONE
 Observed
Alkane   C-H str. (asym.) 2964 2975-2950 52
-CH3   C-H str. (sym.) 2879 2880-2860  ,,
  C-H i.p.def. (asym.) 1434 1470-1435  ,,
Aromatic   C-H  str. 3053 3090-3030 53
  C=C str. 1500 1540-1480  ,,
  C-H i.p.def. 1105 1125-1000  ,,
  C-H o.o.p. (def) 833 835-810  ,,
Imidazo[1,2-a]   C=N str. 1596 1612-1593 52
pyridine   C-N str. 1164 1220-1020  ,,
  C=C str. 1434 1540-1480  ,,
Pyrazolone   C=O str. 1706 1760-1655  ,,
  C=N str. 1629 1660-1580 53
  N-N str. 1028 1050-1010  ”
Type     Ref.
        Reported
Frequency in cm-1
 Vibration
Instrument  : SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range
: 4000-400 cm-1 (KBr disc.)
Mode
-10.0
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
110.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cm
 567.0
 605.6
 688.5
 729.0
 756.0
 833.2
 885.3
1028.0
1053.1
1105.1
1164.9
1213.1
1253.6
1286.4
1363.6
1434.9
1500.5
1596.9
1629.7
1672.1
1706.9
2879.5
2964.4
3053.1
N
N
CH3
CH3
N
N
O
O
CH3
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NMR SPECTRAL STUDIES OF 2-{[7-METHYL-2-(p-METHYLPHENYL)
IMIDAZO[1,2-a]PYRIDIN-3-YL]CARBONYL}-3-METHYL-5,4-DIHYDRO-1H-
PYRAZOL-5-ONE
Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER
Spectrometer (300MHz)
a
b
c
N
N
CH3
CH3
N
N
O
O
CH3
d
Signal
  No.
Signal Position
    (δppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
   1. 2.08 3H singlet Pyra-CH3 -
   2. 2.35 3H singlet Ar-CH3 -
   3. 2.39 3H singlet Ar-CH3 -
   4. 3.79 2H singlet Pyra-CH2 -
   5. 6.87-7.14 4H multiplet Ar-H -
   6. 7.37 1H doublet Ar-H(b) J=6
   7. 7.62 1H doublet Ar-H(c) J=6
   8. 8.01 1H singlet Ar-H(a) -
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MASS SPECTRAL STUDIES OF 2-{[7-METHYL-2-(p-METHYLPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]CARBONYL}-3-
METHYL-5,4-DIHYDRO-1H-PYRAZOL-5-ONE
N
N
CH
3
C
H
3
NN
O
O
C
H
3m
/z
 =
 346
.3
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CODE NO. E. COLI P. AERUGINOSA S. AUREUS S. PYOGENUS
MTCC 442 MTCC 441 MTCC 96 MTCC 443
1 3a 500 1000 500 500
2 3b 1000 1000 250 500
3 3c 100 1000 1000 250
4 3d 250 1000 1000 100
5 3e 250 250 500 50
6 3f 500 250 250 250
7 3g 500 50 250 50
8 3h 1000 500 500 100
9 3i 250 250 100 500
10 3j 1000 1000 250 250
11 AMPICILLIN 100 100 250 100
12 CHLORAMPHENICOL 50 50 50 50
13 CIPROFLOXACIN 25 25 50 50
14 NORFLOXACIN 10 10 10 10
ANTIBACTERIAL ACTIVITY TABLE
MINIMAL BACTERICIDAL CONCENTRATION
SR. 
NO.
CODE NO. C. ALBICANS A. NIGER A. CLAVATUS
MTCC 227 MTCC 282 MTCC 1323
1 3a 500 1000 1000
2 3b 250 250 500
3 3c 250 >1000 >1000
4 3d 500 >1000 >1000
5 3e 500 >1000 >1000
6 3f >1000 500 500
7 3g 500 500 1000
8 3h >1000 >1000 >1000
9 3i 500 1000 1000
10 3j 500 1000 1000
11 NYSTATIN 100 100 100
12 GRESEOFULVIN 500 100 100
SR. 
NO.
ANTIFUNGAL ACTIVITY TABLE
MINIMAL FUNGICIDAL CONCENTRATION
(µg/ml)
(µg/ml)
TABLE: 6 BIOLOGICAL EVALUATION OF 2-{[7-METHYL-2-(p-METHYL-
PHENYL) IMIDAZO[1,2-a]PYRIDIN-3-YL]CARBONYL}-3-ARYL/
ALKYL-5,4-DIHYDRO-1H-PYRAZOL-5-ONE.
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INTRODUCTION
The chemistry of triazole derivatives have attained greater interest because of its
application in medicine, agriculture and industrial chemistry. Triazoles contains three
nitrogen atom in five membered ring system. Triazoles are of two types 1,2,4-triazole (I)
and 1,2,3-triazole (II).
The chemistry of 1,2,4-triazoles described briefly in the literature.1-2 The first
1,2,4-triazole derivatives have been synthesised by Bladin in 1885. 1,2,4-triazole
derivatives are also useful as analytical reagents,3 photographic chemicals4 and in polymer
synthesis.5
SYNTHETIC ASPECT
Several methods have been reported in the literatures for the preparation of 1,2,4-
triazoles. Some procedures of 1,2,4-triazoles have been described as under.
1. Reid and Heindel6 have reported the reaction of aryl acid hydrazide with CS2/
KOH and Hydrazine hydrate furnished triazoles.
2. Bahittin Kahveci 7 have reported that the iminoester hydrochlorides are converted
into ester ethoxycarbonyl hydrazones, which turn into a new series of substituted
4-amino-4,5-dihydro-1H-1,2,4-triazole-5-ones.
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H
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3. Khosrow Zamani and co-worker8 have prepared triazole derivatives from
respective substituted pyridine carboxylic acid hydrazides and 4-methylphenyl
isothiocyanate.
4. Li-Li Liu and Guang Yang9 were described a facile method to prepare 1,2,4-
triazole by the reaction of isonicotinonitrile with excess amount of hydrazine.
5. Shuki Araki and co-worker10 have synthesized 1,2,4-triazoles from 2,3-
diphenyltetrazolium salt. using triethylamine as a base.
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6. The synthesis of dendrons bearing 1,2,4-triazoles moiety is described by Enrique
Diez-Barra et al.11 The synthesis of these compounds was carried out using different
approaches.
7. Kee-Jung lee et al.12 have reported 1,2,4-triazole from the electrocyclic reaction
of conjugated heterocumulenes.
8. Chande et al.13 have reported 4-anilino-5-mercapto-5-triazoles from β-acyl
dithiocarbazinate and phenyl hydrazine at 140-160oC.
9. Shin-ichi Nagai14 have synthesised triazole by the reaction of thiosemicarbazide
with formic acid in the presence of acetic anhydride (AC2O).
10. Yan Shiquaing15 have prepared triazole by the treatment of ferrocenecarboxylic
acid hydrazide with aryl isothiocyanate and cyclization of the product gave 3,4-
disubstituted 4H-1,2,4-triazole-5-thiol.
11. B. J. Rai and Co-workers16 have synthesised 3-amino-5-aryl-2-phenyl-2H-1,2,4-
triazole by reaction of aroyl-cyanide with phenyl hydrazine.
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THERAPEUTIC IMPORTANCE
1,2,4-triazole derivatives have been associated with diverse biological activities.
Therapeutic activity of 1,2,4-triazoles are listed as under.
1. Antiinflammatory17
2. Diuretic18
3. Antiviral19
4. Antihypertensive20
5. Anthelmintics21
6. Bactericidal22
7. Anticonvulsant23
8. Herbicidal24
9. Insecticidal & Acaricidal25
10. Fungicidal26
11. Antimicrobial27
12. Anticancer and anti-HIV28
13. Plant growth regulator29
14. Antileishmanial30
15. Antitumor31
16. Antidepressant and Anxiolytic32
A new series of clubbed thiazolidinone–triazole derivatives(III) were synthesized
by Mahendra R. Shiradkar et al.33 The compounds were evaluated for their anticonvulsant
activity in two animal models of seizures.
O
CH3
N
N
H
N
S O
N
SN
Ar
O
Ar
( III )
Synthesis, Characterisation and....
87
Rossi  Carla 34 was investigated 1,2,4-tr iazoles having antigestat ive
immunosuppressant and antitumor activity. Michael et al.35 have reported triazoles as
potential antibacterial agents. H. Mikali et al.36 have documented triazoles as antimicrobial
agents. Subdtituted 1,2,4-triazole have been reported for their pharmacological activity
by Bahittin Kahveci et al.37 and antifungal activity.38 Liu. Chanjian et al.39 have
investigated triazoles (IV) as IMPDH inhibitors.
A series of 4-amino-5-(substituted phenyl)[1,2,4]triazoles(V) and (VI) were
synthesized by Loredana Salerno et al.40 with the aim of to obtaining new selective 5-
HT1A ligands.  All New compounds were tested in radioligand binding experiments, from
many of them showed a preferential affinity for the 5 - HT1A receptor.
Mari Makoto et al.41 have prepared water soluble triazoles as fungicides.
Laddawahetty et al.42 have synthesised triazole as selective human GABA receptor for
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the treatment of anxiety and enhancing cognition. Eight novel compounds like (VII) were
synthesized and their insecticidal activities were tested by Bing Chai and co-workers.43
The newly designed substituted triazole derivatives (VIII) were synthesized by Maria
Grazia Mamolo et al.44 and tested for their in vitro antifungal and an t i  mycobacterial
activity.
New 1,2,4-triazole compounds (IX), containing a D,L-methionine moiety were
synthesized by Otilia Pintilie et al.45 All compounds exhibited promising antimicrobial
activities. A series of 4-amino-3-(2-furyl)-5-mercapto-1,2,4-triazole (X) were prepared
by Jingde Wu and co-worker.46 All the  synthesized substituted triazole derivatives were
reported as an anti-HIV-1 agents by examined their inhibition activity of HIV-1-induced
cytopathogenicity in MT-4 cells and by determined their inhibitory effect on HIV-1
reverse transcriptase.
A variety of fluconazole derivatives were synthesized by Ruchita Ohlan and co
workers.47 The synthesized compounds (XI) were evaluated for their in vitro antifungal
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activity  against C.albicans and A. niger. Jian-yu Jin and co workers48 have discovered
new 1,2,4-triazole derivatives (XII), which may possess significant biological activities,
Plant growth-regulating activity tests of all compounds showed remarkable effects on
the growth of radish and wheat.
John W. Hull Jr. et al.49 have investigated a new family of functionalized 2,6-
dihaloaryl 1,2,4-triazole (XIII) & (XIV) insecticides featuring. Ibtehal A. Al-Juwaiser et
al.50 have been synthesized anhydronucleosides of 1,2,4-Triazoles (XV) & (XVI) which
showed pronounce biological activities.
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Mevlut Serdar and co worker51 have synthesized a new series of triazole(XVII) and the
all compounds were screened for their antimicrobial and antifungal activities.Thirteen
new triazoles (XVIII) containing 1,3-dioxolane rings were synthesized by Liang-Zhong
Xu et al.52 and their results of preliminary biological tests show that all of these compounds
possess some fungicidal and plant growth regulant activities.
Giorgia pastorin et al.53 have documented 1,2,4-triazoles as adenosine receptor
antagonist and also as human A3 and A2B adenosine receptor. B.Shivarama Holla et al.
54
have screened 1,2,4-triazoles for anticancer property. Uesaka et al.55 documented
triazoles as adrenergic a2C receptor antagonists. Biologically active triazole were reported
by P. V. Chepal  et al.56 Aoki Satosh et al.57 have investigated triazoles as potent
cyclooxygenase inhibitor.
These valid observations led us to synthesise several derivatives of  triazole like
arylamides and 1,3,4-thiadiazoles in order to achieve better therapeutic agents. The
study of 1,2,4-Triazoles is described as under.
PART-IV : STUDIES ON 1,2,4-TRIAZOLES
[A] : SYNTHESIS AND BIOLOGICAL EVALUATION OF
ARYLAMIDES.
[B] : SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,3,4-
THIADIAZOLOTRIAZOLES.
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INTRODUCTION
The characteristics group present in the simple carboxylic amide is CO-NH2.
They are the acyl substitution products of ammonia. Many natural products are amides,
urea, diamides of carbonic acid. The peptides and proteins are linear structure of cyclic
polyamides. The alkaloids of pepper, piperidine are N-substituted amides of unsaturated
acid. N-Isobutyl amides of certain highly unsaturated aliphatic acids occur in plants,
shows inseticidal activity.1 Amides derived from polyacetylenic acid have been isolated
from certain fungi.2
SYNTHETIC ASPECT
Various methods for the synthesis of aryl acetamides are described in literature.3-8
Marayama, Tatsuya and Suzuki Onda9 have synthesised arylamide of imidazole
derivative as under.
New N-substituted amides of 3-(3-ethylthio-1,2,4-triazol-5-yl)propenoic acid
were designed and prepared by Anna Pachuta-Stec et al.10
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M. Romero et al.11 have synthesized substituted arylamides by using a palladium
catalyst, a suitable ligand, and a base.
THERAPEUTIC IMPORTANCE
Substituted amides have widely been used as pharmacologically useful entities.
Some arsano organometallic compounds like tryparsamide and arsacetin having amide
groups have proved to be successful chemotherapeutic agents. The biological activities
of aryl amide derivatives have been reported as under.
1. Anticonvulsant12
2. Antiallergic13
3. Herbicidal14
4. Cardiotonic15
5. Antimicrobial16
6. Analgesic17
7. Antiulcer18
8. MAO inhibitor19
9. Anticancer20
10. Antiinflammatory21
11. Anti HIV22
12. Sodium Channel blockers23
A. K. Mallms24 has reported arylamide derivatives as antitumor agent. More
over S. J. laulloo et al.25 and J. Hazarika26 have prepared some novel biologically active
arylamide derivatives and reported them as antimicrobial agents. Dhanak Dushyant et
al.27 have synthesised arylamide of phenylsulfonylpiperazine derivatives (I), which are
useful as urotensin-II antagonist. E. J. Sanderson Philip et al.28 have synthesised aryl amides
Ar X + R
NH2
O Ar NH
R
O
Pd[P(o-tolyl)3]2Cl2
BINAP / CS2CO3X=Br
X=Tf
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and studied their biological activity. Moloney et al.29 have reported aryl amide derivatives
as antiulcer agents. Foster James et al.30 have synthesised some new amide derivatives
as potent anticonvulsant agents. Mulik et al.31 have studied some aryl amides shows
antibiotic activity. Bridge Gory et al.32 have screened arylamides as anti-HIV agent
laura and co-workers33 have prepared arylamides as antibacterial agents. Hobbs et. al.34 have
designed some biphenylamide derivatives (II) and reported them as MCH-receptor antagonist.
Tabuchi et al.35 have screened arylamide derivatives as human neuropeptide
receptor antagonist. Pieters et al.36 have synthesised novel diazine carboxamides (III)
as anticancer. Anthony and co-workers37 have investigated amides as anti-HIV. Chen et
al.38 have reported arylamides of pyridine derivatives (IV) as antitumor agents.
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Chan39 have recorded substituted benzophenone arylamide derivatives as inhibitor
reverse transcriptase. Steven J. Taylor et al.40 have designed and synthesized substituted
nicotinamides derivatives (V) as inhibitors of soluble epoxide hydrolase. Erin F. DiMauro
and co-workers41 have prepared N-arylamide of oxadiazoles (VI) as potent and selective
agonists of CB2.
Potent FMS inhibitors possessing a 1,2,4-phenylenetriamine core structure were
optimized by Sanath K. Meegalla et al.42 Yong Gong et al.43 have prepared a series of
pyridazinone-functionalized phenylalanine amide (VII) as α4 integrin antagonists. A series
of novel 2,4-disubstituted arylamides (VIII) as potential anti-inflammatory agents was
described by Carl R. Illig et al.44
B. James and co-workers45 have screened arylamides as selective opioid-K
receptor antagonist. Fanrong mu et al.46 have demostrated novel benzene-1,4-diol-
arylamide as anticancer agent. Bin Ho et al.47 have investigated arylamide derivatives
as anticonvulsant agent. Cudahy et al.48 have prepared arylamide of 7-methylfuro[2,3-b]
pyridin-4(7H)-one derivatives and reported them as antiviral agents.
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Smail Khelili et al.49 have synthesized simple arylamides (IX) and reported as
analogues of benzopyran-type potassium channel activators. The Cannabinoid Receptor-2
(CB2) is an attractive therapeutic target for analgesic and anti-inflammatory agents.
Yuan Cheng et al.50 have discovered a novel class of arylamide having oxadiazole moiety
(X), and reported them as a potent and selective CB2 agonist.
Looking to the interesting biological properties of arylamide derivatives, we have
synthesised some new arylamides in which therapeutically active imidazo[1,2-a]pyridine
nucleus is incorporated, which have been described as under.
SECTION - I: SYNTHESIS AND BIOLOGICAL EVALUATION OF 5-[7-METHYL-
2-(p-METHYLPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]3-
MERCAPTO-4H-1,2,4-TRIAZOL-4-YL-ARYLAMIDES.
CH3
O
N O
R
H
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N
O N
Cl F
( IX ) ( X )
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 5-[7-METHYL-2-(p-METHYL-
PHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]3-MERCAPTO--4H-1,2,4-TRIAZOL-
4-YL-ARYLAMIDE.
In view of getting better therapeutic agent with imidazo[1,2-a]pyridine  nucleus,
the preparation of arylamides of Type - IV have been synthesized by the condensation of
3-mercapto-4-amino-5-[2-(p-methylphenyl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-4H-
1,2,4-triazoles with different acid chloride in pyridine shown in reaction scheme.
The constitution of the synthesized compounds have been characterised by
elemental analysis, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all the compounds have been checked by
thin layer chromatography (TLC).
All the compounds have been screened for their in vitro biological
assay like antibacterial activity towards Gram positive and Gram
negative bacterial strains and antifungal activity towards fungus strains
at a different concentration. The biological activity of the synthesized
compounds were compared with standard drugs, as shown in Table-8
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EXPERIMENTAL
S Y N T H E S I S  A N D  B I O L O G I C A L E VA L U AT I O N  O F 3-MERCAPTO-5-
[7-METHYL-2-(p-METHYLPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]-4H-1,2,4-
TRIAZOL-4-YL-ARYLAMIDE.
[A] Preparation of 2-bromo-3-(p-methylphenyl)-ethyl-3-oxopropanoate.
See, Part-2, Section-1 (A).
[B] Preparation of 7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridine-3-ethylcarboxylate.
See, Part-2, Section-1 (B).
[C] Preparation of 7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridine-3-
carbohydrazide.
See, Part-2, Section-1 (C).
[D] Preparation of Potassium salt  of N-{7-methyl-2-(p-methylphenyl)
imidazo[1,2-a]pyridine}-3-dithiocarbazic acid.
A mixture of potassium hydroxide (0.56g, 0.01m) in absolute ethanol (25 ml),
7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridine-3-carbohydrazide(2.80gm,
0.01m) and carbon disulfide (1ml, 0.015 m) was stirred for 15 hrs. The solid product
obtained was filterd and washed with dry ether (150 ml). Yield, 91% (3.29 gm),  m.p.
212°C. Calculated (%) of C17H15N4OSK (362.5); C: 56.33, H: 4.17, N: 15.46,
Found(%) C: 17.41, H: 4.28, N: 15.53.
[E] Preparation of 3-Mercapto-4-amino-5-[7-methyl-2-(p-methylphenyl)
imidazo[1,2-a]pyridin-3-yl]-4H-1,2,4-triazole.
A suspension of potassium salt of N-{7-methyl-2-(p-methylphenyl)imidazo-
[1,2-a]pyridine-3-dithiocarbazic acid.(3.62gm, 0.01m), hydrazine hydrate (95%, 1ml,
0.02m) and water(3 ml)  was refluxed with stirring for 5 hrs. The contents were diluted
with water and acidified with glacial acetic acid to get the product. The isolated product
was crystallised from ethanol. yield, 62%, m.p. 207°C. Calculated (%) of C17H16N6S
(336.3); C: 60.69, H: 4.79, N: 24.98, Found(%) C: 60.51, H: 4.67, N: 24.86.
TLC solvent system : Methanol : Chloroform (1 : 9).
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[F] Preparation of N-{3-mercapto-5-[7-methyl-2-(p-
methylphenyl)imidazo[1,2-a] pyridin-3-yl]-4H-1,2,4-triazol-4-
yl}benzamide.
A mixture of 3-Mercapto-4-amino-5-[7-methyl-2-(p-
methylphenyl)imidazo[1,2-a] pyridin-3-yl]-4H-1,2,4-triazole(3.36g,
0.01M) and benzoylchloride(1.40g, 0.01m) in dry pyridine (20 ml) was
refluxed for 8 hrs. The resulting mixture was poured onto crushed ice
and neutralised with HCl. The product was filtered, washed with cold
water and crystallised from ethanol. Yield, 51%, m.p. 186°C. Calculated
(%) of C24H20N6OS (440.5); C: 65.44, H: 4.58, N: 19.08, Found (%) C:
65.23, H: 4.35, N: 18.87.
TLC solvent system : Ethyl acetate : Hexane (5 : 5).
Similarly other acid chlorides were condensed with 3-Mercapto-
4-amino-5-[7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridin-3-yl]-4H-
1,2,4-triazole. The physical data are recorded in Table-7.
[G] Biological  evaluation of 3-mercapto-5-[7-methyl-2-(p-
methylphenyl)imidazo [1,2-a]pyridin-3-yl]-4H-1,2,4-triazol-4-
yl-arylamide.
Antimicrobial and antifungal testing were carried out as described
in Part-1, Section-I(D). The Minimal  Bactericidal Concentration and
Minimal Fungicidal Concentration (MBC & MFC) of the test solution
are reported in Table-8.
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4a C6H5- C24H20N6OS 440.5 186 51 19.08 18.87 0.50 S2
4b 3-OCH3-C6H4- C25H22N6O2S 470.5 179 54 17.86 17.61 0.58 S1
4c 2,3-(OCH3)2C6H3- C26H24N6O3S 500.5 177 63 16.79 16.52 0.47 S1
4d 3,5-(NO2)2C6H3- C24H18N8O5S 530.5 191 48 21.12 20.91 0.53 S1
4e 2-C5H4N- C23H19N7OS 441.5 160 61 22.21 20.96 0.59 S2
4f 3-C5H4N- C23H19N7OS 441.5 175 53 22.21 21.01 0.51 S2
4g 4-C5H4N- C23H19N7OS 441.5 189 52 22.21 20.98 0.54 S2
4h 2,4,5-(F)3C6H2- C24H17F3N6OS 494.5 204 51 17.00 16.73 0.49 S1
4i 4-Cl-2,5-(F)2-C6H2- C24H17ClF2N6OS 510.9 208(d) 50 16.45 16.21 0.50 S1
4j 3-Cl-2,4,5-(F)3-C6H- C24H16ClF3N6OS 528.9 193 51 15.89 15.63 0.53 S1
S1 Hexane : Ethyl acetate (2 : 8),   S2 Hexane : Ethyl acetate (5 : 5)
Sr.     R    Molecular    Molecular     M.P.    Yield       % of Nitrogen     Rf           Solvent
No                      Formula           Weight           oC            %         Calcd.        Found       Value       System
1      2                          3   4                 5            6              7             8          9            10
TABLE:-7 PHYSICAL CONSTANTS OF  5-[7-METHYL-2-(p-METHYLPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]3-MERCAPTO-
-4H-1,2,4-TRIAZOL-4-YL-ARYLAMIDE
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IR SPECTRAL STUDIES OF N-{3-MERCAPTO-5-[7-METHYL-2-(p-METHYL
PHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]-4H-1,2,4-TRIAZOL-4-YL}BENZAMIDE
 Observed
Alkane   C-H str. (sym.) 2831 2880-2860 51
-CH3   C-H i.p.def. (asym.) 1481 1470-1435  ,,
Aromatic   C-H  str. 3062 3090-3030 52
  C-H i.p.def. 1117 1125-1000  ,,
  C-H o.o.p. (def) 825 835-810  ,,
Imidazo[1,2-a]   C=N str. 1604 1612-1593 51
pyridine   C-N str. 1170 1220-1020  ,,
  C=C str. 1481 1540-1480  ,,
Triazole   S-H str. 2249 2500-2400  ,,
  C=N str. 1590 1650-1580 52
  N-N str. 1036 1050-1010 *
  C-S str. 613 700-600 *
Amide   N-H str. 3213 3300-3100 51
-CO-NH-   C=O str. 1690 1690-1630  ”
Type     Ref.
        Reported
Frequency in cm-1
 Vibration
Instrument  : SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range
: 4000-400 cm-1 (KBr disc.)
Mode
N
N
CH3
CH3
N
N
NNH
O SH
Synthesis, Characterisation and....
106
Signal
  No.
Signal Position
    (δppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
NMR SPECTRAL STUDIES OF N - {3 -MERCAPTO-5- [7-METHYL-2-
(p-METHYL PHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]-4H-1,2,4-TRIAZOL-
4-YL}BENZAMIDE
Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER
Spectrometer (300MHz)
   1. 2.07 1H singlet S-H(f) -
   2. 2.28 3H singlet Ar-CH3 -
   3. 2.36 3H singlet Py-CH3 -
   4. 7.19-7.69 11H multiplet Ar-H -
   5. 7.87 1H singlet Ar-H(a) -
a
b
c
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d' e'
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MASS SPECTRAL STUDIES OF N - {3 -MERCAPTO-5- [7-METHYL-2- (p-METHYL PHENYL)IMIDAZO[1,2-a]
PYRIDIN-3-YL]-4H-1,2,4-TRIAZOL-4-YL}BENZAMIDE
N
N
CH
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H
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N
N
NO
SH
Hm
/z
 =
 440
.5
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CODE NO. E. COLI P. AERUGINOSA S. AUREUS S.PYOGENUS
MTCC 442 MTCC 441 MTCC 96 MTCC 443
1 4a 100 500 500 500
2 4b 500 250 100 25
3 4c 1000 100 200 50
4 4d 250 500 250 100
5 4e 1000 1000 250 500
6 4f 500 500 500 250
7 4g 250 250 1000 250
8 4h 1000 1000 500 250
9 4i 500 250 1000 125
10 4j 250 250 1000 100
11 AMPICILLIN 100 100 250 100
12 CHLORAMPHENICOL 50 50 50 50
13 CIPROFLOXACIN 25 25 50 50
14 NORFLOXACIN 10 10 10 10
ANTIBACTERIAL ACTIVITY TABLE
MINIMAL BACTERICIDAL CONCENTRATION
SR. 
NO.
CODE NO. C. ALBICANS A. NIGER A. CLAVATUS
MTCC 227 MTCC 282 MTCC 1323
1 4a 1000 >1000 >1000
2 4b 500 1000 1000
3 4c 500 >1000 >1000
4 4d 1000 500 500
5 4e 250 1000 1000
6 4f 500 1000 1000
7 4g 1000 500 500
8 4h 1000 500 500
9 4i 200 500 500
10 4j 500 250 500
11 NYSTATIN 100 100 100
12 GRESEOFULVIN 500 100 100
SR. 
NO.
ANTIFUNGAL ACTIVITY TABLE
MINIMAL FUNGICIDAL CONCENTRATION
(µg/ml)
(µg/ml)
TABLE: 8 BIOLOGICAL EVALUATION OF 5-[7-METHYL-2-(p-METHYL
PHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]3-MERCAPTO-4H-1,2,4-
TRIAZOL-4-YL-ARYLAMIDE
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INTRODUCTION
1,3,4-Thiadiazole derivatives have been found to be potent drug in pharmaceutical
industrial and possess a wide spectrum of biological activity. In thiadiazole ring system
one sulphur and two nitrogen atom present in a five membered ring. According to their
position, thiadiazole system are classified as 1,2,3-thiadiazoles (I), 1,2,4-thiadiazoles
(II), 1,3,4-thiadiazoles (III) and 1,2,5-thiadiazoles (IV).
Fischer was described the first 1,3,4-thiadiazoles in 1882 and further developed
by Busch and co-workers. Due to wide range of therapeutic activities, the compounds
having thiadiazole nucleus have greatly accelerated the rate of progress in the field of
pharmaceutical.
The literature of 1,3,4-thiadiazole have been extensively reviewed by  Sandstrom1
(1947),  Sherman2 (1948),  Bambas3 (1952),  Kurzer4 (1977). M. Devis5 (1979),
Campbell6 (1979).
SYNTHETIC ASPECT
Literature survey reveals that several publication and patents7 describe the
synthesis of 1,3,4-thiadiazoles as under.
1. Vinod Mathew et al.8 have prepared 3,6-disubstituted triazolothiadiazoles by
microwave-assisted and conventional methods using DMF as an energy transfer
medium.
2. Q. Bano and co-workers9 have synthesised 6-phenyl amino 1,3,4-thiadiazoles.
N
N N
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Ar'-COOH
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3. M. K. Albrahim et al.10 have synthesised thiadiazoles from hydrazinyl chloride.
4. Sun Xiao-Wen et al.11 and Vikrant S. Palekar et al.12 have synthesized 1,3,4-
thiadiazoles by the cyclisation of acid with triazole in presence of catalyst
like POCl3.
5. Jag Mohan et al.13 have prepared thiadiazole derivatives by the cyclization of
amino mercapto triazole and aryl aldehyde in presense of p-TS-OH.
6. Chande Madhukar et al.14 have synthesized spiro type 1,3,4-thiadiazole from
amino mercapto triazole.
7. In 1982 Bahadur et al.15 have prepared thiadiazole from the thiosemicarbazides
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by the cyclization in sulphuric acid.
8. A number of 3,6-disubstituted triazolo[3,4-b]thiadiazole derivatives have been
prepared by D. A. Ibrahim.16
9. 1,3,4-thiadiazolidines have prepared through the intramolecular Mannich reaction
by Yu Jian-Xian et al.17
THERAPEUTIC IMPORTANCE
Extensive research was carried out to enhance the activity and reduce toxicity of
thiadiazole drugs. Various thiadiazole derivatives have resulted in many potential drugs
and are known to exhibit a broad spectrum of biological activity.
T. Karabasanagouda et al.18 have prepared new 6-aryl-3-{(4-substituted
phenoxy)methyl-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles (V), they deserved more
consideration as potential antimicrobials.Wong Zhong-Yi and co-workers19 have
synthesised some 3,6-diaryl-5,6-dihydrotriazolo [3,4-b]-1,3,4-thiadiazoles (VI) and
documented their in vivo antibacterial and antifungal properties.
Many implications of 1,3,4-thiadiazoles are well proved by a large number of
patents available on it as therapeutic agents. Thiadiazole derivatives are having numerous
pharmacological activities like.
1. Herbicidal20
2. Insecticidal21
3. Amoebicidal22
4. Antiviral23
5. CNS depressent24
6. Antibacterial25
N
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7. Pesticidal26
8. Antagonist agent27
9. Antifungal28
10. Hypoglycemic29
11. Antiinflammatory30
12. Antimicrobial31
13. Antihypertensive32
14. Antiaflatoxigenic33
15. Antitumor34
16. Algaecides and Antifouling35
17. Antitubercular36
18. Antipyratic37
19. Anthelmintic38
20. Antischistosomal39
Jin Fuqliang et al.40 have prepared some novel thiadiazole derivatives useful as
ulser drugs. Turner Steven et al.41 have synthesised thiadiazoles for the treatment of
CMV infection. Song Yuntao42 have tested thiadiazoles as cyclooxygenase 2-inhabitors.
Some thiadiazoles derivatives have shown good activity as antiinflammatory agents.43-44
Manjunath et al.45 have reported antimicrobial and antiinflammatory activity. Prakash
Karegoudar et al.46 have prepared novel series of triazolothiadiazoles (VII), which
exhibited promising antimicrobial activities and moderate to good anti-inflammatory
activity. Ma Zhang et al.47 have screened thiadiazoles (VIII) as fungicides.
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D. Jagadeesh Prasad and co-workers 48 have synthesized some new
triazolothiadiazoles (IX) bearing 4-methylthiobenzyl moiety, having promising
antimicrobial activities. Synthesis and pharmacological evaluation of condensed
heterocyclic 6-substituted-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (X) derivatives of
naproxen have been reported by Mohammad Amir et al.49
Nasser S. A. M. Khalil50 is described novel N- and S-α-l-arabino pyranosyl
[1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles (XI) as antimicrobial agents. Kamel A. Metwally
et al.51 reported antiinflammatory and ulcerogenic potential of novel triazolothiadiazoles (XII).
In view of the therapeutic activities of 1,3,4-thiadiazoles, it was contemplated to
synthesise. 1,3,4-thiadiazolo triazoles in search of agents possessing higher biological
activity with least side effect, which have been described as under.
SECTION-I : SYNTHESIS AND BIOLOGICAL EVALUATION 3-[7-METHYL
-2-(p-METHYLPHENYL)IMIDAZO[1,2-a]PYRIDIN -3-YL]
-6-ARYL[1,2,4]TRIAZOLO[3,4-b] [1,3,4]THIADIAZOLES.
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3 - [ 7 - M E T H Y L - 2 -
(p-METHYL PHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]6-ARYL[1,2,4]
TRIAZOLO[3,4-b][1,3,4]THIADIAZOLES.
The study of 1,3,4-thiadiazoles have revealed that thiadiazole derivatives are
valuable drugs for various diseases. These observations led us to synthesise 1,3,4-
thiadiazolo triazoles of Type-V by the cyclization of 3-mercapto-4-amino-5-[2-(p-methyl-
phenyl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-4H-1,2,4-triazoles with different aromatic
acids in presence of phosphorous oxychloride as shown in reaction scheme.
The constitution of the synthesized compounds have been characterised by
elemental analysis, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all the compounds have been checked by
thin layer chromatography (TLC).
All the compounds have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards fungus strains at a different concentration. The biological
activity of the synthesized compounds were compared with standard drugs, as shown in
Table-10.
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EXPERIMENTAL
S Y N T H E S I S  A N D  B I O L O G I C A L E VA L U AT I O N  O F 3-[7-METHYL-
2-(p-METHYLPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]6-ARYL[1,2,4]
TRIAZOLO[3,4-b][1,3,4]THIADIAZOLES
[A] Preparation of 2-bromo-3-(p-methylphenyl)-ethyl-3-oxopropanoate.
See, Part-2, Section-1 (A).
[B] Preparation of 7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridine-3-ethylcarboxylate.
See, Part-2, Section-1 (B).
[C] Preparation of 7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridine-3-
carbohydrazide.
See, Part-2, Section-1 (C).
[D] Preparation of Potassium salt  of N-{7-methyl-2-(p-methylphenyl)
imidazo[1,2-a]pyridine}-3-dithiocarbazic acid.
See Part-4a, Section-1(D).
[E] Preparation of 3-Mercapto-4-amino-5-[7-methyl-2-(p-methylphenyl)
imidazo[1,2-a]pyridin-3-yl]-4H-1,2,4-triazole.
See Part-4a, Section-1(E).
[F] Preparation of 3-[7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridin-3-yl]-
6-phenyl[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole.
A mixture of 3-mercapto-4-amino-5-[7-methyl-2-(p-methylphenyl)imidazo
[1,2-a]pyridin-3-yl]-4H-1,2,4-triazole (3.36gm, 0.01M) and p-methyl benzoic acid
(1.36g, 0.01M) in phosphorous oxychloride (20 ml) was refluxed for 10 hrs. The resulting
mixture was poured onto crushed ice and neutralised with sodium bicarbonate. The
product was filtered, washed with cold water and crystallised from ethanol. yield 52%
(2.20gm), m.p. 198oC. Calculated (%) of C24H18N6S (422.5); C: 68.23, H: 4.29, N:
19.89, Found (%) C: 68.11, H: 4.18, N: 19.61.
TLC solvent system : Ethyl acetate : Hexane (8 : 2).
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Similarly other aromatic acid condensed with 3-Mercapto-4-amino-5-[7-methyl-
2-(p-methylphenyl)imidazo[1,2-a]pyridin-3-yl]-4H-1,2,4-triazole. The physical data are
recorded in Table-9.
[G] Biological evaluation 3-[7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridin-
3-yl]-6-phenyl[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole.
Antimicrobial and antifungal testing were carried out as described in Part-1,
Section-I(D). The Minimal  Bactericidal Concentration and Minimal Fungicidal
Concentration (MBC & MFC) of the test solution are reported in Table-10.
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5a C6H5- C24H18N6S 422.5 198 52 19.89 19.61 0.55 S1
5b 3-OCH3-C6H4- C25H20N6OS 452.5 183 56 18.57 18.33 0.48 S2
5c 2,3-(OCH3)2C6H3- C26H22N6O2S 482.5 186 58 17.42 17.21 0.51 S2
5d 3,5-(NO2)2C6H3- C24H16N8O4S 512.5 196 50 21.86 21.60 0.49 S1
5e 2-C5H4N- C23H17N7S 423.5 180 59 23.15 22.94 0.51 S2
5f 3-C5H4N- C23H17N7S 423.5 190 55 23.15 22.91 0.47 S2
5g 4-C5H4N- C23H17N7S 423.5 187 54 23.15 22.89 0.48 S1
5h 2,4,5-(F)3C6H2- C24H15F3N6S 476.5 183 57 17.64 17.41 0.51 S2
5i 4-Cl-2,5-(F)2-C6H2- C24H15ClF2N6S 492.9 194 53 17.05 16.83 0.53 S1
5j 3-Cl-2,4,5-(F)3-C6H- C24H14ClF3N6S 510.9 188 54 16.45 16.19 0.52 S1
S1 Hexane : Ethyl acetate (2 : 8),   S2 Chlorofom : Methanol (7 : 3)
Sr.     R    Molecular    Molecular     M.P.    Yield       % of Nitrogen     Rf           Solvent
No                      Formula           Weight           oC            %         Calcd.        Found       Value        System
1      2                          3   4                 5            6              7             8          9            10
TABLE:-9 PHYSICAL CONSTANTS OF 3-[7-METHYL-2-(p-METHYLPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]6-
-ARYL[1,2,4]TRIAZOLO[3,4-b][1,3,4]THIADIAZOLES.
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IR SPECTRAL STUDIES OF 3-[7-METHYL-2-(p-METHYLPHENYL)IMIDAZO
[1,2-a]PYRIDIN-3-YL]-6-PHENYL[1,2,4]TRIAZOLO[3,4-B][1,3,4]THIADIAZOLE
Instrument  : SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range
: 4000-400 cm-1 (KBr disc.)
Alkane   C-H str. (asym.) 2950 2975-2950 52
-CH3   C-H i.p.def. (asym.) 1452 1470-1435  ,,
Aromatic   C-H  str. 3057 3090-3030 53
  C=C str. 1500 1540-1480  ,,
  C-H i.p.def. 1099 1125-1000  ,,
Imidazo[1,2-a]   C=N str. 1641 1612-1593 52
pyridine   C-N str. 1191 1220-1020  ,,
  C=C str. 1539 1540-1480  ,,
Triazole   C=N str. 1588 1650-1580 53
  C-N str. 1315 1360-1310  ,,
  N-N str. 1016 1050-1010  ,,
Thiadiazole   C-S-C str. 715 720-570 52
 Observed
Type
        Reported
Frequency in cm-1
 Vibration
Mode     Ref.
N
N
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CH3
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S
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Signal
  No.
Signal Position
    (δppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
NMR SPECTRAL STUDIES OF 3-[7-METHYL-2-(p-METHYLPHENYL)
IMIDAZO [1,2-a]PYRIDIN- 3-YL]-6-PHENYL[1,2,4]TRIAZOLO[3,4-b][1,3,4]
THIADIAZOLE
Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER
Spectrometer (300MHz)
N
N
CH3
CH3
N
N
NN
S
b
ed
d' e'c
a
   1. 2.31 3H singlet Ar-CH3 -
   2. 2.38 3H singlet Py-CH3 -
   3. 6.98 1H dd Ar-H(b) -
   4. 7.22-7.73 9H multiplet Ar-H -
   5. 7.84 1H doublet Ar-H(c) J=9
   6. 7.88 1H singlet Ar-H(a) -
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MASS SPECTRAL STUDIES OF 3-[7-METHYL-2-(p-METHYLPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]-6-PHENYL-
[1,2,4]TRIAZOLO[3,4-b][1,3,4] THIADIAZOLE
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N
CH
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 =
 422
.5
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CODE NO. E. COLI P. AERUGINOSA S. AUREUS S.PYOGENUS
MTCC 442 MTCC 441 MTCC 96 MTCC 443
1 5a 100 50 500 250
2 5b 500 500 250 500
3 5c 250 250 500 500
4 5d 100 250 1000 1000
5 5e 50 125 500 500
6 5f 25 100 250 100
7 5g 500 500 100 1000
8 5h 100 250 500 500
9 5i 500 500 100 250
10 5j 500 500 1000 100
11 AMPICILLIN 100 100 250 100
12 CHLORAMPHENICOL 50 50 50 50
13 CIPROFLOXACIN 25 25 50 50
14 NORFLOXACIN 10 10 10 10
ANTIBACTERIAL ACTIVITY TABLE
MINIMAL BACTERICIDAL CONCENTRATION
SR. 
NO.
CODE NO. C. ALBICANS A. NIGER A. CLAVATUS
MTCC 227 MTCC 282 MTCC 1323
1 5a 250 500 500
2 5b 1000 >1000 >1000
3 5c 1000 >1000 >1000
4 5d 1000 500 500
5 5e 1000 >1000 >1000
6 5f 1000 500 500
7 5g 500 250 500
8 5h 250 500 500
9 5i 500 500 500
10 5j 250 1000 1000
11 NYSTATIN 100 100 100
12 GRESEOFULVIN 500 100 100
SR. 
NO.
ANTIFUNGAL ACTIVITY TABLE
MINIMAL FUNGICIDAL CONCENTRATION
(µg/ml)
(µg/ml)
TABLE: 10 BIOLOGICAL EVALUATION OF 3-[7-METHYL-2-(p-METHYL
PHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]6-ARYL[1,2,4]-
TRIAZOLO[3,4-b][1,3,4]THIADIAZOLE
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INTRODUCTION
Imidazolinone is a five membered heterocycle having 2-nitrogen atoms at 1 and
3 positions and C=O group at following positions : 2-oxo-imidazoline (I), 4-oxo-
imidazoline (II), 5-oxo-imidazoline (III).
The discovery of the 2-substituted-5-imidazolines dates back to the year
1888, when A. W. Hoffman1 for the first time discovered 5-oxo-imidazoline by heating
N1-diacetylethylene diamine in a stream of dry hydrogen chloride. Moreover, some
compounds were prepared by A. Ladenburg2 by the fusion of two equivalents of sodium
acetate with one equivalent of ethylene diamine dihydrochloride.
SYNTHETIC ASPECT
Various methods have been described in litetrature for the synthesis of
imidazolinones.3 Amminolysis of oxazolone with amine leads to the formation of
imidazolinones.4
1. Allimony et al.5 have synthesized new imidazolinone derivatives by
conventional method.
2 . Feng Jun Cai  et  al . 6 have reported 5-imidazolinone derivatives by
microwaves irradiation.
3. A. Saxena et al.7 have synthesized new imidazolinones as under.
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4. Antonin Klaseka and Antonin Lyekab have prepared new imidazolinone
derivatives via an unexpected pathway.8
5. Atsushi Kawasaki et al.9 prepared novel imidazolinones in methanol as under.
6 . Jean Michel Lerestif  et  al .10 have synthesized imidazolinone from
α-aminoester as under.
THERAPEUTIC IMPORTANCE
Some of the well known drugs containing imidazolinone that are widely being
used are naphazoline hydrochloride as adrenergic stimulants, tolazoline and phenotolamine
as adrenergic blocking agents. Various imidazolinones are known to exhibit a broad
spectrum of biological activities such as,
1. Anticonvulsant11
2. Antihistaminic12
3. Antidiabatic13
4. Antitubercular14
5. Bactericidal15
6. Fungicidal16-17
7. Antiparkinsonian18
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8. Anthelmintic19
9. Sedative and hypnotics20
10. Anticancer21
11. Antimicrobial22
12. Potent CNS depressant23
13. Insecticidal24
14. Antiviral25
15. Hypertensive26
16. Antiinflammatory27
17. Thrombin inhibitor28
Christopher Preston and co-workers29 have reported the triazolopyrimidine and
imidazolinone as herbicides. U. Akyoshi et al.30 have prepared some new imidazolinone
derivatives (IV) and reported their herbicidal activity. Agrochemical activity of
imidazolinones have been reported by Bascou and co-workers.31 A series of imidazolinone
analogues (V) were synthesized as potent antibacterial agent by Joanne J. Bronson et al.32
Moreover Rossello et al.33 have prepared imidazolones as antifungal agent.
A. B. Cooper and co-workers34 have found that imidazolones are inhibitors of farnesyl
protein transferase. Machii Daisuke et al.35 have synthesized new imidazolones as a
telomeres inhibitors and antitumor agents. M. R. Jean et al.36 have synthesized
imidazolones and tested as antileishmanial agent. Chafiq amdouchi et al.37 have reported
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 imidazolinones and screened for their potent and broad spectrum activity.
K. K. Awasthi et al.38 have synthesized some new imidazolinone derivatives (VI)
and reported their antimicrobial activity. A. J. Baxi and co-workers39 have synthesized
several imidazolinone derivatives having good anticonvulsant activity. Rama Sharma and
co-workers40 have reported antimicrobial activity of 5-oxo-imidazolines (VII).
L. Joseph Peter and co-workers41 have prepared substituted imidazolinones which
inhibited the abnormal cell growth in human body. Kazutoshi Watanabe et al.42 have
prepared a series of (VIII) with potent radical-scavenging activity and lipid peroxidation
inhibitory activity. Seth Olsen and Sean C. Smith43 have synthesized imidazolinones like
(IX) having good biological actitity. Stefama Lauter and co-workers44 have isolated
imidazoline and tested for the treatment of cytokine release.
Declera arthur and co-workers45 have prepared imidazoline derivatives showing
anti-HIV activity. Christopher S. Burgey et al.46 have reported phenylimidazolinone (X),
S
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incorporated into the benzodiazepine moity, as a CGRP receptor antagonists for the treatment
of migraine. Aldo Andreani et al.47 have synthesized a new series of imidazo[2,1-b]thiazole
derivatives (XI) as potential acetylcholinesterase and butyrylcholinesterase inhibitors.
James C. Lanter et al.48 were synthesized potential bioisosteres of the nonsteroidal
antiandrogen imidazolidinone (XII). A series of thieno[3,2-b]pyrroloazepinones derivatives
related imidazolinone (XIII) were prepared and tested for CHK1 inhibitory activity
by Jean-Gilles Parmentier and co-workers.49
With a view to getting better therapeutic agent, it was contemplated to synthesize
imidazolinones to enhance the overall activity of resulting compounds which have been
described as under.
SECTION - I   : SYNTHESIS AND BIOLOGICAL SCREENING OF (5Z)-5-
{[7-METHYL-2-(p-METHYLPHENYL)IMIDAZO[1,2-a]PYRIDIN-
3-YL]METHYLENE}-3-ARYL-2-PHENYL-3,5-DIHYDRO-
4H-IMIDAZOL-4-ONES.
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF (5Z)-5-{[7-METHYL-2-(p-
METHYLPHENYL)IMIDAZO[1,2-a]PYRIDINE-3-YL]METHYLENE}-3-ARYL-
2-PHENYL-3,5-DIHYDRO-4H-IMIDAZOL-4-ONES.
Imidazolinones represent one of the most active class of compounds having a
wide spectrum of biological activities. With an aim to getting better therapeutic agent,
the preparation of (5Z)-5-{[7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridine-3-yl]
methylene}-3-aryl-2-phenyl-3,5-dihydro-4H-imidazol-4-ones of Type-VI have been
undertaken by the condensation of azalactone with different aromatic amines as shown
in reaction scheme.
The constitution of the synthesized compounds have been characterised by
elemental analysis, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all the compounds have been checked by
thin layer chromatography (TLC).
All the compounds have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards fungus strains at a different concentration. The biological
activity of the synthesized compounds were compared with standard drugs, as shown in
Table-12.
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Type-VI R=Aryl
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF (5Z)-5-{[7-METHYL-2-(p-
METHYLPHENYL)IMIDAZO[1,2-a]PYRIDINE-3-YL]METHYLENE}-3-ARYL-
2-PHENYL-3,5-DIHYDRO-4H-IMIDAZOL-4-ONES.
[A] Preparation of 2-chloro-1-(p-methylphenyl)ethanone.
See Part:-1, Section:-I(A).
[B] Preparation of 2-(p-methylphenyl)-7-methylimidazo[1,2-a]pyridine.
See Part:-1, Section:-I(B).
[C] Synthesis of 7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridine-3-
carbaldehyde.
A solution of 2-(p-methylphenyl)-7-methylimidazo[1,2-a]pyridine(4.44 gm, 0.02
mol) in 140 ml chloroform was added dropwise to a well mixed solution of phosphorus
oxychloride (11 ml ), chloroform (32 ml) and DMF (8 ml) at 0-10oC and maintained for
30 mins. The mixture was refluxed for 8 hours. The solution was Cooled to room
temprature and evaporated to dry in vaccum. The residue was treated with cold water
and seperated solid was filtered and wash with ether, crystallized from methanol. Yield
90% (2.25gm), m. p. 196oC. Calculated (%) of C14 H8 Cl2 N2O (250.4); C: 76.78, H:
5.64, N: 11.19, Found (%) C: 76.63, H: 5.51, N: 11.07.
TLC solvent system : Ethyl acetate : Hexane (6 : 4)
[D] Synthesis of  (4Z)-4-{[7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridin-3-yl]
methylene}-2-phenyl-1,3-oxazol-5(4H)-one.
A mixture of 7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridine-3-
carbaldehyde (2.50gm, 0.01 mol), acetic anhydride (7.6ml, 0.075 mol), hippuric acid
(4.4gm, 0.025 mol) and sodium acetate (2.46gm 0.03 mol) was heated on a waterbath
for  4-5 hrs. The resulting solution was poured on to crushed ice, filtered and crystallized
from dioxane. Yield, 68% (2.65gm), m.p. 218oC. Calculated (%) of C25 H19 N3O2
(393.4); C: 76.32, H: 4.87, N: 10.68, Found (%) C: 76.21, H: 4.68, N: 10.56.
TLC solvent system : Ethyl acetate : Hexane (7 : 3).
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[E] Synthesis of (5Z)-5-{[7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridine-3-yl]
methylene}-3,2-diphenyl-3,5-dihydro-4H-imidazol-4-ones.
A solution of (4Z)-4-{[7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridin-3-yl]
methylene}-2-phenyl-1,3-oxazol-5(4H)-one(3.93gm, 0.01 mol) and Aniline(0.93gm,
0.01 mol) in dry pyridine (25 ml) was refluxed for 12 hrs. on oil bath. The contents were
poured on to crushed ice and neutralized with HCl. The isolated product was crystallized
from dioxane. Yield 54% (2.52gm), m.p.198oC. Calculated (%) of C31 H24N4O (468.5)
C: 79.46, H: 5.16, N: 11.96, Found (%) C: 79.33, H: 5.03, N: 11.81.
TLC solvent system : Ethyl acetate : Hexane (8 : 2).
Similarly other amines were condensed with (4Z)-4-{[7-methyl-2-(p-methylphenyl)
imidazo[1,2-a]pyridin-3-yl]methylene}-2-phenyl-1,3-oxazol-5(4H)-one. The physical
data are recorded in Table-11.
[F] Biological evaluation of (5Z)-5-{[7-methyl-2-(p-methylphenyl)imidazo[1,2-a]
pyridine-3-yl]methylene}-3-aryl-2-phenyl-3,5-dihydro-4H-imidazol-4-ones
Antimicrobial and antifungal testing were carried out as described in Part-1,
Section-I(D). The Minimal Bactericidal Concentration and Minimal Fungicidal
Concentration (MBC & MFC) of the test solution are reported in Table-12.
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S1 Hexane : Ethyl acetate (2 : 8),   S2 Hexane : Ethyl acetate (4 :6)
TABLE:-11 PHYSICAL CONSTANTS OF (5Z)-5-{[7-METHYL-2-(p-METHYLPHENYL)IMIDAZO[1,2-a]PYRIDINE-3-YL]
METHYLENE}-3-ARYL-2-PHENYL-3,5-DIHYDRO-4H-IMIDAZOL-4-ONES
6a C6H5- C31H24N4O 468.5 198 54 11.96 11.71 0.45 S2
6b 2-C5H4N- C30H23N5O 469.5 183 52 14.92 14.69 0.55 S2
6c 4-C5H4N- C30H23N5O 469.5 186 56 14.92 14.71 0.52 S2
6d 5-CH3-2-C5H3N- C31H25N5O 483.5 196 48 14.48 14.22 0.48 S1
6e 4-CH3-2-C5H3N- C31H25N5O 483.5 180 51 14.48 14.19 0.56 S2
6f 4,6-(Br)2-2-C5H2N- C30H21Br2N5O 627.3 190 51 11.16 10.94 0.54 S1
6g 5-Br-2-C5H3N- C30H22Br2N5O 548.4 187 50 12.77 12.52 0.51 S1
6h 5-Br-3-NO2-2-C5H2N- C30H21BrN6O3 593.4 183 47 14.16 13.93 0.49 S1
6i 2-Cl-4-C5H3N- C30H22ClN5O 503.9 194 58 13.90 13.68 0.56 S1
6j 5-CN-2-C5H3N- C30H22N6O 494.5 188 50 16.99 16.73 0.48 S1
Sr.     R    Molecular    Molecular     M.P.    Yield       % of Nitrogen     Rf           Solvent
No                      Formula           Weight           oC            %         Calcd.        Found       Value        System
1      2                          3   4                 5            6              7             8          9            10
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IR SPECTRAL STUDIES OF  (5Z)-5-{[7-METHYL-2-(p-METHYLPHENYL) IMIDAZO
[1,2-a]PYRIDINE-3-YL]HYLENE}-3 ,2-DIPHENYL-3,5-DIHYDRO-4H -
IMIDAZOL-4-ONES
 Observed
Alkane   C-H str. (asym.) 2957 2975-2950 50
-CH3   C-H str. (sym.) 2872 2880-2860  ,,
  C-H i.p.def. (asym.) 1442 1470-1435  ,,
  C-H o.o.p.def. 1365 1395-1370  ,,
Aromatic   C-H  str. 3041 3090-3030 51
  C-H i.p.def. 1105 1125-1000  ,,
  C-H o.o.p. (def) 829 835-810  ,,
Imidazo[1,2-a]   C=N str. 1598 1612-1593 50
pyridine   C-N str. 1163 1220-1020  ,,
  C=C str. 1504 1540-1480  ,,
Imidazolone   C=O str. 1714 1760-1655  ,,
ring   C=N str. 1633 1650-1580  ,,
Type     Ref.
        Reported
Frequency in cm-1
 Vibration
Instrument  : SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range
: 4000-400 cm-1 (KBr disc.)
Mode
N
N
CH3
CH3
N
N O
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Signal
  No.
Signal Position
    (δppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
NMR SPECTRAL STUDIES OF (5Z)-5-{[7-METHYL-2-(p-METHYLPHENYL)
IMIDAZO[1,2-a]PYRIDINE-3-YL]HYLENE}-3,2-DIPHENYL-3,5-DIHYDRO-
4H-IMIDAZOL-4-ONES
Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER
Spectrometer (300MHz)
   1. 2.26 3H singlet Ar-CH3 -
   2. 2.49 3H singlet Py-CH3 -
   3. 7.01-7.50 10H multiplet Ar-H -
   4. 7.55 2H doublet Ar-H(ee’) J=9
   5. 7.64 2H doublet Ar-H(dd’) J=9
   6. 8.48 2H multiplate Ar-H(a,c) -
   7. 8.72 1H singlet Ar-H(f) -
a
b
c
N
N
CH3
CH3
N
N O
f
d
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MASS SPECTRAL STUDIES OF (5Z)-5-{[7-METHYL-2-(p-METHYLPHENYL)IMIDAZO[1,2-a]PYRIDINE-3-YL]HYLENE}-
3,2-DIPHENYL-3,5-DIHYDRO-4H-IMIDAZOL-4-ONES
N
N
CH
3
C
H
3
NN
O
m
/z
 =
 468
.5
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CODE NO. E. COLI P. AERUGINOSA S. AUREUS S.PYOGENUS
MTCC 442 MTCC 441 MTCC 96 MTCC 443
1 6a 125 250 250 500
2 6b 25 100 25 1000
3 6c 500 100 50 500
4 6d 100 100 125 500
5 6e 500 500 100 250
6 6f 250 125 250 500
7 6g 125 1000 125 1000
8 6h 500 1000 100 500
9 6i 250 25 500 1000
10 6j 125 500 125 1000
11 AMPICILLIN 100 100 250 100
12 CHLORAMPHENICOL 50 50 50 50
13 CIPROFLOXACIN 25 25 50 50
14 NORFLOXACIN 10 10 10 10
ANTIBACTERIAL ACTIVITY TABLE
MINIMAL BACTERICIDAL CONCENTRATION
SR. 
NO.
CODE NO. C. ALBICANS A. NIGER A. CLAVATUS
MTCC 227 MTCC 282 MTCC 1323
1 6a >1000 >1000 >1000
2 6b 500 500 500
3 6c 500 1000 1000
4 6d 250 500 1000
5 6e 250 500 1000
6 6f 500 500 500
7 6g 1000 1000 >1000
8 6h 1000 250 500
9 6i 500 >1000 >1000
10 6j 1000 >1000 >1000
11 NYSTATIN 100 100 100
12 GRESEOFULVIN 500 100 100
SR. 
NO.
ANTIFUNGAL ACTIVITY TABLE
MINIMAL FUNGICIDAL CONCENTRATION
(µg/ml)
(µg/ml)
TABLE: 12 BIOLOGICAL EVALUATION OF  (5Z)-5-{[7-METHYL-2-(p-METHYL
PHENYL)IMIDAZO[1,2-a]PYRIDINE-3-YL]METHYLENE}-3-
ARYL-2-PHENYL-3,5-DIHYDRO-4H-IMIDAZOL-4-ONES.
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INTRODUCTION
Isoxazole is a five membered heterocyclic compound having two hetero atom
oxygen at position 1 and nitrogen at position 2. In 1888, Claisen first reported an isoxazole
(I) for a product from the reaction of 1,3 diketone with hydroxylamine.1 Subsequently a
solid foundation for the chemistry of isoxazole was laid down by Claisen and his students.
It was shown to possess typical properties of an aromatic system but under certain
reaction conditions. Particularly in reducing or basic media, it becomes very highly labile.
The next important contribution to the chemistry of isoxazoles was made by
Quelico2 in 1945, when he begain to study the formation of isoxazoles from nitrile N-
oxide and unsaturated compounds.
SYNTHETIC ASPECT
Isoxazoles can be prepared by various method, which are described as under.
2. Luca Basolo et al.3 have synthesized novel isoxazoles through a one-pot sequential
1,3-dipolar cycloaddition/Pd-catalyzed arylation.
3 . L. S. Crawley and W. J.  Fanshawe4 were prepared isoxazole from  α,β-
unsaturated carbonyl compounds by hydroxyl amine hydrochloride and
KOH in methanol.
O
N
( I )
Y
N
X
CH
R
Y
N
N
O
Ar
R
N+ O-Ar
2% Pd(OAC)2 
X = Hal, Y = CH, N 
R R1
O
+ NH2OH.HCl ON
R R1KOH
Synthesis, Characterisation and....
147
4. Keisuke Suzuki et al.5 have synthesized functionalized isoxazole derivatives by
cyclocondensation of C-chlorooximes with cyclic 1,3-diketones.
5. Mark Lautens and Amelie Roy6 have constructed isoxazoles, which achieved
in good yields via rapid and simple way by using N-acetoacetyl derivatives.
7. A variety of 3,5-disubstituted 4-bromoisoxazoles7 were prepared in good to
excellent yields under mild reaction conditions as below.
8. Isoxazoles were synthesised in moderate to good yields using 1,3-dipolar
cycloaddition of pyrazole derived nitrile oxide with various dipolarophiles such
as diethylacetylene dicarboxylate by K. Karthikeyan and co-workers.8
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REACTION MECHANISM
THERAPEUTIC IMPORTANCE
Isoxazole derivatives exhibit various biological activities such as,
1. Anticonvulsant9,10
2. Anticholestermic11
3. Antibacterial12, 13
4. Anthelmintics14
5. Anticancer15
6. Adenosine antagonist16
7. Fungicidal17-18
8. Herbicidal19
9. Hypoglycemic20
10. Muscle relaxant21-22
11. Nematocidal23
12. Insecticidal24
13. Antiinflammatory25-26
14. Antimicrobial27
15. Antiviral28
R O
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R O
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R O
R1
O
NH2
_
R O
R1
O
NH2
+
_
R
R1
O
NH
OH
R
R1
O
NH
R
R1
O
N
R
R1
O
N _
+
OH-NH2.HCl
_ : :
Proton transfer
-H+ H+
H+
-H+-2H
+
OH
-H2O
Synthesis, Characterisation and....
149
Stefano Chimichi and co-workers29 have investigated cytotoxic activity of 3-
quinolinoyl isoxazoles (II) against leukemia and adenocarcinoma derived cell lines in
comparison to the normal human keratinocytes. Novel cyclohexyl drug resistance
modulators like (III) were synthesized and evaluated for in vitro inhibition of the drug
resistance transporter by BryanH. Norman et al.30
Julia Kaffy et al.31 have synthesized various five membered heterocycles with
oxygen and nitrogen atoms. The 4,5 diarylisoxazole (IV) exhibited greater antitubulin
activity, but modest antiproliferative activity. Kaifan Cheng and Yousef Al-Abed32 have
reported isoxazole derivatives (V), which found quite more potent than 3-(4-
hydroxyphenyl)-4,5-dihydro-5-acetic acid methylesterisoxazole to inhibits MIF
tautomerase with an IC50.
D. Aicher Thomas et al.33 have reported isoxazoles as hypoglycemic agents. H.
H. Parekh et al.34 have synthesized 3-(p-methoxyphenyl)-5-(2'-chloro-7'-methylquinolin-
3'-yl)-isoxazole (VI) and studied thier biologcal activity. A number of derivatives of
N O
CH3
OH O N
( II )
N
N
O
Cl
O CH3
NHO
( III )
N
O
O
CH3
O
CH3
O CH3
O CH3
OH
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isoxazolo[4,5-d]pyrimidine (VII) were prepared by Edwin Wagner et al.35 which
showed strong immunosuppressed activity than that of Cephalosporin A.
M. Matringe et al.36 have reported some new p-hydroxyphenylpyruvates
dioxygenase inhibitor-resistant plants. D. R. Mehlisch et al.37 have synthesized isoxazole
derivatives as analgesic agents of intramuscular parecoxib sodium in postoperative dental
pain. Tony Taldone et al.38 synthesized isoxazoles scaffolds (VIII) as Heat shock protein
90 (Hsp90) inhibitor, which is an important target in cancer. Novel isoxazoles (IX) were
designed and synthesized by cycloaddition, and showed moderate antiviral activities.
The nucleosides were tested against 12 different viruses by Yoon-Suk Lee.39
W. A. Ray et al.40 have reported isoxazole derivatives as cardiovascular toxicity
agents of valdecoxib. M. W. Salter et al.41 have prepared some novel isoxazoles, which
show cellular neuroplasticity mechanism in mediating pain persistence. P. M. Welsing et
al.42 have documented the isoxazoles as tumornecrosis factor blocking agents and
leflunomide for treating rheumatoid arthritis in the Netherlands.
N
N O
NH
O
N
N
CH3
R( VII )( VI )
N
O
N
R
CH3 Cl
O N
OH
OH
CH3CH3
N
O
O
NH
CH3 N
OOR
OR
NH
O
O
O
NH
R1
( VIII ) ( IX )
Synthesis, Characterisation and....
151
S. J. Bingham et al.43 have synthesized isoxazole derivatives as an antiuclear
agents. M. R. Barbachyn et al.44 have described the phenylisoxazolines as novel and
viable antibacterial agents, which active against gram-positive pathogens. Andrew Plant
et al.45 have prepared series novel isoxazoles (X) having antibiotic activity.
Masui et al.46 have prepared isoxazoles having pesticidal activity. Some excellent
herbicidal results obtained by Reddy et al.47 while C. B. Xue et al.48 have reported an
oral antiplatelet effect in dogs.
With an intension of preparing the compounds possessing better therapeutic
activity, we have under taken the preparation of isoxazoles bearing imidazo[1,2-a]pyridine
derivatives which have been described as follows.
SECTION-I  :   SYNTHESIS AND BIOLOGICAL SCREENING OF 7-METHYL
-2-(p-METHYLPHENYL)-3-(3-ARYLISOXAZOL-5-YL)
IMIDAZO[1,2-a]PYRIDINES
N
O
OH
NH
O
O
N
O
O
N
H
OMeO
X
R
X = H, SMe
R = 3-Pyridyl-, (pyridin-2-ylthio)methyl-, (imidazol-2-ylthio)methyl-
( X )
Synthesis, Characterisation and....
152
SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 7-METHYL-2-(p-METHYL
PHENYL)-3-(3-ARYLISOXAZOL-5-YL)IMIDAZO[1,2-a]PYRIDINES.
Isoxazoles have been reported to have various pharmacological activities like
antibacterial, antifungal, insecticidal etc. In order to achieving better drug potency, we
have prepared isoxazole derivatives of Type-VII by the cyclocondensation of (2E)-3-
[7-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]-1-arylprop-2-en-1-one with
hydroxylamine hydrochloride in presence of sodium acetate in glacial acetic acid as shown
in reaction scheme.
The constitution of the synthesized compounds have been characterised by
elemental analysis, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all the compounds have been checked by
thin layer chromatography (TLC).
All the compounds have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards fungus strains at a different concentration. The biological
activity of the synthesized compounds were compared with standard drugs, as shown in
Table-14.
R=ArylType-VII
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NCH3
CH3
O
N
R
Synthesis, Characterisation and....
153
R=Aryl
R COCH3
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 7-METHYL-2-(p-METHYL-
PHENYL)-3-(3-ARYLISOXAZOL-5-YL)IMIDAZO[1,2-a]PYRIDINE.
[A] Preparation of 2-chloro-1-(p-methylphenyl)ethanone.
See Part:-1, Section:-I(A).
[B] Preparation of 2-(p-methylphenyl)-7-methylimidazo[1,2-
a]pyridine.
See Part:-1, Section:-I(B).
[C] Synthesis of 7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridine-3-
carbaldehyde.
See Part:-5, Section:-I(C).
[D] Synthesis of  (2E)-3-[7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridin-3-yl]-
1-phenylprop-2-en-1-one.
Dissolve 7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridine-3-carbaldehyde
(2.50gm, 0.01mol) in a mixture of methanol (5.0ml) & DMF (5.0ml). Then add
acetophenone (1.20gm, 0.01mol) and methanol (5.0ml). Stirr contents at room
temperature for 24 hrs. in presence of catalytical amount of 40% KOH solution. The
resulting solution was poured in to crushed ice, seprated solid was filterated and
crystallized from ethanol, Yield 60% (2.11gm), m. p. 186oC. Calculated (%) of
C24H20N2O (352.4) C: 81.79, H: 5.72, N: 7.95, Found (%) C: 81.68, H: 5.61, N: 7.83.
TLC solvent system : Ethyl acetate : Hexane (5 : 5).
Similarly, other aromatic ketones condensed with 7-methyl-2-(p-methyl-
phenyl)imidazo[1,2-a]pyridine-3-carbaldehyde.
[E] Synthesis of  7-methyl-2-(p-methylphenyl)-3-(3-phenylisoxazol-5-yl)
imidazo[1,2-a]pyridine.
Anhydrous sodium acetate (0.739gm, 0.01 mol) and hydroxylamine hydrochloride
(0.59 gm, 0.01 mol) in acetic acid were added to a solution of (2E)-3-[7-methyl-2-(p-
methylphenyl)imidazo[1,2-a]pyridin-3-yl]-1-phenylprop-2-en-1-one (3.52 gm, 0.01 mol)
in ethanol (25 ml). The reaction mixture was refluxed on oil bath for 7-8 hrs. The
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product  was isolated and crystallized from ethanol. Yield 62% (2.26gm), m.p. 161oC.
Calculated (%) of C24H19N3O (365.4); C: 78.88, H: 5.24, N: 11.50, Found (%)
C: 78.53, H, 5.02, N, 11.33.
TLC solvent system : Ethyl acetate : Hexane (8 : 2).
Similarly other 7-methyl-2-(p-methylphenyl)-3-(3-arylisoxazol-5-yl)imidazo[1,2-a]
pyridine are prepared. The physical data are recorded in Table-13.
[F] Biological evaluation of 7-methyl-2-(p-methylphenyl)-3-(3-arylisoxazol-5-yl)
imidazo[1,2-a] pyridine.
Antimicrobial and Antifungal testing were carried out as described in Part-1,
Section-I(D). The Minimal Bactericidal Concentration and Minimal Fungicidal
Concentration(MBC & MFC) of the test solution are reported in Table-14.
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7a C6H5- C24H19N3O 365.4 161 62 11.50 11.33 0.52 S1
7b 4-CH3-C6H4- C25H21N3O 379.4 148 66 11.07 10.89 0.49 S1
7c 4-OCH3-C6H4- C25H21N3O2 395.4 156 55 10.63 10.41 0.51 S1
7d 3-Cl-C6H4- C24H18ClN3O 399.8 168 68 10.51 10.28 0.50 S1
7e 4-F-C6H4- C24H18FN3O 383.4 146 53 10.96 10.73 0.48 S1
7f 4-NH2-C6H4- C24H20N4O 380.4 160 58 14.73 14.50 0.41 S2
7g 3-NH2-C6H4- C24H18N4O 380.4 157 62 14.73 14.48 0.43 S2
7h 4-NO2-C6H4- C24H18N4O3 410.4 163 64 13.65 13.43 0.51 S1
7i 3-NO2-C6H4- C24H18N4O3 410.4 144 52 13.65 13.40 0.53 S1
7j 4-0H-C6H4- C24H19N3O2 381.4 158 42 11.02 10.81 0.40 S2
S1 Hexane : Ethyl acetate (2 : 8),   S2 Chlorofom : Methanol (7 : 3)
Sr.      R    Molecular    Molecular     M.P.    Yield       % of Nitrogen     Rf          Solvent
No                  Formula               Weight          oC            %          Calcd.        Found       Value       System
1        2                       3   4                 5             6              7             8          9            10
TABLE:-13  PHYSICAL CONSTANTS OF 7-METHYL-2-(p-METHYLPHENYL)-3-(3-ARYLISOXAZOL-5-YL)
 IMIDAZO[1 ,2 -a ]PYRIDINES
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IR SPECTRAL STUDIES OF 7-METHYL-2-(p-METHYLPHENYL)-3-(3-
PHENYLISOXAZOL-5-YL) IMIDAZO[1,2-a]PYRIDINE
 Observed
Alkane   C-H str. (asym.) 2920 2975-2950 49
-CH3   C-H str. (sym.) 2856 2880-2860  ,,
  C-H i.p.def. (asym.) 1450 1470-1435  ,,
  C-H o.o.p.def. 1330 1395-1370  ,,
Aromatic   C-H  str. 3024 3090-3030 50
  C=C str. 1535 1540-1480  ,,
  C-H i.p.def. 1060 1125-1000  ,,
Imidazo[1,2-a]   C=N str. 1593 1612-1593 49
pyridine   C-N str. 1213 1220-1020  ,,
  C=C str. 1502 1540-1480  ,,
Isoxazole   C=C str. 1658 1680-1550  ,,
  C=N str. 1502 1690-1460  ,,
  N-O str. 823 850-810  ,,
Type     Ref.
        Reported
Frequency in cm-1
 Vibration
Instrument  : SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range
: 4000-400 cm-1 (KBr disc.)
Mode
N
N
CH3
CH3
O
N
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Signal
  No.
Signal Position
    (δppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
NMR SPECTRAL STUDIES OF 7-METHYL-2-(p-METHYLPHENYL)-3-(3-
PHENYLISOXAZOL-5-YL) IMIDAZO[1,2-a]PYRIDINE
Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER
Spectrometer (300MHz)
   1. 2.42 3H singlet Ar-CH3 -
   2. 2.45 3H singlet Py-CH3 -
   3. 6.52 1H singlet Ar-H(f) -
   4. 7.19-7.42 7H multiplet Ar-H -
   5. 7.29 2H doublet Ar-H(ee’) J=9
   6. 7.66 2H doublet Ar-H(dd’) J=9
   7. 8.78 1H singlet Ar-H(a) -
N
N
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MASS SPECTRAL STUDIES OF 7-METHYL-2-(p-METHYLPHENYL)-3-(3-PHENYLISOXAZOL-5-YL)
IMIDAZO[1,2-a]PYRIDINE
N
N
CH
3
C
H
3
ON
m
/z
 =
 365
.4
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CODE NO. E. COLI P. AERUGINOSA S. AUREUS S.PYOGENUS
MTCC 442 MTCC 441 MTCC 96 MTCC 443
1 7a 500 250 500 1000
2 7b 250 100 250 500
3 7c 500 500 500 500
4 7d 100 250 500 250
5 7e 250 250 125 500
6 7f 100 250 1000 100
7 7g 1000 500 1000 250
8 7h 500 1000 500 250
9 7i 250 250 250 500
10 7j 100 500 125 500
11 AMPICILLIN 100 100 250 100
12 CHLORAMPHENICOL 50 50 50 50
13 CIPROFLOXACIN 25 25 50 50
14 NORFLOXACIN 10 10 10 10
ANTIBACTERIAL ACTIVITY TABLE
MINIMAL BACTERICIDAL CONCENTRATION
SR. 
NO.
CODE NO. C. ALBICANS A. NIGER A. CLAVATUS
MTCC 227 MTCC 282 MTCC 1323
1 7a 1000 500 250
2 7b 250 500 500
3 7c 500 100 500
4 7d >1000 250 500
5 7e 1000 500 500
6 7f 500 250 500
7 7g 250 >1000 >1000
8 7h 500 500 250
9 7i 500 500 500
10 7j 1000 500 >1000
11 NYSTATIN 100 100 100
12 GRESEOFULVIN 500 100 100
SR. 
NO.
ANTIFUNGAL ACTIVITY TABLE
MINIMAL FUNGICIDAL CONCENTRATION
(µg/ml)
(µg/ml)
TABLE:14 BIOLOGICAL EVALUATION OF 7-METHYL-2-(p-METHYL-
PHENYL)-3-(3-ARYLISOXAZOL-5-YL)IMIDAZO[1,2-a]PYRIDINES.
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INTRODUCTION
Pyridine with different functional groups, exhibit wide range of applications in
the field of medicine, agriculture and dyes. Although many substituted pyridine compounds
and other heterocyclic compounds are synthesized with their functional group present
from a cyclic compounds. The simple pyridine compounds are prepared by the cyclization
of aliphatic raw material. 3-cyanopyridines, nicotinamide and nicotinic acid use as
synthetic intermediates of pharmaceutical substances.
Most of pyridine derivatives are synthesized by manipulation of pyridine and
its simple homologues in a similar manner to chemistry of the benzenoid chemistry.
However the simple pyridine compounds are prepared by the cyclization of aliphatic
raw materials. In our research work in the chemistry of pyridine nucleus, we have
undrtaken the synthesis of imidazo[1,2-a]pyridine derivatives such as  4-[7-methyl-2-
(p-methylphenyl)imidazo[1,2-a]pyridin-3-yl]-2-methoxy-6-arylnicotinonitriles via
chalcones.
SYNTHETIC ASPECT :
Different methods for the preparation of 3-cyanopyridines are available in
literature.1-6 The well known methods are
1. Atul R. Gholap and co-worker7 have prepared substituted cyanopyridines by
the condensation of  3-aminocyclohex-2-en-1-one with substituted benzylidene
propanedinitrile.
2. Substituted cyanopyridine derivatives were prepared from 3-substituted phenyl
pyrazolone derivatives with malononitrile.8
3. Matthew D. Bowman et al.9 have synthesized fluorescent cyanopyridine
O
NH2
+
CN
CN
N
CN
NH2
O
n-propanol
Reflux
R
R
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and deazalumazine dyes using small molecule macroarrays.
4. Sakurai and Midorikaw10,11 have reported that the malononitrile reacts with
α,β-unsaturated ketones to give 2-amino-3-cyano-4,6-disubstituted pyridines.
5. Reaction of 4-arylmethylene-3,4-dihydro-[1]-benzothiepin-5(2H)-ones  with
malononitrile in the appropriate alcohol in the presence of sodium have been
reported by Adel S. Girgis.12
6. Simon J. Teague13 have prepared substituted 3-cynopyridine by reacting 2-(1-
phenyl ethylidenepropanedinitriles with dimethyl N-cyanodithioiminocarbonate.
7. Microwave-assisted multicomponent reactions of aldehydes, 3-aryl-3-oxopropane
nitrile, 2-acetylpyridine, and ammonium acetate was reported by Bo Jiang et al.14
8. Lirong Wen15 have synthesized cynopyridine via sequence of Knoevenagel condensation,
Michael addition, cyclization, and intramolecular nucleophilic substitution,which
is first catalyzed by KF/neutral Al2O3 under microwave irradiation.
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MECHANISM
The reaction proceeds through conjugate addition of active methylene compounds
to the α,β-unsaturated system as shown below.
THERAPEUTIC IMPORTANCE
Cyanopyridines have attracted considerable attention as they appeare of interest
to possess antibacterial, anticholestemic, antifungal, antihypertensive and antidiabetic
activities. E. G. Hammana Abou and co-workers16 have studied anticancer and anti HIV
activity of 3-cyanopyridines. Abdallah Navine et al.17 have prepared cyanopyridine
derivatives which showed analgesic and antiinflammatory activity. Manna Fedele and
co-workers18 have reported the antiinflammatory activity of  3-cyanopyridines. H. Yoshida
et al.19 have studied the antihistaminic and antiallergic activity of 3-cyanopyridine
H2C
CN
CN NaOCH 3
HC
CN
CN
_
R O
R1
HC
CN
CN
_
R O
R1
CN
N
H
+
R O
R1
CN
N
R
R1
CN
OCH 3O NN
R1
R OCH 3
CN
OH
H
N
R1
R OCH 3
CN
N
R1
R OCH 3
CN
NaOCH 3
+
-OH
NaOCH 3
R
R1
CN
OCH 3O HN
NaOCH 3
_
_
_
-2H
H
+
H
+
Synthesis, Characterisation and....
167
derivatives. Abd El-Galil and co-workers20 have prepared 3-cyanopyridines (I) and
studied their pharmacological activity. Gadaginamath et al.21 have synthesized various
cyanopyridyl derivatives (II) and documented their variety of biological activities.
Many naturally occurring and synthetic compounds containing the pyridine scaffold
possess interesting pharmacological properties.22 Among them, 2-amino-3-cyanopyridines
have been identified as IKK-2 inhibitors.23
W. Von Behenburg et al.24 have synthesized 2-amino-3,6-disubstituted pyridines
as antiepileptic agents. V. Scott and E. Joseph25,26 have prepared 2-amino-3-cyanopyridine
derivatives which were found to be useful as antipsoriasis  pharmaceuticals. J. A. Vann
Allan et al.27 have prepared fused heterocyclic 3-cyanopyridine (III). Abu and
co-workers28 have prepared novel fused cyanopyridines (IV) for the treatment and
preparation of systemic fungal infection.
J. J. Baldwin29-31 have prepared cyanopyridines, exhibit antihypertensive activity.
Streightoff 32 and Seydal33 have studied the bacteriostatic effect of some  substituted
3-cyanopyridines. Francis and co-workers34 have studied the effect of some substituted
pyridines on the growth of the walker carcinosarcome-256 in tissue culture.
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Barton et al.35 have reported fungicidal and insecticidal properties of 3-
cynopyridines. Abdel Galil E. Amr et al.36 have synthesized heterocyclic  pyridine
derivatives (V) fused with steroidal structure. Initially the acute toxicity of the compounds
was assayed via the determination of their LD50. Heterocyclic pyridine fused with steroid
structure are active as antiinflammatory agents. Henryk foks et al.37 investigated new
3-cyanopyridine derivatives show an antibacterial activity. Mourad Chioua38 prepared
novel cynopyridines (VI) having protein kinase inhibitor activity.
Marco J. L. et al.39 have synthesized acetylcholinesterase inhibitors. Moustafa
M. A. et al.40 have prepared antibacterial agents. Eduardo H. S. Sousa et al.41 documented
thionicotinamide coordinated to the a model system for the in vitro activation of thioamides
antituberculosis drugs. Rosentreter Ulrich et al.42 have synthesized a new cyanopyridine
(VII) as receptor agonists in the treatment of cardiac or urogenital disease cancer, inflammation
and neurodegenerative disease. Gary T. Wang and co-workers43 have synthesized of
o-trifluoromethylbiphenyl substituted 2-amino-nicotinonitriles (VIII) as inhibitors of
farnesyl transferase.
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Edwin B. Villhauer and co-workers44 have synthesized new cynopyridine derivatives
(IX) via solid-phase synthesis which was having excellent oral bioavailability and potent
antihyperglycemic activity. Biqi Wu45 prepared novel cynopyridine (X) which inhibited
PKCè activity.
Junjun Wu et al.46 have isolated 3-cynopyridine derivatives (XI), which act as a
selective inhibitors of tumor progression loci-2 (Tpl2) kinase with potent inhibition activity
of TNF-α production in human whole blood. Recentely Amar S. Prashad et al47 synthesized
novel cynopyridine derivatives (XII), having PKCè inhibition activity.
In view of therapeutic activities shown by cyanopyridines, it was contemplated
to synthesize some new cyanopyridines in search of agents possessing higher biological
activity with least side effect which have been described as under.
SECTION-I    : SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-[7-
METHYL-2-(p-METHYLPHENYL)IMIDAZO[1,2-a]PYRIDIN
-3-YL]-2-METHOXY-6-ARYLNICOTINONITRILES
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-[7-METHYL-2-
(p-METHYLPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]-2--METHOXY-
6-ARYLNICOTINONITRILES.
Pyridine nucleus plays an important role in medicine, agriculture and industrial
chemistry.  In the light of these biological activities and variety of industrial applications,
some new  4-[7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridin-3-yl]-2-methoxy-6-
arylnicotinonitriles derivative of Type-VIII have been prepared by the cyclocondensation
of (2E)-3-[7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridin-3-yl]-1-arylprop-2-en-
1-one with malononitrile in presence of sodium methoxide as in reaction scheme.
The constitution of the synthesized compounds have been characterised by
elemental analysis, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all the compounds have been checked by
thin layer chromatography (TLC).
All the compounds have been screened for their in vitro biological
assay like antibacterial activity towards Gram positive and Gram
negative bacterial strains and antifungal activity towards fungus strains
at a different concentration. The biological activity of the synthesized
compounds were compared with standard drugs, as shown in Table-16
R=ArylType-VIII
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N
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-[7-METHYL-2-(p-METHYL
P H E N Y L ) I M I D A Z O [ 1 , 2 - a ] P Y R I D I N - 3 - Y L ] - 2 - METHOXY-6-ARYL
NICOTINONITRILES.
[A] Preparation of 2-(p-methylphenyl)-7-methylimidazo[1,2-a]pyridine.
See Part:-1, Section:-I(B).
[B] Synthesis of 7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridine-3-carbaldehyde.
See Part:-5, Section:-I(C).
[C] Synthesis of  (2E)-3-[7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridin-3-yl]-
1-phenylprop-2-en-1-one.
See Part:-6, Section:-I(D).
[D] Synthesis of  4-[7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridin-3-yl]-2-
methoxy-6-phenylnicotinonitriles.
Freshly prepared sodium methoxide was added to a solution of (2E)-3-[7-methyl-
2-(p-methylphenyl)imidazo[1,2-a]pyridin-3-yl]-1-phenylprop-2-en-1-one (3.52 gm, 0.01
mol) and malononitrile (0.60gm, 0.01 mol) in methanol (10ml). The contents were heated
under reflux with srirring for 12 hrs. The reaction mixture was cooled and poured on to
crushed ice and the seperated solid was filtered out and crystallized from ethanol. Yield
67%, m.p. 163oC. Calculated (%) of C28H22N4O (430.5); C: 78.12, H: 5.15, N: 13.01,
Found (%) C: 77.91, H, 4.93, N,12.79.
TLC solvent system : Ethyl acetate : Hexane (7 : 3).
Similarly other 4-[7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridin-3-yl]-2-
methoxy-6-arylnicotinonitriles. are prepared. The physical data are recorded in Table-15.
[E] Biological evaluation of 4-[7-methyl-2-(p-methylphenyl)imidazo[1,2-a]
pyridin-3-yl]-2-methoxy-6-arylnicotinonitriles.
Antimicrobial and antifungal testing were carried out as described in Part-1,
Section-I(D). The Minimal  Bactericidal Concentration and Minimal Fungicidal
Concentration (MBC & MFC) of the test solution are reported in Table-16.
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8a C6H5- C28H22N4O 430.5 163 67 13.01 12.79 0.54 S1
8b 4-CH3-C6H4- C29H24N4O 444.5 159 54 12.60 12.38 0.56 S1
8c 4-OCH3-C6H4- C29H24N4O2 460.5 148 59 12.17 11.95 0.50 S2
8d 3-Cl-C6H4- C28H21ClN4O 464.9 165 61 12.05 11.81 0.53 S1
8e 4-F-C6H4- C28H21FN4O 448.4 151 64 12.49 12.21 0.41 S2
8f 4-NH2-C6H4- C28H23N5O 445.5 153 54 15.72 15.50 0.62 S2
8g 3-NH2-C6H4- C28H23N5O 445.5 155 56 15.72 15.53 0.55 S2
8h 4-NO2-C6H4- C28H21N5O3 475.4 161 68 14.73 14.51 0.54 S1
8i 3-NO2-C6H4- C28H21N5O3 475.4 142 65 14.73 14.48 0.65 S1
8j 4-0H-C6H4- C28H22N4O2 446.5 151 51 12.55 12.32 0.46 S2
S1 Hexane : Ethyl acetate (3 : 7),   S2 Chlorofom : Methanol (9 : 1)
Sr.      R    Molecular  Molecular      M.P.    Yield       % of Nitrogen     Rf           Solvent
No                  Formula              Weight           oC            %          Calcd.        Found       Value       System
1        2                       3   4                 5             6              7             8          9             10
TABLE:-15 PHYSICAL CONSTANTS OF 4-[7-METHYL-2-(p-METHYLPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]-2-
-METHOXY-6-ARYLNICOTINONITRILES
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 Observed
Alkane   C-H str. (asym.) 2958 2975-2950 48
-CH3   C-H str. (sym.) 2870 2880-2860  ,,
  C-H o.o.p.def. 1380 1395-1370  ,,
Aromatic   C-H  str. 3073 3090-3030 49
  C=C str. 1528 1540-1480  ,,
  C-H i.p.def. 1083 1125-1000  ,,
Imidazo[1,2-a]   C=N str. 1605 1612-1593 48
pyridine   C-N str. 1222 1220-1020  ,,
  C=C str. 1499 1540-1480  ,,
Pyridine   C=C str. 1605 1650-1520 49
  C=N str. 1534 1580-1550  ,,
Ether   C-O-C str. 1241 1260-1200  ,,
Nitrile   C=N str. 2238 2240-2120  ,,
Type     Ref.
        Reported
Frequency in cm-1
 Vibration
Instrument  : SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range
: 4000-400 cm-1 (KBr disc.)
Mode
N
N
CH3
CH3
N
OCH3
N
IR SPECTRAL STUDIES OF 4-[7-METHYL-2-(p-METHYLPHENYL)IMIDAZO
[1,2-a]PYRIDIN-3-YL]-2- METHOXY-6-PHENYLNICOTINONITRILE
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NMR SPECTRAL STUDIES OF 4-[7-METHYL-2-(p-METHYLPHENYL)
IMIDAZO[1,2-a]PYRIDIN-3-YL]-2-METHOXY-6-PHENYLNICOTINO
NITRILE
Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER
Spectrometer (300MHz)
   1. 2.33 3H singlet Ar-CH3 -
   2. 2.42 3H singlet Py-CH3 -
   3. 4.24 3H singlet Py-OCH3 -
   4. 7.12 2H doublet Ar-H(ee’) J=6
   5. 7.17 1H doublet Ar-H(b) J=9
   6. 7.26 2H doublet Ar-H(dd’) J=6
   7. 7.46 1H singlet Py-H(f) -
   8. 7.49-7.91 7H multiplet Ar-H -
a
b
c
ed
d' e'
N
N
CH3
CH3
N
OCH3
N f
Signal
  No.
Signal Position
    (δppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
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MASS SPECTRAL STUDIES OF 4-[7-METHYL-2-(p-METHYLPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]-2-METHOXY-6-
PHENYLNICOTINONITRILE
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CODE NO. E. COLI P. AERUGINOSA S. AUREUS S.PYOGENUS
MTCC 442 MTCC 441 MTCC 96 MTCC 443
1 8a 100 500 500 250
2 8b 500 500 500 1000
3 8c 25 125 500 500
4 8d 500 250 100 500
5 8e 250 250 100 250
6 8f 250 500 250 125
7 8g 1000 500 500 500
8 8h 100 250 500 500
9 8i 100 100 250 500
10 8j 250 250 125 250
11 AMPICILLIN 100 100 250 100
12 CHLORAMPHENICOL 50 50 50 50
13 CIPROFLOXACIN 25 25 50 50
14 NORFLOXACIN 10 10 10 10
ANTIBACTERIAL ACTIVITY TABLE
MINIMAL BACTERICIDAL CONCENTRATION
SR. 
NO.
CODE NO. C. ALBICANS A. NIGER A. CLAVATUS
MTCC 227 MTCC 282 MTCC 1323
1 8a >1000 500 500
2 8b 500 500 1000
3 8c 1000 500 1000
4 8d 1000 >1000 >1000
5 8e 500 500 500
6 8f 250 500 500
7 8g 500 >1000 >1000
8 8h 1000 >1000 >1000
9 8i >1000 250 250
10 8j >1000 >1000 >1000
11 NYSTATIN 100 100 100
12 GRESEOFULVIN 500 100 100
SR. 
NO.
ANTIFUNGAL ACTIVITY TABLE
MINIMAL FUNGICIDAL CONCENTRATION
(µg/ml)
(µg/ml)
TABLE: 16 BIOLOGICAL EVALUATION OF 4-[7-METHYL-2-(p-METHYL-
PHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]-2-METHOXY-6-
ARYLNICOTINONITRILES.
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INTRODUCTION
Thiourea, itself was one of the first new drug employed to depress, the clinically
over active thyroid in thyrotoxicosis1 but some of the cyclic thioureides such as thiouracil
and it’s derivatives have been found better suited. All of these are prone of produce
adverse reduction in susceptible patients and found more potent and less likely to produce
side effects and is being used widely.2
SYNTHETIC ASPECT
The first primary synthesis of thiopyrimidine derivatives was carried out by
Frankland and Kolbs. The formation of thiopyrimidine is a cycloaddition process. Since
1948 many synthetic methods have been devised3-4 and other methods are as follows:-
 (i) By the condensation of β-keto ester with N-methyl thiourea.5
 (ii) By the condensation of β-dinitriles with thiourea and guanidines.6
 (iii) By the condensation of β-aldehydronitrile with formamidine and thiourea.7
 (iv) 2-Mercaptopyrimidines was synthesised by G. N. Anderson8 through condensation
of thiourea and substituted β-ketoester in presence of sodium ethoxide.
 (v) Bigineli 9 investigated that the reaction of an aromatic aldehyde with α β-
ketoester and urea or thiourea can yields pyrimidine derivatives.
 (vi) Wang Jinjun10 have prepared some new benzo[c]pyrano[4,3-d]pyrimidine
derivatives.
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THERAPEUTIC IMPORTANCE
Thiopyrimidines are excellent reservoir of bioactive substances. The important
pharmacological activities known from  litrature are
(1) Antifilarial11
(2) Antiinflammatory and analgesic12
(3) Antileishmanial13
(4) Anticancer and Herbicidal14
(5) Antineoplastic15
(6) Antiviral and Antitumor16
(7) Antimicrobial17
(8) Anti AIDS and Antitumor18
(9) Antitubercular19
(10) Antileishmanial and Antiviral20
(11) Antagonists21
(12) Antitumor22
(13) Herbicidal23
Moreover, V. Peesapati et al.24 and H. Allimony25 have synthesised thiopyrimidine
derivatives of imidazopyridine as potent antimicrobial agent. M. S. More et al.26 have
prepared pyrazolyl thiopyrimidines llike (I) as anti-inflammatory agents.  S. A. Swelam27
have reported furopyrimidines which possess antitumor activity. Soneyashi et al.28
prepared thiopyrimidine nucleosides (II) as anticancer and antiviral agents.
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Mahran and co-workers29 have prepared heterocyclic system containing
thiopyrimidene nucleus as antimicrobial and antitumor agent. Danel et al.30 have
synthesised some novel pyrimidine derivatives of 2,3-Dihydro-7H-thiazolo[3,2-a]
pyrimidin-7-ones possissing Anti HIV activity. Corbett et al.31 assessed thiopyrimidine
derivatives as HIV reversetranscriptas inhibitors. Thiopyrimidine derivatives are having
numerous pharmacological activity like antagonists,32 antiinflammatory and analgesic33
antileishmanial,34 dehydrotoluate reductase inhibitors35 and antimicrobial36 activity. C.
J. Shishoo and coworkers37 have reported thiopyrimidine derivatives as receptor
antagonists. Recently, Abou El-Foltoh et al.38 synthesised thiopyrimidine derivatives which
showed anticancer activity.
B. J. Ghiya et al.39 have synthesised mercapto pyrimidine derivatives and screened
for their anticancer, antitubercular and anti HIV activities. Mohammad Nasrk et al.40
prepared novel thiopyrimidine nucleosides and screened as antiviral agent. Activities of
certain 5-substituted thiopyrimidine nucleosides against orthopoxvirus infections have
been reported by E. R. Kern et al.41
SAR of thiopyrimidines as mGluR5 antagonists was carried out by L. G.
Hammerland et al.42 R. R. Kamble and B. S. Sudha43 were prepared new thiopyrimidines
(III) and all the synthesized compounds were screened for antibacterial, antifungal,
anti-inflammatory, and anticonvulsant activities. Pratibh Sharma et al.44 have prepared
4,6-dimethyl-5-[2-(2-methylprop-1-enyl)-1H-benzimidazol-1-yl] pyrimidine-2(5H)-
thiones derivatives (IV), which showed significant biological activity.
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Claudia Mugnaini et al.45 have developed a small library of 4-alkylamino-6-(2-
hydroxyethyl)-2-methylthiopyrimidines (V), which were found to possess proper-
ties of anti-RV agents. Aurelio Orjales and co-workers46 have synthesized new
series of pyrimidines (VI) and evaluated as cyclooxygenase-2 (COX-2) inhibitors.
Fggenweiler Hans Michael et al.47 prepared thieno[2,3-d]pyrimidine derivatives
as phosphodiesterase v inhibitors. Patricia Fernandez-Ferri et al.48 synthesised pyrimidine
derivatives as inhibitors of some leukocyte functions. Yadav Bodke & S. S. Sangapure49
prepared pyrimidine derivatives as biologically active compounds. Dumas et al.50 have
prepared some pyrimidine derivatives as for treatment of hyperproliferative disorders.
Chamanlal J. Shishoo et al.51 have reported pyrimidine derivatives as antihistaminic agents.
Thus the important role played by thiopyrimidine nucleus for various physiological
activities prompted us to explore thiopyrimidine chemistry by synthesising its derivatives
bearing different heterocyclic ring system of therapeutic importance. The newly
synthesized compounds are described as follows
SECTION-I: SYNTHESIS AND BIOLOGICAL EVALUATION OF 6-[7-METHYL-
2-(p-METHYLPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]-4-
ARYLPYRIMIDIN-2(1H)-THIONES
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 6-[7-METHYL-2-(p-METHYL-
PHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]-4-ARYLPYRIMIDIN-2(1H)-
THIONES.
Thiopyrimidines represent one of the most active classes of compounds possesing
a wide spectrum of biological activities, such as significant in vitro activity against
unrelated DNA and RNA viruses including polio viruses, diuretic, antitubercular
spermidine etc.These valid observation led us to synthesize 6-[7-methyl-2-(p-
methylphenyl)imidazo[1,2-a]pyridin-3-yl]-4-arylpyrimidine-2(1H)-thiones ofType-IX by
cyclocondensation of (2E)-3-[7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridin-3-yl]-
1-arylprop-2-en-1-one and thiourea in presence of HCl as catalysts
The constitution of the synthesized compounds have been characterised by
elemental analysis, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all the compounds have been checked by
thin layer chromatography (TLC).
All the compounds have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards fungus strains at a different concentration. The biological
activity of the synthesized compounds were compared with standard drugs, as shown in
Table-18
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 6-[7-METHYL-2-
( p - M E T H Y L P H E N Y L ) I M I D A Z O [ 1 , 2 - a ] P Y R I D I N - 3 - Y L ] -4-ARYL-
PYRIMIDIN-2(1H)-THIONES.
[A] Preparation of 2-(p-methylphenyl)-7-methylimidazo[1,2-a]pyridine.
See Part:-1, Section:-I(B).
[B] Synthesis of 7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridine-3-carbaldehyde.
See Part:-5, Section:-I(C).
[C] Synthesis of  (2E)-3-[7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridin-3-yl]-
1-phenylprop-2-en-1-one.
See Part:-6, Section:-I(D).
[D] Synthesis of  6-[7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridin-3-yl]-
4-phenylpyrimidin-2(1H)-thiones.
A mixture of (2E)-3-[7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridin-3-yl]-
1-phenylprop-2-en-1-one (3.52 gm, 0.01 mol) and thiourea (0.78gm, 0.01 mol) in
methanol (15 ml) was refluxed in presence of alcoholic KOH for 10 hrs. The solvent
was distilled off and the residue was neutralized with dilute HCl, the separated solid was
filtered out and crystallized from ethanol. Yield 61%, m.p. 148oC. Calculated (%) of
C25H20N4S (408.5); C:73.50, H: 4.93, N: 13.71, Found (%) C: 73.28, H: 4.63, N:13.49.
TLC solvent system : Ethyl acetate : Hexane (5 : 5).
Similarly, other 6-[7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridin-3-yl]-
4-arylpyrimidin-2(1H)-thiones were prepared. The physical data are recorded in
Table-17.
[E] Biological evaluation of 6-[7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridin-
3-yl]-4-phenylpyrimidin-2(1H)-thiones.
Antimicrobial and antifungal testing were carried out as described in Part-1,
Section-I(D). The Minimal  Bactericidal Concentration and Minimal Fungicidal
Concentration (MBC & MFC) of the test solution are reported in Table-18.
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9a C6H5- C25H20N4S 408.5 148 61 13.71 13.49 0.45 S2
9b 4-CH3-C6H4- C26H22N4O 422.5 161 54 13.26 13.02 0.53 S1
9c 4-OCH3-C6H4- C26H22N4OS 438.5 153 58 12.78 12.52 0.55 S1
9d 3-Cl-C6H4- C25H19ClN4S 442.9 161 51 12.65 12.41 0.51 S2
9e 4-F-C6H4- C25H19FN4S 426.5 142 60 13.14 12.97 0.48 S2
9f 4-NH2-C6H4- C25H21N5S 423.5 146 54 16.54 16.31 0.60 S1
9g 3-NH2-C6H4- C25H21N5S 423.5 151 57 16.54 16.29 0.53 S1
9h 4-NO2-C6H4- C25H19N5O2S 453.5 138 53 15.44 15.19 0.51 S1
9i 3-NO2-C6H4- C25H19N5O2S 453.5 142 56 15.44 15.23 0.48 S2
9j 4-0H-C6H4- C25H20N4OS 424.5 152 51 13.20 12.96 0.50 S1
S1 Hexane : Ethyl acetate (3 : 7),   S2 Hexane : Ethyl acetate (5 : 5)
Sr.      R    Molecular    Molecular     M.P.    Yield       % of Nitrogen     Rf            Solvent
No                  Formula               Weight          oC            %          Calcd.        Found       Value        System
1        2                       3   4                 5             6              7             8          9             10
TABLE:-17 PHYSICAL CONSTANTS OF 6-[7-METHYL-2-(p-METHYLPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]-4-
-ARYLPYRIMIDIN-2(1H)-THIONES
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IR SPECTRAL STUDIES OF 6-[7-METHYL-2-(p-METHYLPHENYL)
IMIDAZO [1,2-a]PYRIDIN-3-YL]-4-PHENYLPYRIMIDIN-2(1H)-THIONE
 Observed
Alkane   C-H str. (asym.) 2958 2975-2950 52
-CH3   C-H str. (sym.) 2875 2880-2860  ,,
  C-H i.p.def. (asym.) 1472 1470-1435  ,,
  C-H o.o.p.def. 1375 1395-1370  ,,
Aromatic   C-H  str. 3079 3090-3030 53
  C=C str. 1530 1540-1480  ,,
  C-H i.p.def. 1100 1125-1000  ,,
Imidazo[1,2-a]   C=N str. 1607 1612-1593 52
pyridine   C-N str. 1205 1220-1020  ,,
  C=C str. 1512 1540-1480  ,,
Thiopyrimidine   C=C str. 1651 1650-1520 53
ring   N-H str. 3292 3300-3150  ,,
  C=S str. 1575 1590-1550  ,,
Type     Ref.
        Reported
Frequency in cm-1
 Vibration
Instrument  : SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range
: 4000-400 cm-1 (KBr disc.)
Mode
N
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S
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NMR SPECTRAL STUDIES OF (6-[7-METHYL-2-(p-METHYLPHENYL)
IMIDAZO [1,2-a]PYRIDIN-3-YL]-4-PHENYLPYRIMIDIN-2(1H)-THIONE
Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER
Spectrometer (300MHz)
   1. 2.32 3H singlet Ar-CH3 -
   2. 2.41 3H singlet Py-CH3 -
   3. 6.11 1H singlet Py-NH -
   4. 6.65 1H singlet Py-H(f) -
   5. 7.10 2H doublet Ar-H(ee’) J=9
   6. 7.15-8.02 7H multiplate Ar-H -
   7. 7.58 2H doublet Ar-H(dd’) J=9
   8. 8.72 1H singlet Ar-H(e) -
a
b
c
ed
d' e'
N
N
CH3
CH3
NH
N
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f
Signal
  No.
Signal Position
    (δppm)
 Relative No.
  of protons
Multiplicity Inference
   J Value
    In Hz
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MASS SPECTRAL STUDIES OF (6-[7-METHYL-2-(p-METHYLPHENYL)IMIDAZO[1,2-a ]PYRIDIN-3-YL]-4-
PHENYLPYRIMIDIN-2(1H)-THIONE
N
N
CH
3
C
H
3
NH
N
S
m
/z
 =
 408
.5
Synthesis, Characterisation and....
192
CODE NO. E. COLI P. AERUGINOSA S. AUREUS S.PYOGENUS
MTCC 442 MTCC 441 MTCC 96 MTCC 443
1 9a 100 500 250 250
2 9b 250 200 250 1000
3 9c 250 100 500 100
4 9d 1000 500 250 500
5 9e 250 500 125 1000
6 9f 100 125 100 500
7 9g 125 1000 1000 500
8 9h 250 1000 250 100
9 9i 500 250 500 1000
10 9j 100 500 500 250
11 AMPICILLIN 100 100 250 100
12 CHLORAMPHENICOL 50 50 50 50
13 CIPROFLOXACIN 25 25 50 50
14 NORFLOXACIN 10 10 10 10
ANTIBACTERIAL ACTIVITY TABLE
MINIMAL BACTERICIDAL CONCENTRATION
SR. 
NO.
CODE NO. C. ALBICANS A. NIGER A. CLAVATUS
MTCC 227 MTCC 282 MTCC 1323
1 9a 500 250 500
2 9b >1000 1000 500
3 9c 1000 250 500
4 9d 250 500 250
5 9e 500 1000 1000
6 9f 500 500 500
7 9g 250 1000 >1000
8 9h 500 250 500
9 9i 1000 500 >1000
10 9j 1000 >1000 500
11 NYSTATIN 100 100 100
12 GRESEOFULVIN 500 100 100
SR. 
NO.
ANTIFUNGAL ACTIVITY TABLE
MINIMAL FUNGICIDAL CONCENTRATION
(µg/ml)
(µg/ml)
TABLE: 18 BIOLOGICAL EVALUATION OF 6-[7-METHYL-2-(p-METHYL-
PHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]-4-ARYLPYRIMIDIN-
-2(1H)-THIONES.
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INTRODUCTION
Azomethine derivatives have been found to be potent drugs in pharmaceutical
industries and possess a wide spectrum of biological activity. Azomethines are also known
as Schiff’s base and they are well known intermediate for the preparation of azetidinone,
thiazolidinone, formazone, arylacetamide and many other derivatives. These are the
compounds contain characteristic -C=N group.
Azomethines are obtained mainly by warming the aldehyde and aromatic amine
together. However, it is more convenient to work in a solvent such as alcohol, dilute
acetic acid or glacial acetic acid. Some time the reaction is completed by trace of acid.
In other cases the hydrochloride of the amines can be used in the synthesis.
In general Schiff’s bases do not react further with either of the reagents used in
their preparation as do most of the other types of simple intermediates.
SYNTHETIC ASPECT
1. General account and the summary of reaction between aldehydes and amines
(aromatic or aliphatic) has been reviewed by Murray.1
R-CHO R'-NH2 R-CH=N-R'+
2. Strache2 and Van Alphen3 have prepared imines, which involves two steps.
(a) Addition of the amine to the carbonyl group of the aldehyde gives aldol.
The aldol is rarely capable of isolation.
(b) The loss of water to give an imine (azomethine), this corresponds
tothe “crotonaldehyde stage” of the aldol condensation.
R-CH=N-R'R-CHOHNHR' + H2O
3. Oddo and Tognacchini4 have introduced the comparative rates of formation
of Schiff ’s base from aniline, substituted aniline and aromatic aldehyde
using a cryoscopic method follow the course of reaction.
R-CHO R'-NH2+ R-CHOHNHR'
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4. Amanda J. Gallant et al.5 have prepared schiff bases by the condensation of
of 3,6 diformyl catechol and substituted o-phenylenediamine.
5. Pierre L. Beaulieu and co-workers6 have synthesized (E)-N-phenylmethylene
glycineethyl ester by the cyclocondensation of glycine ethylesterhydrochloride,
t-butylmethyl ether (TBME) and benzaldehyde followed by anhydrous
Na2SO4 and triethylamine.
THERAPEUTIC IMPORTANCE
Schiff’s bases exhibit a wide range of pharmacological activities like antifungual,7
antibacterial,8 antiviral,9 antiinflammatory.10  B. Shivarama Holla et al.11 have reported
anticancer activity of some new Schiff’s bases.Chien-Hung Sung et al.12 have been
synthesized a series of novel schiff base (I) having great biological activity.
R. P. Pawar et al.13 have synthesized azomethines by the condensation of
iodovanillin with different substituted aromatic amines and tested for antibacterial activity.
O OHO OH
OH
O
+
NH2
NH2
OR
OR
HCl.H2N
COOEt N COOEtNEt3 / Na2SO4 / TBME
48 HrsCHO
O
OH
OH
OOH
OH
N
OR
( I )
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Ergenc and co-workers14 have synthesised azomethine derivatives having antifungal
activity. Yadav Bodke15 have synthesized some novel azomethines and tested for their
biological activity. V. M. Patel16 have synthesized some new  Schiff’s bases having good
antibacterial activity.
Brian N. Cook and co-workers17 have introduced the discovery of Interleukin-2
inducible T-cell kinase (ITK) inhibitors (II) through structure-based design, where high-
resolution crystal structural information was used to optimize interactions within the kinase
specificity pocket of the enzyme to improve both potency and selectivity. Jinbing Liu et
al.18 have prepared a series of compounds like (III) having significant antibacterial activity.
Ravindra V. Chambhare et al.19 have reported some biological active azomethines
as antimicrobial agents. B. Shivarama Holla et al.20 have synthesized azomethines  having
antibacterial and anti-inflammatory activity. Ali Yousif et al.21 have synthesized some
Schiff’s base derivatives of glucose  containing acetylenic bond and tested for their
bactericidal activity against E. coli and Staphylococcus aureus. New mesogenic
compounds containing a cholesteryl ester and a pyrimidine moiety connected through a
polymethylene spacer like (IV) have prepared by K.C. Majumdar et al.22 Prakash G.
Jagtap and co-workers23 have synthesized potent adenosine A2A and A3 receptor agonist
(V) from the modification of adenosine-52 -N-ethylcarboxamide (NECA). Heba A.
Hassan et al.24 have prepared a novel Schiff’s base exhibited moderate antidepressant
activity as compared to imipramine.
( II ) ( III )
CH3 CH3
O N
OEt
CH2
N
CH3
N
H
N
O
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N
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Wang and Yangang26 have synthesized diazomethines having  plant hormone
activity. Das Arima et al.27 have prepared Schiff’s bases of  aminohydroxy guanidine
(SB-AHG5) and tested  for antiviral  activity against Herpes Simplex virus  (HSV-1)
and adenovirus (Ad-5) along with 11 other heterocyclic SB-AHG5.
A series of substituted Schiff’s bases of 3-formylchromone have been synthe-
sized and screened against thymidine phosphorylase enzyme by Khalid Mohammed Khan et
al.28  Peter D. Frischmann et al.29 have developed methodology for the formation of a
new family of metal-free Schiff ’s base macrocycles (VII) & (VIII) and utilized the
differential exchange rates of aldimines and ketimines.
Synthesis, characterization and anti-microbial studies of novel Schiff’s bases
of 3-amino-6,8-dibromo-2-phenylquinazolin-4(3H)-ones like (VI) against the standard
Gram-posi t ive ,  Gram-negat ive  and fungus s t ra ins  were described by Perumal
P a n n e e r s e l v a m  a n d  c o - workers.25
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Looking to the interesting properties of azomethines, we have synthesized some
new azomethines, which have been described as under.
SECTION-1: SYNTHESIS CHARACTERISATION AND BILOGICAL
EVALUATION OF N-[(1Z)-7-METHYL-2-(p-METHYLPHENYL)
IMIDAZO[1,2-a]PYRIDINE-ARYL-METHYLENE]-
3-CARBOHYDRAZIDE.
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF N-[(1Z)-7-METHYL-2-(p-
METHYLPHENYL)IMIDAZO[1,2-a]PYRIDINE-ARYLMETHYLENE]3-
CARBOHYDRAZIDE.
The growing patent literature of recent years demonstrates that the azomethine
derivatives are used as better therapeutic agents. In view of these findings, it would be
interest to synthesize Schiff’s base of the Type-X by the condensation of  2-(p-methyl
phenyl)-7-methyl-imidazo[1,2-a]pyridine-3-carbaldehyde  with various aromatic amines
as shown in reaction scheme.
The constitution of the newly synthesized compounds have been characterised
by elemental analysis, infrared and 1H nuclear magnetic resonance spectroscopy and
further supported by mass spectrometry. Purity of all the compounds have been checked
by thin layer chromatography (TLC).
All the compounds have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards fungus strains at a different concentration. The biological
activity of the synthesized compounds were compared with standard drugs, as shown in
Table-20.
Type-X
N
NCH3
CH3
O
NH
NR
R=Aryl
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R CHO
Ethanol
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REACTION SCHEME
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 7-METHYL- 2-(p-METHYL
PHENYL)IMIDAZO[1,2-a]PYRIDINE-N-[(1Z)-ARYLMETHYLENE]-3-
CARBOHYDRAZIDE.
[A] Preparation of 2-bromo-3-(p-methylphenyl)-ethyl-3-oxopropanoate.
See, Part-2, Section-1 (A).
[B] Preparation of 7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridine-3-ethylcarboxylate.
See, Part-2, Section-1 (B).
[C] Preparation of 7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridine-3-
carbohydrazide.
See, Part-2, Section-1 (C).
[D] Preparation of 7-methyl-2-(p-methylphenyl)imidazo[1,2-a] pyridine-N-[(1Z)-
phenylmethylene] 3-carbohydrazide.
In a round bottom flask a solution of 7-methyl-2-(p-methylphenyl)imidazo[1,2-a]
pyridine-3-carbohydrazide (2.80g, 0.01m) and benzaldehyde (1.06g, 0.01M) in ethanol
(20 ml) was refluxed in presence of glacial acetic acid for 6 hr. The contents were cooled
and the isolated product was crystallised from ethanol. Yield 58% (2.14 gm),  m.p.
168°C. Calculated (%) of C23H20N4O (368.4); C: 74.98, H: 5.47, N: 15.21, Found
(%) C: 74.76, H: 5.29, N: 15.00.
TLC solvent system : Ethyl acetate : Hexane (8 : 2).
Similarly other aromatic aldehydes are condensed with 7-methyl-2-(p-methylphenyl)
imidazo[1,2-a]pyridine-3-carbohydrazide. The physical constants are recorded in
Table-19.
[E] Biological evaluation of 7-methyl-2-(p-methylphenyl)imidazo[1,2-a]
pyridine-N-[(1Z)-arylmethylene] 3-carbohydrazide..
Antimicrobial and antifungal testing were carried out as described in Part-1,
Section-I(D). The Minimal  Bactericidal Concentration and Minimal Fungicidal
Concentration (MBC & MFC) of the test solution are reported in Table-20.
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10a C6H5- C23H20N4O 368.4 168 58 15.21 15.00 0.54 S1
10b 4-OCH3-C6H4- C24H22N4O2 398.4 136 60 14.06 13.81 0.56 S1
10c 4-F-C6H4- C23H19FN4O 386.4 154 59 14.50 14.28 0.51 S1
10d C6H11- C23H26N4O 374.4 193 62 14.96 14.73 0.48 S2
10e 4-C5H4N- C22H19N5O 369.4 172 54 18.96 18.75 0.53 S1
10f 2-C5H4N- C22H19N5O 369.4 168 57 18.96 18.71 0.49 S2
10g 3,4-(OCH3)2C6H3- C25H24N4O3 428.5 171 61 13.08 12.83 0.43 S2
10h CH2-4-C5H4N- C23H21N5O 383.4 158 56 18.26 18.02 0.61 S1
10i CH2-3-C5H4N- C23H21N5O 383.4 154 63 18.26 18.04 0.50 S2
10j C6H9- C22H24N4O 360.4 161 54 15.54 15.31 0.56 S1
S1 Hexane : Ethyl acetate (2 : 8),   S2 Hexane : Ethyl acetate (4 : 6)
Sr.     R    Molecular    Molecular     M.P.    Yield       % of Nitrogen     Rf            Solvent
No                      Formula           Weight           oC           %          Calcd.        Found       Value        System
1      2                           3   4                 5              6              7             8          9            10
TABLE:-19 PHYSICAL CONSTANTS OF N-[(1Z)-7-METHYL-2-(p-METHYLPHENYL)IMIDAZO[1,2-a]PYRIDINE-ARYL-
-METHYLENE] 3-CARBOHYDRAZIDE
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 Observed
Alkane   C-H str. (asym.) 2965 2975-2950 30
-CH3   C-H str. (sym.) 2871 2880-2860  ,,
  C-H i.p.def. (asym.) 1453 1470-1435  ,,
  C-H o.o.p.def. 1370 1395-1370  ,,
Aromatic   C-H  str. 3048 3090-3030 31
  C=C str. 1499 1540-1480  ,,
  C-H i.p.def. 1100 1125-1000  ,,
  C-H o.o.p. (def) 816 835-810  ,,
Imidazo[1,2-a]   C=N str. 1620 1612-1593  ,,
pyridine   C-N str. 1150 1220-1020  ,,
Schiff base   C=N str. 1590 1660-1580 30
Amide   N-H str. 3218 3300-3100 31
-CO-NH-   C=O str. 1623 1690-1630  ,,
Type     Ref.
        Reported
Frequency in cm-1
 Vibration
Instrument  : SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range
: 4000-400 cm-1 (KBr disc.)
Mode
N
N
CH3
CH3
NH
N
O
IR SPECTRAL STUDIES OF 7-METHYL-2-(p-METHYLPHENYL)IMIDAZO-
[1,2-a]PYRIDINE-N-[(1Z)-PHENYLMETHYLENE]3-CARBOHYDRAZIDE
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Signal
  No.
Signal Position
    (δppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
NMR SPECTRAL STUDIES OF 7-METHYL-2-(p-METHYLPHENYL)
IMIDAZO[1,2-a]PYRIDINE-N-[(1Z)-PHENYLMETHYLENE]3-CARBOHYDRAZIDE
Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER
Spectrometer (300MHz)
   1. 2.39 3H singlet Ar-CH3 -
   2. 2.39 3H singlet Py-CH3 -
   3. 6.99 1H singlet CO-NH(d) -
   4. 7.31-7.93 10H multiplet Ar-H -
   5. 7.95 2H multiplate Ar-H(a,c) -
   6. 12.25 1H singlet Ar-H(e) -
a
b
c
d
e
N
N
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MASS SPECTRAL STUDIES OF 7-METHYL-2-(p-METHYLPHENYL)IMIDAZO[1,2-a]PYRIDINE-N-[(1Z)-PHENYL
METHYLENE]3-CARBOHYDRAZIDE
N
N
CH
3
C
H
3
N
N
O
H
m
/z
 =
 368
.4
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CODE NO. E. COLI P. AERUGINOSA S. AUREUS S. PYOGENUS
MTCC 442 MTCC 441 MTCC 96 MTCC 443
1 10a 500 250 250 500
2 10b 250 500 500 250
3 10c 100 500 200 500
4 10d 250 100 250 100
5 10e 1000 250 250 250
6 10f 250 125 1000 1000
7 10g 200 250 125 200
8 10h 1000 100 250 1000
9 10i 100 250 250 500
10 10j 250 500 100 500
11 AMPICILLIN 100 100 250 100
12 CHLORAMPHENICOL 50 50 50 50
13 CIPROFLOXACIN 25 25 50 50
14 NORFLOXACIN 10 10 10 10
ANTIBACTERIAL ACTIVITY TABLE
MINIMAL BACTERICIDAL CONCENTRATION
SR. 
NO.
CODE NO. C. ALBICANS A. NIGER A. CLAVATUS
MTCC 227 MTCC 282 MTCC 1323
1 10a 1000 500 500
2 10b 500 500 500
3 10c 500 250 500
4 10d 250 500 1000
5 10e 500 250 500
6 10f 250 500 500
7 10g 500 1000 250
8 10h 500 1000 500
9 10i 500 250 250
10 10j 1000 500 500
11 NYSTATIN 100 100 100
12 GRESEOFULVIN 500 100 100
SR. 
NO.
ANTIFUNGAL ACTIVITY TABLE
MINIMAL FUNGICIDAL CONCENTRATION
(µg/ml)
(µg/ml)
TABLE: 20 BIOLOGICAL EVALUATION OF N-[(1Z)-7-METHYL-2-(p-METHYL-
PHENYL)IMIDAZO[1,2-a]PYRIDINE-ARYL-METHYLENE]3-
CARBOHYDRAZIDES.
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INTRODUCTION
Thiazolidinones, which belong to an important group of heterocyclic compounds
have been extensively explored for their applications in the field of medicine.
Thiazolidinones, with a carbonyl group at position 2 (I), 4 (II) and 5 (III), have been
subjected of extensive study in the recent past. Numerous reports have appeared in the
literature which highlight their chemistry and use.
4-Thiazolidinones are derivatives of thiazolidine with carbonyl group at 4-position
(II). Substituent in the 2, 3 and 5 positions may be varied, but the greatest differente in
structure and properties is exerted by the groups attached to carbon atom at the
2-position and to nitrogen atom at the 3-position. The cyclic structure was assigned
after recognition of mercaptoacetic acid as a primary product of hydrolysis of 3-phenyl-
2-phenylimino-4-thiazolidinones.1
The chemistry of 4-thiazolidinones was reviewed in depth by F. Brown2 in 1961
and G. Newkome and A. Nayak3 in 1979.
SYNTHETIC ASPECT
Several methods for the preparation of 4-thiazolidinones are reported in literature4-7
1. Wilson Cunico et al.8 have reported thiazolidin-4-ones from valine, arenealdehydes
and mercaptoacetic acid
S NH
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2. Jerome Blanchet et al.9 have prepared 2-imino-4-thiazolidinones from readily accessible
alkyl (aryl) trichloromethylcarbinols and thioureas under mild conditions.
3. Amit Verma, and Shailendra K. Saraf10 have synthesized novel 4-Thiazolidinones
scaffolds via accessible root.
MECHANISM
The reaction proceeds by the attack of the mercapto acetic acid upon the C=N
group, with the HS-CH2-COOH adding to the carbon atom followed by the capture of
a proton by nitrogen and subsequent cyclisation.
In the reaction, the uncyclised intermediate is formed in several cases. The
uncyclised products was isolated.11 The nucleophilic attack of mercapto acetic acid anion
on carbon of azomethine, which has got possitive character while nitrogen has negative
character is evidenced, simultaneously removal of water as it forms in reaction, helps in
condensation and determination of the reaction time.
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THERAPEUTIC IMPORTANCE
The thiazolidinones, substituted at 2 and 3 position show a wide variety of
biological activity. The frequent ocurrence of the group HN-CO-NH or its tautomer in
compound possess in vitro tuberculostatic activity.12
The following types of biological activity have reported.
1. Antibacterial13
2. Antitubercular14
3. Anti HIV and anticancer15
4. Antidiabetic16
5. Insecticidal17
6. Herbicidal18
7. Anthelmintics19
8. Cardiovascular20
9. Mosquito repellent21
10 Antiviral22
11. Hypnotic23
12. Antifungal24
13. Antitumor25
14. Antiulcer26
15. Local anesthetic27
16. Antimicrobial28
Moreover Albuquerque and co-workers29 have  prepared 4-thiazolidinones, which
shows antidiabetic and antiinflammatory activity. Tagama et al.30 have synthesized
thiazolidinone derivatives as allergy inhibitor. R. S. Lodhi and co-workers31 have
synthesized and studied antimicrobial, antiinflammatory and analgesic property of
4-thiazolidinone and arylidene derivatives. Goel Bhawna et al.32 have documented
thiazolidinone derivatives and compared their antiinflammation potency, ulcerogenic
liability, cardiovascular and CNS effect. Pawar and co-workers33 reported synthesis
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and in vitro antibacterial activity of some 4-thiazolidinone derivatives. In other study,
some thiazolidinone derivatives have been found to be promising antibacterial agent.34,35
Mohammad et al.36 have prepared substituted thiazolidinone (IV) and reported their
antibacterial, antifungal, antithyroid and amoebicidal properties. N.D. Sonawane and
A. S. Verkman37 prepared thiazolidinone derivatives (V) and reported as CFTR inhibitors.
Tamura et al.38 have reported antimicrobial activity of 4-thiazolidinone derivatives.
B. Lohary et al.39 have documented and reported hypolipidemic activity of thiazolidinone
derivatives. Bhawana et al.40 have assessed some new 4-thiazolidinone as antiinflammatory
agents. Eldin Sanaam41 was reported antifungal and antibacterial activity of substituted
thiazolidinone . Many scientist have  reported 4-thiazolidinone as antibacterial,42
anticancer,43 antiinflammatory and analgesic agent.44 Toni Kline et al.45 reported Tethered
thiazolidinone dimers (VI) as inhibitors of the bacterial type-III secretion system.
Ashok Kumar and co-workers46 synthesized and characterized some new bromo-
quionazolin-4-one derivatives (VII) which possess antiinflammatory and analgesic
activities. Steroidal thiazolidinone derivatives  (VIII) were prepared by Salman Ahmad
Khan and Mohammed Yusuf 47 from the steroidal thiosemicarbazones and evaluated
as antibacterial agents, results were compared with the standard drug Amoxicillin.
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R. Dayam et al.48 have reported some novel thiazolidinone derivatives as novel
class of HIV-1 integrase inhibitors. N. D. Sonawane et al.49 have synthesized some new
thiaolidinone derivatives as CFTR inhibitors in rodents. M. H. Shih et al.50 have described
the synthesis and evaluation of antioxidant activity of sydnonyl substituted thiazolidinone
and 4-thiazoline derivatives(IX). D. Reigada et al.51 have reported some novel
thiazolidinone derivatives which release of ATP from retinal pigment epithelial cells
involveing both CFTR and vesicular transport. Synthesis, characterization and in vitro
antimicrobial activity of novel 2-thioxo-4-thiazolidinones and 4,4-bis(2-thioxo-4-
thiazolidinone-3-yl) diphenylsulfones (X) by Mohamed S.A. El-Gaby et al.52
A. Rao et al.53 have described some novel thiazolidinone derivatives like 2-(2,6-
dihalophenyl)-3-(pyrimidin-2-yl)-1,3-thiazolidin-4-ones as non-nucleoside HIV-1 reverse
transcriptase inhibitors. C. Muanprasat et al.54 have prepared some new thiazolidinone
derivatives as CFTR inhibitors.
Moreover, D. B. Salinas et al.55 have documented the thiazolidinone derivatives as
CFTR inhibitor. X. F. Wang et al.56 have reported some novel thiazolidinone derivatives
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and described as new cystic fibrosis transmembrane conductance regulator inhibitor
on Cl-conductance in human sweat ducts. F. Ur et al.57 have constructed some  6-
methylimidazo[2,1-b]thiazole-5-carbohydrazide derivatives and tested their antimicrobial
activities.
Recently, D. Maclean et al.58 have reported thiazolidinone library as agonists of
the follicle stimulating hormone receptor (XI). J. R. Thiagarajah et al.59 have synthesized
a small molecule thiazolidinone as CFTR inhibitor. Hend N. Hafez et al.60 synthesized
novel thiazolidinone (XII), which shows inhibitory effects on the growth of a wide range
of cancer cell lines.
In view of the therapeutic activities of  thiazolidinones and imidazo[1,2-a] pyridine
derivatives, it was contemplated to synthesis some novel 4-thiazolidinone in search of
agent possessing higher biological activity with least side effect, which have been described
as under.
SECTION - I: SYNTHESIS AND BIOLOGICAL EVALUATION OF 7-METHYL
-2-(p-METHYLPHENYL)IMIDAZO[1,2-a ]PYRIDINE-
3-CARBOXAMIDE -N-(2-ARYL-4-OXO-1,3-THIAZOLIDIN-3-YL)
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 7-METHYL-2-(p-METHYL
PHENYL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE-N-(2-ARYL-4-OXO-1,3-
THIAZOLIDIN-3-YL).
4-Thiazolidinone and its derivatives represent one of the most active classes of
compounds possesing a wide spectrum of pharmacological activities Looking to their
versatile properties, it was planed to generate a series 7-methyl-2-(p-methylphenyl)
imidazo[1,2-a]pyridine-3-carboxamide-N-(2-aryl-4-oxo-1,3-thiazolidin-3-yl) of Type-XI
by cyclocondensation of Schiff’s bases of Type-X with mercaptoacetic acid as shown in
reaction scheme.
The constitution of the synthesized compounds have been characterised by
elemental analysis, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all the compounds have been checked by
thin layer chromatography (TLC).
All the compounds have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards fungus strains at a different concentration. The biological
activity of the synthesized compounds were compared with standard drugs, as shown in
Table-22.
Type-XI R=Aryl
N
NCH3
CH3
O
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R
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 7-METHYL-2-(p-METHYL
PHENYL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE-N-(2-ARYL- 4-OXO-
1,3-THIAZOLIDIN-3-YL).
[A] Preparation of 2-bromo-3-(p-methylphenyl)-ethyl-3-oxopropanoate.
See, Part-2, Section-1 (A).
[B] Preparation of 7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridine-3-ethylcarboxylate.
See, Part-2, Section-1 (B).
[C] Preparation of 7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridine-3-
carbohydrazide.
See, Part-2, Section-1 (C).
[D] Preparation of 7-methyl-2-(p-methylphenyl)imidazo[1,2-a] pyridine-N-[(1Z)-
phenylmethylene] 3-carbohydrazide.
See, Part-9, Section-1 (D).
[E] Preparation of 7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridine-3-
carboxamide-N-(2-phenyl-4-oxo-1,3-thiazolidin-3-yl).
A solution of 7-methyl-2-(p-methylphenyl)imidazo[1,2-a] pyridine-N-[(1Z)-
phenylmethylene]-3-carbohydrazide (3.68gm, 0.01mol) and mercaptoaceticacid
(0.92gm, 0.01mol) in dry toluene (20ml) was refluxed on heating mentle using dean
stark water separator for 10 hrs. The reaction mixture was cooled and excess toluene
was distilled in vacuo. An oily liquid was obtained, which was poured in n-hexane and
kept overnight. The solid separated was filtered and recrystlized from ethanol. Yield
50% (2.21gm),  m.p. 171°C. Calculated (%) of C25H22N4O2S (442.5), C: 67.85, H:
5.01, N: 12.66, Found (%) C: 67.64, H: 4.85, N: 12.41.
TLC solvent system : Ethyl acetate : Hexane (7 : 3).
Similarly other 7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide
-N-(2-aryl-4-oxo-1,3-thiazolidin-3-yl) were prepared. The physical constants are
recorded in Table-21.
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[F] Biological evaluation of 7-methyl-2-(p-methylphenyl)imidazo[1,2-a]
pyridine-3-carboxamide-N-(2-aryl-4-oxo-1,3-thiazolidin-3-yl).
Antimicrobial and antifungal testing were carried out as described in Part-1,
Section-I(D). The Minimal  Bactericidal Concentration and Minimal Fungicidal
Concentration (MBC & MFC) of the test solution are reported in Table-22.
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11a C6H5- C25H22N4O2S 442.5 171 50 12.66 12.41 0.51 S1
11b 4-OCH3-C6H4- C26H24N4O3S 472.5 143 55 11.86 11.63 0.53 S1
11c 4-F-C6H4- C25H21FN4O2S 460.5 148 59 12.17 11.92 0.46 S2
11d C6H11- C25H28N4O2S 448.6 172 54 12.49 12.24 0.58 S2
11e 4-C5H4N- C24H21N5O2S 443.5 168 61 15.79 15.56 0.60 S1
11f 2-C5H4N- C24H21N5O2S 443.5 176 53 15.79 15.51 0.47 S2
11g 3,4-(OCH3)2C6H3- C27H26N4O4S 502.6 158 60 11.15 10.94 0.53 S1
11h CH2-4-C5H4N- C25H23N5O2S 457.6 163 56 15.31 15.10 0.52 S1
11i CH2-3-C5H4N- C25H23N5O2S 457.6 151 58 15.31 15.08 0.50 S2
11j C6H9- C24H26N4O2S 434.6 179 57 12.89 12.56 0.56 S1
S1 Hexane : Ethyl acetate (3 : 7),   S2 Chlorofom : Methanol (8 : 2)
Sr.     R    Molecular    Molecular     M.P.    Yield       % of Nitrogen     Rf            Solvent
No                      Formula           Weight           oC           %          Calcd.        Found       Value        System
1      2                           3   4                 5              6              7             8          9            10
TABLE:-21 PHYSICAL CONSTANTS OF 7-METHYL-2-(p-METHYLPHENYL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE-
-N-(2-ARYL-4-OXO-1,3-THIAZOLIDIN-3-YL)
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 Observed
Alkane   C-H str. (asym.) 2962 2975-2950 61
-CH3   C-H str. (sym.) 2864 2880-2860  ,,
  C-H i.p.def. (asym.) 1461 1470-1435  ,,
  C-H o.o.p.def. 1382 1395-1370  ,,
Aromatic   C-H  str. 3056 3090-3030 62
  C=C str. 1517 1540-1480  ,,
  C-H i.p.def. 1105 1125-1000  ,,
Imidazo[1,2-a]   C=N str. 1595 1612-1593 61
pyridine   C-N str. 1175 1220-1020  ,,
Amide   N-H str. 3318 3300-3100 62
  C=O str. 1636 1690-1630  ,,
Thiazolidinone   C-S-C str. 733 720-570 61
  C=O str. 1661 1680-1636  ,,
Type     Ref.
        Reported
Frequency in cm-1
 Vibration
Instrument  : SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range
: 4000-400 cm-1 (KBr disc.)
Mode
N
N
CH3
CH3
NH
N
O
S
O
IR SPECTRAL STUDIES OF 7-METHYL-2-(p-METHYLPHENYL)IMIDAZO[1,2-a]
PYRIDINE-3-CARBOXAMIDE-N-(2-PHENYL-4-OXO-1,3-THIAZOLIDIN-3-YL)
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NMR SPECTRAL STUDIES OF 7-METHYL-2-(p-METHYLPHENYL) IMIDAZO[1,2-a]
PYRIDINE-3-CARBOXAMIDE-N-(2-PHENYL-4-OXO-1,3-THIAZOLIDIN-3-YL)
Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER
Spectrometer (300MHz)
   1. 2.28 3H singlet Ar-CH3 -
   2. 2.32 3H singlet Py-CH3 -
   3. 3.51 1H doublet Thia-CH2(d) J=6.0
   4. 3.58 1H doublet Thia-CH2(e) J=6.0
   5. 5.85 1H singlet Thia-CH(f) -
   6. 7.02 1H doublet Ar-H(b) J=9
   7. 7.37-8.26 9H multiplet Ar-H -
   8. 8.10 1H doublet Ar-H(c) J=9
   9. 8.91 1H singlet Ar-H(a) -
Signal
  No.
Signal Position
    (δppm)
 Relative No.
  of protons
Multiplicity Inference
a
b
c
d
e
f
N
N
CH3
CH3
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O
S
O
H
H
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    In Hz
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MASS SPECTRAL STUDIES OF 7-METHYL-2-(p-METHYLPHENYL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE-N-(2-PHENYL-
4-OXO-1,3-THIAZOLIDIN-3-YL)
N
N
CH
3
C
H
3
NHN
O
S
O
m
/z
 =
 442
.5
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CODE NO. E. COLI P. AERUGINOSA S. AUREUS S.PYOGENUS
MTCC 442 MTCC 441 MTCC 96 MTCC 443
1 11a 325 25 540 500
2 11b 250 500 250 250
3 11c 500 1000 500 125
4 11d 1000 1000 1000 62.5
5 11e 500 1000 1000 500
6 11f 250 1000 1000 500
7 11g 250 500 250 250
8 11h 25 500 250 500
9 11i 25 100 500 500
10 11j 1000 250 1000 1000
11 AMPICILLIN 100 100 250 100
12 CHLORAMPHENICOL 50 50 50 50
13 CIPROFLOXACIN 25 25 50 50
14 NORFLOXACIN 10 10 10 10
ANTIBACTERIAL ACTIVITY TABLE
MINIMAL BACTERICIDAL CONCENTRATION
SR. 
NO.
CODE NO. C. ALBICANS A. NIGER A. CLAVATUS
MTCC 227 MTCC 282 MTCC 1323
1 11a 1000 500 500
2 11b 500 500 500
3 11c 250 500 1000
4 11d 250 1000 1000
5 11e 500 1000 1000
6 11f 250 1000 1000
7 11g 1000 250 500
8 11h 500 500 500
9 11i 250 500 500
10 11j 500 1000 >1000
11 NYSTATIN 100 100 100
12 GRESEOFULVIN 500 100 100
SR. 
NO.
ANTIFUNGAL ACTIVITY TABLE
MINIMAL FUNGICIDAL CONCENTRATION
(µg/ml)
(µg/ml)
TABLE: 22 BIOLOGICAL EVALUATION OF 7-METHYL-2-(p-METHYL-
PHENYL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE- -N- (2-
ARYL-4-OXO-1,3-THIAZOLIDIN-3-YL).
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INTRODUCTION
Azetidin-2-one, also called β-Lactam, is a four member cyclic amide which was
first synthesized by Staudinger in 1907.1
 
Because of the discovery of penicillin in 1928
by Fleming and its structural confirmation by X-ray crystallography,2
 
led to intensive
investigation of β-lactam.3 Before 1970, penicillin and cephalosporins were the antibiotics
that attracted most synthetic effort. Subsequently, many derivatives have been developed.
Carbacephems are analogues of cephalosporins that are also used as antibiotics. The
trans relationship between substituents at C3
 
and C4
 
in the β–lactam ring is different
with the cis one in penicillin and cephalosporin. GV 104326, a tricyclic β-lactam
(trinem), is a highly potent, broad-spectrum antibacterial agent which also contains the
trans relationship. Recently, some β-lactams were found to be potential cholesterol
absorption inhibitor.4
The β-lactam is an essential structural motif for a number of medicinally important
natural and unnatural products.5 In addition to their bioactivities, enatiomerically pure
β-lactams are versatile building blocks for the synthesis of a various of natural products,
such as β-amino acids, oligopeptides, labeled peptides and azetidines.6 Much efforts
have been put into the synthesis of simpler β-lactam.
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SYNTHETIC ASPECT
Inspired by the pharmacological applications of β-lactams and due to the
limitations associated with their biosynthesis, chemical synthesis of this kind of
compounds has attracted considerable attention over the last 80 years.7-11 The
four-member ring of β–lactam can be constructed by any of the four single-bond
formations or by cycloaddition.
(i) The biosynthetic way of the β-lactam synthesis is mainly focused on the formation
of C4-N
 
bond.12
(ii) The C-C bond construction involves the formation of a nucleophilic centre at C3
and an electrophilic centre at C4
, 
or vice versa.13
(iii) The olefin-isocynate cycloaddition is more efficient, which constructs the β–lactam
four-member ring in just one step reaction.14
(iv) Compared with the single-bond construction approach of β–lactam synthesis,
the ketene-imine cycloaddition which includes carbenoid insertion and the
Staudinger reaction is more widely used.15
(v) C2-C3
 
bond formation was rare. One methodology involving a tributylstannane-
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mediated ring closure has been reported.16
(vi) The formation of the amide (N-C2) bond is the most obvious approach and was
utilized in the synthesis of penicillin.17
A stereoselective synthesis of 2-azetidinone as a new fluorine-containing
intermediate, is described by Ivan Plantan.18 The synthetic key step relies upon the
dynamic kinetic resolution (DKR) of ethyl 2-benzamidomethyl-4-fluoro-3-oxo-butanoate
via asymmetric transfer hydrogenation catalyzed by [Ru(η6-arene)(S,S)-R2NSO2DPEN].
Girija S. Singh and Patrick Luntha19 have been prepared 2-azetidinones under
thermal condition. Novel polyfunctionalized N-alkyl-β-lactams have been prepared in
an efficient manner by a palladium-catalyzed [2+2] carbonylative cycloaddition by Luigino
Troisi et al.20
THERAPETIC IMPORTANCE
Ishwar K. Bhat21 and co-workers have synthesized Azetidinones (I) from p-anisidine
and evaluated antibacterial and antifungal potential of the synthesized compounds. K. H. Patel
and A.G. Mehta22 have synthesized some novel azetidinones (II) and having significant
antimicrobial activity.
( I ) ( II )
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Munish Mittal et al.23  have prepared novel 1,3,4-trisubstituted monocyclic β-
lactams (III) and described its antidepressant activity. Sudhir Kumar Bhati and Ashok
Kumar24 synthesized new azetidinones (IV). All compounds were also evaluated for
their anti-inflammatory, ulcerogenic and analgesic activities.
Ashok Kumar and Chatrasal Singh Rajput25 have synthesized new substituted 3-
(3-chloro-2-oxo-4-substituted-aryl-azetidin-1-yl)-2-(5-pyridin-4-yl-[1,3,4]-oxadiazol-
2-yl-sulfanylmethyl)-substituted-3H-quinazolin-4-ones derivatives (V) and screened for
their anti-inflammatory activity. A series of spiro-piperidine azetidinone (VI) were
synthesized and evaluated as potential TRPV1 antagonists by Dong Xiao et al.26
Fourteen new 2-azetidinones derivatives(VII), (VIII) and (IX) of cholesterol
absorption inhibitors have been synthesized by Yubin Wang and co-workers.27 All the
new compounds were evaluated for activity to inhibit cholesterol absorption in rats.  A
new class of chimeric molecules ( X ) have been developed by Basab Roy et al.28
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The compounds were good antibacterial against E. Coli as well as moderate inhibition
of RNA. Allan Urbach et al.29 have been tried prepared reactive β-lactams as a new
antibacterial agents, which based on large flexible 1,3-bridged 2-azetidinones featuring a
“planar amide” instead of the traditional “twisted amide” found in the penicillin family.
Thus, in search of a more potential therapeutic agent by incorporating azetidinone
moiety in imidazo[1,2-a]pyridine nucleus, it was contemplated to synthesis β-lactam of
type ( XII ) by the condensation of chloro acetyl chloride with schiff's bases in presence
of triethyl amine which has been described as under.
SECTION-I: SYNTHESIS AND BIOLOGICAL EVALUATION OF 7-METHYL-2-
(p-METHYLPHENYL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE
-N-(3-CHLORO-4-ARYL-2-OXOAZETIDIN-1-YL)
( VII ) ( VIII )
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 7-METHYL-2-(p-METHYL
PHENYL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE-N-(3-CHLORO-4-
ARYL-2-OXOAZETIDIN-1-YL).
In view of the powerful antibiotic activity shown by monocyclic β-lactoms, the
preparation of 2-azetidinones of Type-XII has been under taken, the synthesis was carried
out by condesation of schiff’s bases of Type-X with chloroacetyl chloride in presence of
triethyl amine as shown in reaction scheme
The constitution of the synthesized compounds have been characterised by
elemental analysis, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all the compounds have been checked by
thin layer chromatography (TLC).
All the compounds have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards fungus strains at a different concentration. The biological
activity of the synthesized compounds were compared with standard drugs, as shown in
Table-24.
Type-XII R=Aryl
N
NCH3
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O
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N R
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 7-METHYL-2-(p-METHYL
PHENYL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE-N-(3-CHLORO-4-
ARYL-2-OXOAZETIDIN-1-YL).
[A] Preparation of 2-bromo-3-(p-methylphenyl)-ethyl-3-oxopropanoate.
See, Part-2, Section-1 (A).
[B] Preparation of 7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridine-3-ethylcarboxylate.
See, Part-2, Section-1 (B).
[C] Preparation of 7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridine-3-
carbohydrazide.
See, Part-2, Section-1 (C).
[D] Preparation of 7-methyl-2-(p-methylphenyl)imidazo[1,2-a] pyridine-N-[(1Z)-
phenylmethylene] 3-carbohydrazide.
See, Part-9, Section-1 (D).
[E] Preparation of 7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridine-3-
carboxamide-N-(3-chloro-4-phenyl-2-oxoazetidin-1-yl).
A solution of 7-methyl-2-(p-methylphenyl)imidazo[1,2-a] pyridine-N-[(1Z)-
phenylmethylene]-3-carbohydrazide (3.68gm, 0.01mol) in dry dioxane was added to a
well stireed mixture of chloroacetylchloride (1.90ml, 0.02mol) and triethylamine (3.35 ml,
0.024mol)in dry dioxane at 0oC. Then the reaction mixture was stirred for 10-12 hrs.
The product was isolated and recrystallised from dioxane. Yield 59%(2.62gm),  m.p.
154°C. Calculated (%) of C25H21N4O2Cl (444.9); C: 67.49, H: 4.76, N: 12.59, Found
(%) C: 67.31, H: 4.59, N: 12.41.
TLC solvent system : Ethyl acetate : Hexane (6 : 4).
Similarly other 7-methyl-2-(p-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide
-N-(3-chloro-4-aryl-2-oxoazetidin-1-yl) were prepared. The physical constants are
reported in Table-23.
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[F] Biological evaluation of 7-methyl-2-(p-methylphenyl)imidazo[1,2-a]
pyridine-3-carboxamide-N-(3-chloro-4-aryl-2-oxoazetidin-1-yl).
Antimicrobial and antifungal testing were carried out as described in Part-1,
Section-I(D). The Minimal  Bactericidal Concentration and Minimal Fungicidal
Concentration (MBC & MFC) of the test solution are reported in Table-24.
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12a C6H5- C25H21N4O2Cl 444.9 154 59 12.59 12.41 0.59 S1
12b 4-OCH3-C6H4- C26H23N4O3Cl 474.9 156 61 11.80 11.67 0.53 S1
12c 4-F-C6H4- C25H20FN4O2Cl 462.9 142 63 12.10 11.94 0.48 S2
12d C6H11- C25H27N4O2Cl 450.9 161 58 12.42 12.28 0.54 S1
12e 4-C5H4N- C24H20N5O2Cl 445.9 173 57 15.71 15.51 0.51 S2
12f 2-C5H4N- C24H20N5O2Cl 445.9 178 56 15.71 15.59 0.60 S1
12g 3,4-(OCH3)2C6H3- C27H25N4O4Cl 504.9 151 61 11.10 10.96 0.52 S2
12h CH2-4-C5H4N- C25H22N5O2Cl 459.9 146 55 15.23 15.11 0.50 S2
12i CH2-3-C5H4N- C25H22N5O2Cl 459.9 156 60 15.23 15.04 0.56 S1
12j C6H9- C24H25N4O2Cl 436.9 163 52 12.82 12.63 0.55 S1
S1 Hexane : Ethyl acetate (4 : 6),   S2 Chlorofom : Methanol (9 : 1)
Sr.     R    Molecular    Molecular     M.P.    Yield       % of Nitrogen     Rf            Solvent
No                      Formula           Weight           oC           %          Calcd.        Found       Value        System
1      2                           3   4                 5              6              7             8          9            10
TABLE:-23 PHYSICAL CONSTANTS OF 7-METHYL-2-(p-METHYLPHENYL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE-
-N-(3-CHLORO-4-ARYL-2-OXOAZETIDIN-1-YL)
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IR SPECTRAL STUDIES OF 7-METHYL-2-(p-METHYLPHENYL)IMIDAZO[1,2-a]
PYRIDINE-3-CARBOXAMIDE--N-(3-CHLORO-4-PHENYL-2-OXOAZETIDIN-1-YL)
 Observed
Alkane   C-H str. (asym.) 2918 2975-2950 30
-CH3   C-H str. (sym.) 2854 2880-2860  ,,
  C-H i.p.def. (asym.) 1446 1470-1435  ,,
  C-H o.o.p.def. 1363 1395-1370  ,,
Aromatic   C-H  str. 3024 3090-3030 31
  C=C str. 1502 1540-1480  ,,
  C-H i.p.def. 1109 1125-1000  ,,
Imidazo[1,2-a]   C=N str. 1539 1612-1593 30
pyridine   C-N str. 1149 1220-1020  ,,
Amide   N-H str. 3304 3300-3100 31
  C=O str. 1695 1690-1630  ,,
Azetidinone   C-N str. 1207 1220-1020 30
  C=O str. 1708 1710-1630  ,,
  C-Cl str. 758 800-600 31
Type     Ref.
        Reported
Frequency in cm-1
 Vibration
Instrument  : SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range
: 4000-400 cm-1 (KBr disc.)
Mode
N
N
CH3
CH3
NH
N
O
O
Cl
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Signal
  No.
Signal Position
    (δppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
NMR SPECTRAL STUDIES OF 7-METHYL-2-(p-METHYLPHENYL)
IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE-N-(3-CHLORO-4-PHENYL-2-
OXOAZETIDIN-1-YL)
Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER
Spectrometer (300MHz)
   1. 2.99 3H singlet Ar-CH3 -
   2. 3.02 3H singlet Py-CH3 -
   3. 4.55 1H doublet Aze-H(e) J=9
   4. 5.37 1H doublet Aze-H(f) J=9
   5. 7.02-7.33 10H multiplet Ar-H -
   6. 7.24 1H singlet CO-NH(d) -
   7. 7.98-8.02 2H multiplet Ar-H(a,c) -
a
b
c
d
e
f
N
N
CH3
CH3
NH
N
O
O
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MASS SPECTRAL STUDIES OF 7-METHYL-2-(p-METHYLPHENYL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE-N-(3-
CHLORO-4-PHENYL-2-OXOAZETIDIN-1-YL)
N
N
CH
3
C
H
3
NHN
O
O
Cl
m
/z
 =
 444
.9
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CODE NO. E. COLI P. AERUGINOSA S. AUREUS S.PYOGENUS
MTCC 442 MTCC 441 MTCC 96 MTCC 443
1 12a 250 125 500 1000
2 12b 250 250 250 1000
3 12c 500 500 500 500
4 12d 500 250 500 500
5 12e 250 250 1000 500
6 12f 1000 1000 1000 500
7 12g 1000 500 1000 250
8 12h 500 500 500 1000
9 12i 250 125 250 500
10 12j 250 125 125 500
11 AMPICILLIN 100 100 250 100
12 CHLORAMPHENICOL 50 50 50 50
13 CIPROFLOXACIN 25 25 50 50
14 NORFLOXACIN 10 10 10 10
ANTIBACTERIAL ACTIVITY TABLE
MINIMAL BACTERICIDAL CONCENTRATION
SR. 
NO.
CODE NO. C. ALBICANS A. NIGER A. CLAVATUS
MTCC 227 MTCC 282 MTCC 1323
1 12a >1000 250 250
2 12b >1000 500 500
3 12c 500 500 500
4 12d >1000 250 250
5 12e 1000 500 500
6 12f 500 1000 >1000
7 12g 500 >1000 >1000
8 12h 500 500 >1000
9 12i 250 500 >1000
10 12j 250 1000 >1000
11 NYSTATIN 100 100 100
12 GRESEOFULVIN 500 100 100
SR. 
NO.
ANTIFUNGAL ACTIVITY TABLE
MINIMAL FUNGICIDAL CONCENTRATION
(µg/ml)
(µg/ml)
TABLE: 24 BIOLOGICAL EVALUATION OF 7-METHYL-2-(p-METHYL-
PHENYL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE-N-(3-
CHLORO-4-ARYL-2-OXOAZETIDIN-1-YL).
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1a C 4H 8O-
1b C 4H 8-
1c C 5H 11N-
1d C 6H 13N-
1e C 5H 10-
1f C 7H 14-
1g C 4H 11N-
1h C 9H 19N-
1i C 2H 6-
1j C 4H 10-
2a C6H5-
2b 3-OCH3-C6H4-
2c 2,3-(OCH3)2C6H3-
2d 3,5-(NO2)2C6H3-
2e 2-C5H4N-
2f 3-C5H4N-
2g 4-C5H4N-
2h 2,4,5-(F)3C6H2-
2i 4-Cl-2,5-(F)2-C6H2-
2j 3-Cl-2,4,5-(F)3-C6H-
3a CH3-
3b CF3-
3c C 3H 7-
3d C 2H 5-
3e C 3H 7-
3f C 6H 5-
3g C6H2F 3-
3h C6H2ClF2-
3i C6HClF3-
3j 3-CF3-C6H4
4a C6H5-
4b 3-OCH3-C6H4-
4c 2,3-(OCH3)2C6H3-
4d 3,5-(NO2)2C6H3-
4e 2-C5H4N-
4f 3-C5H4N-
4g 4-C5H4N-
4h 2,4,5-(F)3C6H2-
4i 4-Cl-2,5-(F)2-C6H2-
4j 3-Cl-2,4,5-(F)3-C6H-
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5a C6H 5-
5b 3-OCH3-C6H4-
5c 2,3-(OCH3)2C6H3-
5d 3,5-(NO2)2C6H3-
5e 2-C5H4N-
5f 3-C5H4N-
5g 4-C5H4N-
5h 2,4,5-(F)3C6H2-
5i 4-Cl-2,5-(F)2-C6H2-
5j 3-Cl-2,4,5-(F)3-C6H-
6a C 6H 5-
6b 2-C5H4N-
6c 4-C5H4N-
6d 5-CH3-2-C5H3N-
6e 4-CH3-2-C5H3N-
6f 4,6-(Br)2-2-C5H2N-
6g 5-Br-2-C5H3N-
6h 5-Br-3-NO2-2-C5H2N-
6i 2-Cl-4-C5H3N-
6j 5-CN-2-C5H3N-
7a C 6H 5-
7b 4-CH3-C6H4-
7c 4-OCH3-C6H4-
7d 3-Cl-C6H4-
7e 4-F-C6H4-
7f 4-NH2-C6H4-
7g 3-NH2-C6H4-
7h 4-NO2-C6H4-
7i 3-NO2-C6H4-
7j 4-0H-C6H4-
8a C 6H 5-
8b 4-CH3-C6H4-
8c 4-OCH3-C6H4-
8d 3-Cl-C6H4-
8e 4-F-C6H4-
8f 4-NH2-C6H4-
8g 3-NH2-C6H4-
8h 4-NO2-C6H4-
8i 3-NO2-C6H4-
8j 4-0H-C6H4-
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9a C 6H 5-
9b 4-CH3-C6H4-
9c 4-OCH3-C6H4-
9d 3-Cl-C6H4-
9e 4-F-C6H4-
9f 4-NH2-C6H4-
9g 3-NH2-C6H4-
9h 4-NO2-C6H4-
9i 3-NO2-C6H4-
9j 4-0H-C6H4-
10a C6H5-
10b 4-OCH3-C6H4-
10c 4-F-C6H4-
10d C 6H 11-
10e 4-C5H4N-
10f 2-C5H4N-
10g 3,4-(OCH3)2C6H3-
10h CH2-4-C5H4N-
10i CH2-3-C5H4N-
10j C6H9-
11a C 6H 5-
11b 4-OCH3-C6H4-
11c 4-F-C6H4-
11d C 6H 11-
11e 4-C5H4N-
11f 2-C5H4N-
11g 3,4-(OCH3)2C6H3-
11h CH2-4-C5H4N-
11i CH2-3-C5H4N-
11j C 6H 9-
12a C6H5-
12b 4-OCH3-C6H4-
12c 4-F-C6H4-
12d C 6H 11-
12e 4-C5H4N-
12f 2-C5H4N-
12g 3,4-(OCH3)2C6H3-
12h CH2-4-C5H4N-
12i CH2-3-C5H4N-
12j C6H9-
